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CHAPTER 1. INTRODCTION
1.1 Carbohydrates as essential chemical messengers in intercellular communication
Carbohydrates are polyhydroxylated aldehydes or ketones with the empirical formula
(CH2O)n and are by far the most abundant organic molecules found in nature. Nearly all organisms
synthesize and metabolize carbohydrates. Most carbohydrates found in nature exist as
polysaccharides, glycoconjugates, or glycosides, in which simple sugar units such as the hexoses
(glucose, galactose, mannose, and fucose), or the N-acetyl aminosugars (N-acetylglucosamine and
N-acetylgalactosamine) are attached to one another or to aglycones through O-glycosidic bonds.1
The structural variability and complexity of carbohydrates allows them to function as energy
source molecules, signaling molecules, recognition molecules and adhesion molecules.2
Biologically, the biosynthesis of such O-glycosidic linkages is engineered by the
glycosyltransferases that assemble monosaccharide units into linear and branched glycan chains
with excellent regio- and stereospecificity. These enzymes generally utilize nucleotide phosphate
sugar donors such as UDP-N-acetylglucosaine, UDP-galactose, GDP-fucose, or CMP-sialic acid
that are transferred onto the acceptors such as monosaccharides, oligosaccharides, lipids and
proteins (Scheme 1).2

Scheme 1. Enzyme catalyzed assembly of a complex carbohydrate

2

Other chemical methods that have evolved for the assembly of such complex structures
include the automated one pot solution phase and solid phase glycan assembly.3 The automated
solution phase method involves synthesis of glycans by exploiting the differences in the anomeric
reactivity of a large set of diverse thioglycoside building blocks. Wong and co-workers described
the automated synthesis of the Globo H analogue 7 by employing the reactivity difference between
the thioglycosides 4 and 5 (Scheme 2).4

Scheme 2. A one-pot automated assembly of Globo H analogue 7
The automated solid phase glycan assembly method uses a sugar acceptor often attached
to the solid polymer surface via a cleavable linker. An example in this case was the synthesis of
Ley-Lex antigen analogue 14 by Seeberger and co-workers (Scheme 3).5 Since its inception,6 the

3

automated approach has received wide application in synthesis of bacterial and plant
oligosaccharides,7-8 cis-and trans-glycosidic linkages,9-10 assembly of glycosamino sugars11 as
well as the sialylated glycans.12

Complex carbohydrates coat the surfaces of cells and have the potential to carry the
information necessary for cell-cell recognition. Most cells are completely covered with a glycan
layer, which consists of glycoproteins and glycolipids inserted in the cell membrane, and

4

proteoglycans, which may be more loosely associated with the cell surface.13-14 Many investigators
have demonstrated that cell-surface carbohydrates and sugar-specific receptors (lectins) mediate
cell-cell communication.12 Such carbohydrate-directed cell communication appears to be
important in many intercellular activities where glycans function as receptors for phages and
bacteriocins; specific surface antigens that can determine the pathogenicity of microbes as well as
functioning as highly specific receptors in eukaryotes for viruses, bacteria, hormones, and
toxins.15-16
1.1.1 Significance of lectin-carbohydrate interactions in leguminous plants
Carbohydrates on the cell surface of bacteria can function in the intercellular recognition
process as in the case between rhizobia and the plant root hair cells. Furthermore, studies have
shown that the bacterial recognition of its host (leguminous plant) is related to the carbohydrates
on its cell surface and the rhizobial species with different host specificity have different cell surface
carbohydrates, respectively.17
Lectins comprise a structurally very diverse class of proteins characterized by their ability
to covalently bind carbohydrates with high specificity and in a reversable manner. They are found
in organisms ranging from viruses and plants to humans and serve to mediate biological
recognition events occuring in the terminal or intermediate positions of the glycan structure.
Legume lectins represent the largest family of carbohydrate binding proteins, and their biological
properties have been broadly studied.18-25 For example, studies by Bohlool and co-workers on the
specificity of the interaction of the rhizobia with legumes provide an example of an interaction
between specific carbohydrates on a cell surface and a lectin protein from the legume plant cell.
That is, Bohlool’s group attempted to correlate the binding of lectins to the surface of
rhizobium cells with the ability of the rhizobium to establish a symbiotic relationship with the
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legume from which the lectin was isolated. They found that soybean lectin binds specifically to R.
japonicum, but not to other rhizobia species. Thus, these results indicated that the rhizobium which
nodulated soybeans had a surface distinct from the rhizobium which did not nodulate soybeans.
This suggested that binding between the plant's lectin proteins, and carbohydrates on the surface
of rhizobium cells determined which legumes the rhizobium could nodulate.26
1.1.2 The symbiotic nitrogen cycle, its mechanism and significance in leguminous plants
growth
Nitrogen as an element plays a vital role in the formation of DNA or RNA nucleotides,
amino acids, proteins and in the growth of tissues of all animals, plants, and other living organisms.
Nitrogen in its inert form (N2) accounts for approximately 78% of the atmosphere’s volume; yet
because of its features such as a strong covalent N≡N triple bond (226 kcal mol−1), high ionization
potential, and negative electron affinity, most organisms, including plants, are unable to
metabolize nitrogen. The process of converting nitrogen gas into ammonia is referred to as nitrogen
fixation and can be accomplished via any of the following processes: (i) through geochemical
processes such as lightning, (ii) industrially through the Haber−Bosch process, and (iii)
biologically through the action of specific microorganisms such as endophytic diazotrophic
bacteria through a nitrogenase that is rich in Fe and Mo.27
Rhizobium is a symbiotic soil bacteria that induces root nodule formation on
leguminous plants, in which they are able to fix atmospheric nitrogen gas to a form utilizable
ammonia, thus providing the host plant with all of its essential nitrogen requirement. In return the
plant provides the bacterium with carbohydrates. The infectious process often occurs via the
deformation or curling of the developing root hairs by the plant host. Within infected cells,
molecular nitrogen is reduced to ammonia by the bacteroids, which synthesize nitrogenase
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enzymes that catalyze the reduction of atmospheric nitrogen gas to ammonia. The nitrogenase
enzyme is a two-component system composed of the Mo-Fe protein dinitrogenase, the electrontransfer Fe protein dinitrogenase reductase, and Mg-ATP required for the catalysis cycle. The Fe
protein and Mo-Fe protein associate and dissociate in a catalytic cycle involving single electron
transfer and Mg-ATP hydrolysis. Additionally, the Mo-Fe protein contains two metal clusters: the
iron−molybdenum cofactor, which provides the active site for substrate binding and reduction, and
the P-cluster, that is involved in electron transfer from the Fe protein to iron−molybdenum
cofactor. The reduction catalytic cycle is summarized in Equation 1.28-31

This process, and the ensuing nodule development, are host specific, in that a particular
rhizobium species will only nodulate a small, defined range of plants. Conversely, bacterial
mutation analysis has shown that nodule development is controlled by the rhizobial nodulating
genes, that are involved in the production of secreted rhizobial signals called Nod factors. The Nod
factors are sufficient to initiate root-hair deformations and to trigger nodule development, albeit
only on specific host legumes.32
1.1.3 The structure and role of Nod-factors
Nod factors are a group of biologically active oligosaccharide signals that are secreted by
symbiotic bacteria of the family rhizobiaceae. Their biosynthesis and secretion are determined by
rhizobial nodulation (nod) genes and are specifically induced in response to flavonoids secreted
from the roots of host leguminous plants. The nodulation genes are often categorized as regulatory
(nodD), or (nodABC). The presence of nodABC genes in all symbiotically rhizobial species
suggests that they are involved in the biosynthesis of a common structural feature present in all
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Nod factors.33-35 The NodC protein has been shown to have N-acetylglucosamine β-(1,4)transferase activity,36 while NodB has chitin oligosaccharide terminal N-deacetylase activity,37 and
NodA is an N-acyltransferase.38 Structurally, all Nod factors are short oligomers of β-l,4-linked Nacetylglucosamine (Figure 1). This core structure may be modified by a number of specific
substituents and the modifications are often governed by rhizobial host specificity nod genes. The
biological activity of purified Nod factors mirrors the host specificity, indicating that the symbiotic
host range of individual rhizobium species is, at least partially, determined by the variety of Nod
factors they are able to produce.35

Figure 1. General structure of nodulation factors with ‘n’ indicating variation in oligosaccharide
chain length
1.1.4 Structure and role of O-antigen lipopolysaccharides
Lipopolysaccharides are glycoconjugates that form part of the outer membrane surface of
Gram-negative bacteria. Previous studies have identified these conjugates as undergoing structural
modifications during symbiotic processes to allow them to perform functions such as root hair
infection and suppression or triggering of host defense responses.39-40 In general, the structure of
many of these polysaccharides are still not fully elucidated, however, well-known components
include the KDO, which interconnects the lipid A with the outer core glycans and the O-antigenic
polysaccharide (Figure 2).
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Figure 2. Rhizobial LPS structure
The O-antigen side chain is the most significant component and varies from one strain of
bacteria to another. For example, studies indicate that different strains of rhizobia possess
variations in their O-antigen side chain (Figure 3). The putative role of the O-antigen side chain
could be facilitation of establishment of symbiosis through provision of a direct contact channel
between the plant and the rhizobia for molecular signal exchange.35, 39
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Figure 3. Structures of the repeating units of O-antigen side chain of rhizobial strains
1.2 Photosynthetic Bradyrhizobia
As a subclass of proteobacteria, Bradyrhizobia are symbiotic nitrogen fixers generally
found in specific leguminous plant roots. As is evident from the literature, almost all leguminous
plants forming a symbiotic relationship with rhizobia have a universal signal transduction
mechanism.

41

As such, studies by the Giraud and Chaintreuil groups have demonstrated that

Bradyrhizobia species strains (ORS285) contain the known nodulation genes nodABC that induces
nodulation in most Aeschynomene plant species via the classical known molecular transduction
mechanism.42 However, recent studies have revealed that Aeschynomene indica and sensitiva
plant species are able to have a mutual relationship with specific bradyrhizobia strains in the
absence of nod factors. For example, Giraud and co-workers in their preceding works discovered
that the Aeschynomene indica and sensitiva plant species could still be nodulated by the
Bradyrhizobia strains (ORS285 and BTAil) even after mutation of the nodABC genes present in
ORS285. This Nod-independent symbiotic process indicates a new alternative molecular signaling
pathway for the nitrogen fixation. However, a great challenge in identifying the factors that entirely
control the whole process still exists.43
Many hypotheses have been used to explain the occurrence of this new phenomena, based
on a closer look at the outer membrane structure of the Bradyrhizobia strains of interest. First,
Bradyrhizobia is thought to be coated by non-immunogenic surface polysaccharides such as

10

exopolysaccharides (EPS), and capsular polysaccharides (CPS) that have previously been shown
to be involved in symbiosis by suppressing plant innate immunity, masking surface antigens or
directly functioning as molecular signals.44,45 Secondly, it has also been suggested that
Bradyrhizobia release yet to be determined non-nod signals that initiate the symbiotic process as
well as suppressing the plant innate immunity.46
Through their recent study on the structure of lipopolysaccharide O-antigen side chain of
Bradyrhizobium species (BTAil) strains, Molinaro and co-workers proposed a new hypothesis that
could further explain the unknown mechanism involved in the symbiotic process between the
Bradyrhizobia (ORS278, BTAil) strains and the A. indica and sensitiva plant species. Unlike the
presence of lipochitooligosaccharides in LPS of rhizobia32 15 (Figure 4), they discovered that the
LPS O-antigen of photosynthetic Bradyrhizobia consisted of monomeric repeating units 19 with a
unique bicyclic chemical structure called bradyrhizose, whose presence is thought to result in
suppression of the plant innate immune system as well as triggering of the release of transduction
signals.47

Figure 4. General structure of rhizobial nodulating factors 15 and the structure of the repeating
units of O-antigen side chain of bradyrhizobial (ORS278, BTAil) strains 19.
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1.2.1 Isolation and structure elucidation of bradyrhizose
Bradyrhizose is an inositol-fused monosaccharide that forms a polymeric unit via an α(1→7) glycosidic linkage (Figure 5). The findings of Molinaro and co-workers revealed that the
monomeric unit 20 is made up of an inositol ring which is trans-fused onto another six-membered
ring resulting into a ten-carbon bicyclic compound. Interestingly, further conformational analysis
revealed that the polymer adopts a compact two-fold right-handed helicoidal structure with all
methylene groups pointing inwards while the hydroxy and methyl groups are exposed outwards.47

Figure 5. The polysaccharide unit of bradyrhizose with an α-(1→7) glycosidic linkage 19, the
monomeric unit of bradyrhizose 20 and its Fischer projection 21.
Indeed, 1H NMR spectral analysis revealed nine signals that confirmed the monomeric
structure of bradyrhizose 20 and its α-configuration (Figure 6a). Thus, the characteristic single
peak observed in the anomeric region at 4.97 ppm corresponded to an -anomeric configuration
as was supported by the 3JH-1,H-2 coupling constant of 3.9 Hz (Table 1). Additionally, the 2D
experimental analysis done by Molinaro and co-workers confirmed the correlation of the anomeric
proton at δH 4.97 with H-2 at 3.77 ppm and H-3 at 4.06 ppm, with the 3JH-2,H-3 coupling constant
of 10 Hz confirming the axial orientation of H-2 and H-3. Similarly, further 2D analysis showed a
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correlation between the diastereotopic methylene protons (H6ax and H-6eq) at 1.73-1.97 ppm and
both the H-5 proton at 4.26 ppm and the H-7 proton at 3.72 ppm. Molinaro and co-workers also
showed by NMR data analysis that the singlet observed at 1.34 ppm corresponded to a methyl
group located on a tetra-substituted carbon. The isolation of 20 as a single anomer with the αconfiguration was further confirmed by both
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C and DEPT NMR analysis. Such analysis by

Molinaro and group showed the presence of ten carbon signals, two of which were quaternary
carbons at δC 75.0, corresponding to C-4, and at δC 74.5, which corresponded to C-8. The
methylene carbon at δC 27.5 was associated with the H-6ax and H-6eq, while the anomeric carbon
at δC 96.6 (Figure 6b) confirmed the α-configuration of the monomer. (Table 1). Subsequently,
they demonstrated that carbon peaks observed at δC 69.2, 75.0, 65.8, and 75.0 corresponded to C2, C-3, C-5 and C-9, respectively, with the C-methyl peak being observed at δC 19.9.
Table 1. 1H and 13C spectral analysis of bradyrhizose 20 by Molinaro and co-workers
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Figure 6a. The 1H NMR spectrum of the isolated bradyrhizose O-antigen from Bradyrhizobium
sp. BTAil reproduced with permission from reference 47

Figure 6b. The 13C NMR and DEPT spectra of the isolated bradyrhizose O-antigen from
Bradyrhizobium sp. BTAil reproduced with permission from reference 47
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1.3 Literature total syntheses of bradyrhizose
1.3.1 Bradyrhizose synthesis by Yu group
Yu and co-workers reported a total synthesis of bradyrhizose 20 (Scheme 4) from D-glucal
22 which involved 26 steps with an overall yield of 9%. Their strategy involved key steps such as
the preparation of the conjugated glycal 24 via the Pd(OAc)2-catalyzed C(2)-functionalization of
the activated glycal, the regio- and stereoselective introduction of the trans 1,2-diol via
epoxidation-hydrolysis on the conjugated glycal 24, and the Ferrier type II rearrangement of a
glucopyranoside derivative 29 mediated by the mercuric acetate system. The rearrangement on the
pyranoside derivative 29 proved to be an effective method for accessing the polyhydroxy inositol
scaffold. Further functional group adjustment gave 32 in good yield. The Yu group also
demonstrated that the construction of the galactose scaffold was of equal importance and they
achieved this by further elaboration on the trans-ene scaffold 32 via the Sharpless asymmetric
dihydroxylation conditions. This transformation led to installation of the galactose 2,3-diol.
Subsequently, a selective elaboration on the anomeric aldehyde mediated by the
TEMPO/trichloroisocyanuric acid system followed by simultaneous formation of the hemiacetal
from a polyol resulted in 34, which upon subjection to hydrogenolysis conditions gave 20 as a
mixture.48 With an overall yield of 6%, Yu and co-workers synthesis was characterized by use of
multiple protecting groups and of numerous synthetic steps.
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Scheme 4. The Yu synthesis of bradyrhizose from D-glucal
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1.3.2 Synthesis of bradyrhizose oligosaccharides with α-(1→7) glycosidic linkages that are
relevant to the bradyrhizobium O-antigen
In a subsequent communication, Yu and co-workers demonstrated that the bradyrhizose
dimer, tetramer, and pentamer having an α-(1→7) glycosidic linkages could be achieved in good
yields in a TBSOTf-mediated glycosylation reaction using 3-O-acetyl-2-O-benzyl protected
imidate donors and bradyrhizopyranoside acceptors in toluene at temperatures between -40 to -65
o

C (Scheme 5).49 The benzyl ethers were used as protecting groups to enhance the reactivity of the

donors given that the rigid structure of bradyrhizose renders it less reactive. Such protecting groups
were also strategically installed to minimize the laborious work of the selective installation and
removal of protecting groups.
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Scheme 5. Synthesis of bradyrhizose oligosaccharides with α-(1→7) glycosidic linkages
Additionally, the immunogenicity studies conducted on the deprotected oligobradyrhizopyranosides revealed that they did not induce ROS in Xanthomonas campestris pv.
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campestris LPS. This observation was consistent with previous studies that had shown that the
whole LPS of bradyrhizobium did not induce any immune responses in its host plant or in other
plant families.47
1.3.3 The Lowary synthesis of bradyrhizose
Lowary and co-workers have recently demonstrated that they could synthesize
bradyrhizose 20 from myo-inositol 43 in 25 steps with an overall yield of 6% (Scheme 6).50 The
key transformations in their synthesis involved the derivatization of the ketone intermediate 44
from inositol 43 in 15 steps as well as the stereoselective introduction of the propargylic alcohol
45 onto the ketone 44 using LDA and a propargyl ester. Subsequent functional group adjustments
followed by the asymmetric dihydroxylation on trans-ene intermediate 49 yielded the desired
trans-1,2-diol 50 as a racemic mixture. Studies on the resolution of the racemate revealed that
upon treatment of 50 with (S)-(−)-α-methoxy-α-(trifluoromethyl)phenylacetic acid 52, enantiomer
D-50 reacted preferentially to give L-51 in 50% yield, while the other reacted with (S)-MTPA to

give D-51 in 14% yield. The unreacted D-50 was recovered and its purity determined by chiral
HPLC. Construction of the galactose framework then began by treatment of the enantiopure D-50
with tetra-n-butylammonium fluoride giving 53 and 54 as inseperable mixture. Subsequent
reduction of the mixture using DIBAL-H followed by global deprotection on 55 led to 20 that was
obtained as a mixture. Similar to the observations previously made in the Yu synthesis of
bradyrhizose, the synthesis of 20 by the Lowary group was also characterized by the use of
multiple steps, as well as the intermediacy of racemate 50 that had to be resolved. Additionally,
the generation of intermediates 53 and 54 as inseperable mixtures also was a major challenge in
this synthesis.
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Scheme 6. Key steps in the Lowary synthesis of bradyrhizose from myo-inositol
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1.3.4 Comparison of 1H and 13C spectral data from the bradyrhizose syntheses by the Yu48
and the Lowary50 laboratories and the Molinaro47 material from degradation of the polymer
An inspection of the 1H NMR spectra of 20 in D2O with acetone as an internal standard by
the Yu group revealed that this bicyclic structure gave rise in solution to an equilibrium mixture
consisting of two different pyranose forms a and b, the regioisomer c, and the furanose forms d
and e (Figure 7). Similar observations were made by Lowary group using acetone as an external
standard. These observations contradicted the report by Molinaro group who observed a single
anomer of 20.
Based on the Yu data, the 1 H NMR spectrum of 20 in D2O shows anomeric signals of H1 at δH 4.50 and 5.10 ppm corresponding to the - and -anomers of pyranose forms a and b with
3

JH1,H2 coupling constants of 8.07 and 3.90 Hz, respectively (Table 2). In the same manner the

Lowary group report shows the anomeric signals at δH 4.62 and 5.23 ppm corresponding to the H1 - and -anomers of pyranose forms a and b with 3JH1,H2 coupling constants of 8.1 and 4.0 Hz,
respectively. In contrast, Molinaro and co-workers reported the existence of only the -anomer at
4.97 ppm with 3JH1,H2 coupling constant value of 3.9 Hz. Subsequently, the Yu group indicated
that the further H-1 anomeric signals observed at δH 4.93 and 5.14 ppm corresponded to the - and
-anomers of furanose forms d and e, respectively, while the anomeric signal observed at 4.93
ppm was attributed to the regioisomeric form c with a 3 JH1,H2 coupling constant of 5.0 Hz (Table
2). On the other hand, the Lowary data revealed that the H-1 anomeric signals they observed
between 5.07-5.05 ppm corresponded to the - and -anomers of furanose forms d and e
respectively, while the anomeric signal observed at 5.27 ppm was attributed to the regioisomeric
form c with a 3 JH1,H2 coupling constant of 5.3 Hz. The deviations in both the 1H and 13C NMR
spectra chemical shifts observed in (Table 2) possibly resulted from the use of acetone as either
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an internal standard as in the case of Yu and Molinaro, or as an external standard as in the case of
the Lowary group.

Figure 7. Different forms of bradyrhizose 20 in solution
Table 2. Comparison of 1H and 13C spectral data of bradyrhizose syntheses by the Yu47 and the
Lowary50 laboratories and the Molinaro47material from degradation of a polymer
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1.4 Synthesis of structurally related bradyrhizose motifs
In addition to the total syntheses of bradyrhizose reported by the Yu and Lowary labs, the
construction of bicyclic mimetics of bradyrhizose and of related compounds has also been
reported. Thus, in 2014, Ziegler and co-workers described the synthesis of deca-5,6-diulose 62
from the hex-1-enitols 56 and 57. Key steps in this synthesis involved the generation of the transdec-5-enitol 58 through a cross-coupling reaction of 56 with 57 in the presence of Hoyveda-Grubbs
catalyst, dihydroxylation of dec-5-enitol 58 by treatment with osmium tetraoxide and Nmethylmorpholine N-oxide, oxidation and subsequent formation of the bicyclic framework via
cyclization.51

Scheme 7. Synthesis of deco-5,6-diulose 62 by Ziegler and co-workers
Subsequently, Ziegler and co-workers described the synthesis of 2,10-dioxadecalins 69 and
71 (Scheme 8) featuring a mannose ring trans-fused onto a pyranose moiety. In this work, the
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synthesis of the bicyclic compound 69 bearing syn-configuration at the vicinal stereogenic centers
was achieved via a reaction sequence that consisted of a manno-selective vinylation on the ketone
65, construction of the 1,2-annulated alkene 67 through a ring-closing metathesis, and the
diastereoselective dihydroxylation on alkene 67, followed by hydrogenation that afforded the
polyhydroxylated bicyclic compound 69. Compound 71 bearing the anti-configuration at the
vicinal stereogenic centers was achieved via a reaction sequence that consisted of the epoxidation
on the 1,2-annulated alkene 67 followed by subsequent nucleophilic epoxide opening on 70.52

Scheme 8. Synthesis of 2,10-dioxadecalins 69 and 71 by Ziegler and co-workers
Crich and co-workers reported the synthesis of similar bicyclic scaffolds and demonstrated
their application as models in an in-depth study of the 3JH5,H6 coupling constants for the prediction
of the side chain conformation of hexopyranoses. Their work relied on the synthesis and use of the
diastereomeric mixtures of 72, 76, 80 and 84, by a series of Grignard reactions. The bicyclic
derivatives 75, 79, 83 and 87 were obtained in good yields through a general reaction sequence of
ring closing metathesis, hydrogenation, and finally methylation (Scheme 9).53
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Scheme 9. Synthesis of structurally related compounds by Crich and co-workers
Similarly, the importance of these complex bicyclic motifs is evident from the recent work
by Giuliano and co-workers resulting in an asymmetric carbohydrate-based synthesis of
diplopyrone analogue 99. This molecule displayed good antibacterial activity against common
bacterial pathogens such as Edwardsiella ictaluri and Flavobacterium columnare that cause
enteric septicemia and columnaris disease, respectively. Key steps in this work involved the
pyranose side chain elongation via a C-alkynylation-rearrangement of the glycal 93 with
bis(trimethylsilyl)-acetylene, the Lindlar reduction on 95, and the construction of the pyranopyran
98 via ring closing metathesis (Scheme 10).54
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Scheme 10. Synthesis of of diplopyrone analogue 99 by Giuliano and co-workers
1.5 Occurence and role of ulosonic acids in Gram-negative bacteria
2-ulosonic acids are a diverse family of monosaccharides that play important roles as
components of natural glycoconjugates. Neuraminic acid 100 is found in bacterial glycoconjugates
where it occupies the non-reducing end of oligosaccharide chains. Other 2-ulosonic acids
structurally related to NeuAc include 3-deoxy-D-glycero-D-galacto-2-nonulosonic acid (KDN)
101, commonly identified as a constituent of polysialoglycoproteins in mammalian tissues, and 3deoxy-D-manno-oct-2-ulosonic acid 102 (Figure 8).55

Figure 8. Examples of 2-ulosonic acids commonly found as constituents of glycoconjugates
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3-Deoxy-D-manno-oct-2-ulosonic acid 102 is an 8-carbon sugar consisting of an α-keto
carboxylic acid and four consecutive hydroxylated carbon atoms of D-manno configuration linked
together through one methylene unit (Figure 9).56 This sugar is found in the lipopolysaccharides
of a wide variety of Gram-negative bacteria and is a component of bacterial capsular
polysaccharides as well.57

Figure 9. The Structure of KDO and its Fischer configuration
Other oct-2-ulosonic acids structurally related to KDO that are found in Gram-negative
bacteria are shown in (Figure 10).58

Figure 10. Structures of KO and KDO8N
1.5.1 Biosynthesis of KDO in Gram-negative bacteria
Biosynthesis of KDO begins from D-ribulose 5-phosphate 106, which is converted into Darabinose 5-phosphate 107 with the aid of D-arabinose-5-phosphate isomerase. Condensation of
D-arabinose 5-phosphate with phosphoenol-pyruvate 108 is catalyzed by KDO 8-phosphate

synthase and affords KDO 8-phosphate 109. Then, KDO 8-phosphate phosphatase hydrolyzes
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KDO 8-phosphate to KDO 102 and releases an inorganic phosphate. Finally, the formation of the
activated sugar nucleotide derivative KDO cytidine monophosphate (CMP) 110 from KDO and
cytidine triphosphate is catalyzed by CMP-KDO synthetase. CMP-KDO is the substrate of
monofunctional or bifunctional glycosyltransferases, which sequentially add one or two KDO
residues to lipid A to initiate the core biosynthesis.59,60

Scheme 11. The biosynthesis of KDO
1.5.2 Occurrence of KDO in bacterial lipopolysaccharides
Lipopolysaccharides are major surface components of Gram-negative bacteria and in the
LPS that have been studied, α-linked KDO residues located at the reducing ends of the
polysaccharide domain, provide a bridge between lipid A and the core oligosaccharide.60 Most
Gram-negative bacterial lipopolysaccharides share an α-(2→4) linked KDO-KDO disaccharide
unit as a common inner core structure (Figure 11). This core disaccharide can be further linked to
KDO or other pyranose moieties mostly with α-glycosidic linkages. For example, the investigation
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of the E. coli K12 W3100 LPS 111 by Raina and co-workers revealed that a substitution of the C5
of the KDO-KDO disaccharide with an α-D-heptose or α-L-rhamnose residue forms the inner core
tetrasaccharide of Rha-α-L-(1→5)-KDO-α-D-(2→4)-KDO-α-D-(2→4)-KDO-α-D-(1→5)-Hep.61
The structural elucidation of the lipopolysaccharides from Legionella pneumophila 112 by Helbig
and co-workers revealed that the oligosaccharide is constituted of GalNAc-α-D-(1→4)-Man-α-D(1→5)-KDO-α-D-(2→4)-KDO glycosidic linkages.62 Additionally, 4-amino-4-deoxy-β-Larabinose (Ara4N) residues have been detected glycosidically‐linked to the LPS core sugar 3‐
deoxy‐D‐manno‐oct‐2‐ulosonic acid. In particular, Ara4N has been found in a α‐(1→8) linkage to
KDO in the LPS of Burkholderia pyrrocinia BTS7 113.63
As facultative pathogens, Providencia alcalifaciens are considered to cause infections such
as urinary tract infections and wound infections. Structural studies of the Providencia alcalifaciens
O36 lipopolysaccharide 114 by Rozalski and co-workers64 showed that the O-polysaccharide unit
consists of a linear tetrasaccharide repeating unit containing 2-acetamido-2-deoxygalactose, 6deoxy-L-talose, and 3-deoxy-D-manno-oct-2-ulosonic acid with a Tal-α-L-(1→4)-GalNAc-β-D(1→7)-KDO-α-D-(2→3)-Tal glycosidic linkage pattern. Additionally, Neisseria meningitidis
serotype B, that is perceived to cause life-threatening illness in individuals who lack the necessary
protective antibodies, has been shown to contain a repeating pentasaccharide unit composed of Dheptose, 2-acetamido-2-deoxy-D-galactose and 3-deoxy-manno-oct-2-ulosonic acid residues with
GalNAc-α-D-(1→2)-Hep-α-D-(1→3)-Hep-α-D-(1→5)-KDO-α-D-(2→4)-KDO

glycosidic

linkages 115.65 A bacterial lipopolysaccharide of Acinetobacter baumannii NCTC 10303 has also
been shown to be composed mainly of tetrasaccharide repeating oligosaccharide units of KDO-αD-(2→5)-KDO-α-D-(2→5)-KDO-α-D-(2→4) 116 with substitution at the C8 and C4 positions

with L-rhamnose and D-glucose respectively.66
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Figure 11. Structures of KDO containing oligosaccharides present in the LPS of various Gramnegative bacteria
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1.5.3 Occurrence of KDO in bacterial capsular polysaccharides
Polysaccharide capsules are often involved in virulence and possess functions that range
from masking of bacterial surface antigens and protection against serum killing, to prevention of
phagocytosis. A bacterial capsular polysaccharide is composed mainly of repeating
oligosaccharide units that frequently contain the KDO residue that is equatorially linked to another
pyranose moiety at the KDO C2 position (Figure 12).67
The structural elucidation of the capsule of Cronobacter dublinensis HPB 316968 by Perry
group indicated that the the repeating unit of the capsule is made up of 2-acetamido-2deoxyglucose, L-rhamnose, and 3-deoxy-D-manno-oct-2-ulosonic acid that forms a polymer of
Rha-α-L-(1→5)-KDO-β-D-(2→3)-Rha-β-D-(1→4)-GlcNAc 117. Similarly, a Rha-α-L-(1→5)KDO-β-D-(2→3)-Rha-α-L-(1→2)-Rha polymeric unit has been isolated from E. coli K12 antigen
capsule by Jann and co-workers.69 Such findings have been supported by the recent work by
Whitfield and co-workers who demonstrated that KpsS and KpsC in E. coli and N. meningitidis
are β-KDO transferases that insert poly-β-KDO linkers onto a phosphatidyl-glycerol lipid moiety
in such bacteria.70
The structural analysis of K. kingae type b, K. kingae strain 269-492 and type c capsules
by St. Geme and co-workers71 revealed that type b and the K. kingae strain 269-492 capsules are
a polymer of GalNAc-α-D-(1→5)-KDO-β-D-(2→3)-GalNAc 120 while the type c capsule is a
polymer

of

Rib-β-D-(1→2)-Rib-β-D-(1→2)-Rib-β-D-(1→4)-KDO-β-D-(2→3)-Rib

119,

respectively. Heulin and co-workers have described the structure of the capsule expressed by
Burkholderia caribensis strain MWAP7172 as a polymer composed of D-glucose, 6-deoxy-Ltalose and 3-deoxy-D-manno-oct-2-ulosonic acid with a structure comprised of KDO-β-D-(2→3)Tal-β-L-(1→3)-Glc 122. Moreover, similar KDO-β-D-(2→3)-Tal glycosidic connections have
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also been observed in Pseudoalteromonas flavipulchra NCIMB 2033.73 KDO-β-D-(2→6)GalNAc glycosidic linkages 123 have also been identified in the capsular polysaccharide of K.
kingae strain PYKK181 as well as in the CPS of Moraxella nonliquefaciens 123.74

Figure 12. Structures of KDO containing oligosaccharides present in the CPS of various Gramnegative bacteria.
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1.5.4 Development of KDO containing glycoconjugate vaccines as potential therapeutics for
treatment of pathogenic infections
The incorporation of KDO is a vital step in both the LPS and CPS biosynthesis, and indeed,
in growth of the Gram-negative bacteria. Therefore, the immunochemistry, biochemistry, and
synthetic carbohydrate chemistry involving KDO has become of increasing interest in scientific
research. Noteworthily, the use of defined synthetic and pure oligosaccharides is of necessity in
order to provide a rational basis for future vaccine development. As such, several stereo-controlled
glycosylation methodologies have been used in the synthesis of larger oligosaccharide containing
KDO fragments equipped with reactive spacer group.75 For example, Davis and co-workers have
described the synthesis of a carbohydrate-based glycoconjugate vaccine bearing diphtheria toxin
(DT-Lys51Glu/Glu148Lys) mutant or BSA (Figure 13). Immunochemical studies involving the
(Hep2Kdo2)4-DT or (Hep2Kdo2)4-BSA conjugates revealed that they induced specific serum
antibodies in rabbit.76 Such immunochemical and structural studies on KDO specific antibodies
clearly support the immune-relevance of KDO residues in the discovery of carbohydrate-based
vaccines.

Figure 13. Carbohydrate-based glycoconjugate vaccine bearing diphtheria toxin mutant or BSA
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1.6 Challenges and opportunities in KDO glycoside chemistry
The enzymatic or chemical synthesis of KDO-containing portions of capsular
polysaccharides has continued to draw much attention amongst scientists due to their relevance in
pharmaceutical research. However, the stereoselective synthesis of KDO glycosides has been met
with various challenges that stem from the lack of a hydroxyl group at the C-3 position, which
excludes the use of the neighboring group participation eﬀect. Secondly, the presence of an
electron-withdrawing carboxylic group at C-1 deactivates and hinders the anomeric position and
in some cases results in formation of the undesirable glycal esters.77
1.6.1 Stereoselective synthesis of axial and equatorial KDO glycosides
Much progress has been made in the development of efficient and stereoselective
glycosylation methodologies for synthesizing KDO glycosides with the axial configuration.78-81 In
contrast, the synthesis of KDO glycosides having the thermodynamically less stable equatorial
conﬁguration has been less explored. In this respect, it is worth mentioning the work by Boons and
co-workers who described the synthesis of β-KDO glycosides 127 mediated by NIS/TfOH in a 1,2
dichloroethane solvent system using peracetylated KDO thioglycoside donor 125 with spacer 126
(Scheme 12).82 However, such conditions are not stereoselective as α-KDO glycosides were
obtained in equal quantities.

Scheme 12. Synthesis of β-KDO glycosides using peracetylated KDO thioglycoside donor
Ling and co-workers have demonstrated that they could furnish β-glycosides 132-134 in
great selectivity and better yields using KDO 1-C-arylglycal donor under NIS-mediated
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glycosylations (Table 3).83 Isolation of the major β-isomer followed by oxidation in the presence
of a RuCl3/NaIO4 reagent, gave the corresponding KDO glycoside 139 (Scheme 13). The access
of β-KDO glycosides relied on radical deiodination using toxic tin reagents which are often
difficult to isolate from products, as well as use of strong oxidizing agents such as RuCl3 to cleave
the arene to the carboxylate functional group.
Table 3. Synthesis of β-KDO glycosides using peracetylated KDO 1-C-arylglycal donor
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Scheme 13. Oxidation of 132 to the corresponding KDO derivative 135
Similarly, Mong and co-workers reported a β-selective glycosylation method for the
synthesis of β-KDO glycosides using a KDO donor having a pre-installed carboxylate at C1 (Table
4). The coupling reactions were mediated by NIS/TMSOTf in a 1:2 CH2Cl2/CH3CN solvent system
and resulted in the formation of α- and β-KDO glycosides with ratios of up to 1:20. Subsequent
radical deiodination on the β-anomer in the presence of tributyltin hydride and azobis(isobutyro)nitrile furnished the deoxy derivative 142 (Scheme 14).84
Table 4. Synthesis of β-KDO glycosides using peracetylated KDO glycal donor
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Scheme 14. Deiodination of 139 to the corresponding KDO derivative 142
Synthesis of β-KDO glycosides with nonglycal donors has also been reported by Oscarson
and co-workers who described the synthesis of β-KDO glycosides using various KDO
thioglycoside donors under different promoter systems (Table 5). Their findings revealed that
formation of β-KDO glycosides bearing the 2-(4-(trifluoroacetamidophenyl)ethyl as a spacer were
best achieved when peracetylated KDO thioglycosides were activated at low temperatures using
IBr/AgOTf as a promoter in a CH2Cl2/CH3CN solvent system. However, NIS/AgOTf-mediated
glycosylations only led to the formation of α-KDO glycosides with the isolation of the glycal ester
in large quantities.85
Table 5. Synthesis of β-KDO glycosides using peracetylated and perbenzoylated KDO
thioglycoside donors
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Recently, Gauthier and co-workers developed a novel class of peracetylated KDO
thioglycoside donor bearing the participating 4′-methoxyphenacyl ester at C1, which upon
activation with NIS/AgOTf, in CH3CN at -10 oC led to the stereoselective formation of β-KDO
glycosides with ratios of up to 1:11 (Table 6).86 The observed β-selectivity was rationalized as
rising from the long range participating effect of 4′-methoxyphenacyl ester auxiliary group which
forms a covalent six-membered α-spiro intermediate 158 that would then be preferentially attacked
by the acceptor from the β-face, furnishing the desired glycoside (Scheme 15).
Table 6. Synthesis of β-KDO glycosides using peracetylated KDO thioglycoside donor
appended with 4′-methoxyphenacyl ester
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Scheme 15. Mechanistic hypothesized role of 4′-methoxyphenacyl ester in favoring formation of
β-KDO glycosides
The enhancement of β-selectivity via the hydrogen bond directing effect has also been
described by the Yang group. In this work, Yang and co-workers discovered that KDO
thioglycosides equipped with a 2-quinolinecarboxyl group at C5-position could undergo βglycosylation with primary alcohols, mediated by NIS/TfOH (Table 7). Despite the fact that βselectivity was realized in good yields with reactive primary alcohols, a complete reversal in
selectivity was observed when secondary and tertiary acceptors were employed under the
activation of NIS/TfOH system or IBr/AgOTf system.87 Moreover, a considerable amount of
eliminated product was isolated in the latter case.
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Table 7. Synthesis of β-KDO glycosides using KDO thioglycoside donor appended with 2quinolinecarboxyl group

More recently, Yang and co-workers reported a β-glycosylation of o-hexynylbenzoate
KDO donor under the activation by gold(I)-catayst that furnished β-KDO glycosides in good yields
(Table 8).88 However, this approach employs an expensive catalyst.
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Table 8. Synthesis of β-KDO glycosides using o-hexynylbenzoate KDO donor

1.7 Role of side chain conformation in stereo-controlled glycosylation reactions
The stereoselective formation of glycosidic bonds in glycosylation reactions is not
straightforward, as such, a considerable effort has been made to better understand factors that play
key roles in such reactions. In a recent review, Crich and co-workers discussed in a broader scope
the influence factors such as the leaving group and protecting group, solvent, promoter,
temperature and additives have on glycosylation reaction outcome.89 Similarly, the pyranosyl side
chain configuration and conformation have been shown to be important contributing factors in
influencing the reactivity and selectivity of glycosyl donors.
The importance of side chain configuration and conformation stems from earlier
experimental findings, which have shown that in solution, the side chain of the hexopyranoses 172
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and 173 exist in an equilibrium mixture of three staggered conformations: gauche,gauche (gg),
gauche,trans (tg), and trans,gauche (tg) conformers. The description of these is based on the
relationship of the C6-O6 bond to the C5-C4 and C5-O5 bonds (Figure 14).90 Additionally, it has
also been revealed that the three staggered conformations for the glucose series 172a-c are
populated in an approximate ratio of 6:4:0, gg:gt:tg, while in the galactose series 173a-c an
approximate population ratio of 2:6:2, gg:gt:tg has been reported. Of note is that these values vary
slightly in different solvent systems.

Figure 14. The three staggered conformations of hexopyranoses 172 and 173 in solution
In a study of the coupling reactions of mannosyl sulfoxide donors with primary and
secondary alcohols, Crich and co-workers found that working with 4,6-O-benzyledine-protected
mannosyl sulfoxides in dichloromethane at −78 °C with pre-activation with triflic anhydride prior
to addition of an acceptor gave excellent β-selectivities compared to the 4,6-di-O-benzyl mannosyl
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sulfoxide donors (Table 9).91 Consistent with the previous observations made by Fraser-Reid on
the disarming effect of a 4,6-O-benzyledine group,92 the Crich group reasoned that the
conformational deformation imposed on the pyranose ring by the 4,6-O-benzylidene group,
favored the formation of the covalently bonded axial triflate intermediate which was displaced by
an acceptor from the β-face leading to formation of β-mannosides.
Table 9. Synthesis of β-mannosyl glycosides using mannosyl sulfoxide donors

Further information on the influence of C−O bonds on the anomeric reactivity of glycosyl
donors was highlighted in the work of Bols and co-workers. Thus, it was demonstrated that the
acid-catalyzed hydrolysis of methyl or dinitrophenyl glucopyranosides occurred faster with
torsionally free monocyclic derivative 184 than with torsionally restricted 186, 187 and the 4,6-Omethylidene derivative 185 (Table 10). Noteworthily, the locked gg conformer 186 and the gt
conformer 187 both lacking the O6 were 0.3 and 0.4 times more reactive than the tg conformer
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185 respectively. Bols group concluded that the less reactivity nature of compound 185 was
influenced by torsional disarming effect as well as the imposition of the tg conformation on the
glucopyranosyl side chain by 4,6-O-acetal. Thus, the resulting conformational change maximized
the electron-withdrawing effect of the C6−O6 bond thereby destabilizing the formation of the
solvent separated ion pair (SSIP) intermediate.93
Table 10. Relative hydrolysis rates of glucopyranosides as examined by Bols and co-workers

In yet a further study on the influence of C−O bonds on the anomeric reactivity of glycosyl
donors, Crich and co-workers conducted experiments to determine the relative rates of hydrolysis
of methyl or dinitrophenyl galactopyranosides under acidic conditions (Table 11).94 These studies
revealed that the bicyclic dinitrophenyl galactopyranosides were less reactive in comparison to the
monocyclic derivatives and that compound with the 4,6-O-alkylidene group 191 was the least
reactive. Thus, it was concluded that the imposition of a tg conformation on the galactocopyranosyl
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side chain by 4,6-O-acetal retarded the formation of the solvent separated ion pair (SSIP). These
observations were consistent with Bols observations in the glucose series.
Table 11. Relative hydrolysis rates of galactopyranosides as examined by Crich and coworkers

In 2016, Crich and co-workers prepared a series of bicyclic mannopyranosyl donors
192, 193, 194, 195 with the C6−O6 bond locked in either the gg, gt, or tg conformations
respectively, and investigated how the side chain conformation influenced selectivity trend
in glycosylation reactions. Such studies revealed that the mannopyranosyl donor 195 with
a tg conformation was the most β-selective while mannopyranosyl donor 192 with a gg
conformation was the least β-selective (Table 12). It was reasoned that in a tg conformation
the electron-withdrawing effect of the C6−O6 bond is maximized thereby stabilizing the
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covalently bonded axial triflate intermediate. Therefore, the acceptor would preferentially
approach from the β-face resulting to the formation of β-glycosides.95
Table 12. The selectivity trends of bicyclic thiomannoside donors as reported by Crich and coworkers

1.7.1 Influence of side chain conformation in stereoselective synthesis of sialosides
Crich and co-workers have successfully synthesized and applied various sialic acid
thioglycosyl donors as models in glycosylation reactions to gain a further understanding of how
changes in the side chain configuration and conformation of a sialic acid pyranosyl ring influences
the reactivity and selectivity of such donors. Focusing on the neuraminic acid, specifically the
O4,N5-oxazolidinone thioglycoside donors, the Crich group demonstrated that a change in the
configuration of a single stereogenic center in the side chain of N-acetyl neuraminic acid donor
201 to the 7-epi-isomer 202 (Figure 15) resulted to a change in a conformation of the O7-C7 bond
from gg in 201 to gt in 202.96 The change in side chain conformation was supported by the 1H
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NMR studies that revealed a 3J6,7 coupling constant of 2.4 Hz for donor 202, suggesting that a gt
conformation about the C6−C7 bond predominated while a 3J6,7 coupling constant of 1.5 Hz was
reported for the donor 201 suggesting that a gg conformation about the C6−C7 bond predominated.

Figure 15. Inversion of the configuration at C7 of compound 201
Employing 7-epi-thioglycoside donor 202, primary and secondary acceptors in
glycosylation reactions under the mediation of NIS/TfOH in CH2Cl2/CH3CN at -78 oC furnished
both α,β-neuraminic acid glycosides in modest yields (Table 13).96Conversely, excellent αselectivity was observed under the same glycosylation conditions when the natural thioglycoside
donor 201 was used. Crich and co-workers concluded that the less selectivity nature observed in
coupling reactions involving donor 202 was as a result of a change in its side conformation to a gt,
whereby is such a conformation the α-face of the SSIP is shielded thereby preventing approach of
the acceptor from α-face while promoting a competing β-selective associative mechanism.
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Table 13. The coupling reactions of compound 201 and 202 with selected acceptors

Noteworthily, ESI mass spectrometry fragmentation experiments using a standard cone
voltage of 40 V, revealed that the fragmentation for the natural phosphate isomer 209 was
detectable at a cone voltage of 85 V, while the 7-epi-phosphate isomer 210 required a cone voltage
of 98 V in order for the fragmentation to occur (Table 14). Such experiments clearly demonstrated
that a change in the side chain conformation from a gg to gt had an effect on the reactivity of the
donors as donor 209 with a gg conformation proved to be readily fragmented hence more reactive
compared to phosphate donor 210 with a gt conformation. In fact, competitive glycosylation
experiments done by the Crich group (Scheme 16) was in support of the latter observation made
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in the fragmentation studies as donor 201 with a gg conformation was easily activated and
consumed in the presence of donor 202 with a gt conformation which was recovered in large
quantities.
Table 14. The ESI mass spectrometry fragmentation experiments of compounds 209 and 210

Scheme 16. Competition glycosylation experiment involving donors 201, 202 and acceptor 211
In their subsequent communication on related works, the Crich group demonstrated that a
change in the configuration of a stereogenic center in the side chain of the 5-Azido thioglycosyl
donor 213 to the 5-epi-isomer 214 (Figure 16) resulted to a change in the conformation of the O7C7 bond from gauche,gauche (gg) in 213 to gauche,trans (gt) in 214.97 This notable change in side
chain conformation was supported by the 1H NMR studies that revealed 3J6,7 coupling constants
of 2.2 Hz and 8.8 Hz that were observed for compounds 213 and 214 respectively.
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Figure 16. Inversion of the configuration at C5 of compound 213
Additionally, experimental results revealed that the neuraminic acid thioglycoside donor
214 was β-selective even in cases where less reactive acceptors such as 215 were used (Table 15).
Considering the fact that 5-azido group in 214 occupies the axial position it would be expected
that axial glycosides would be formed in good amounts since the axial C−N bond would be gauche
to the O6 ring oxygen thereby stabilizing the developing positive charge at the ring oxygen during
glycosylation. However, the above observations were not made by the Crich group. Therefore, it
was concluded that the β-selectivity observed with donor 214 was as a result of the influence of
the predominant gt side chain conformation of 214 that did offset the effect of the axial azide
group. Conducting such glycosylation experiments at low temperatures was noted to be equally
important.97
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Table 15. The coupling reactions of compound 214 with selected acceptors

Most recently, Crich and co-workers demonstrated that epimerization at each of the C5,
C7 and C8 centers of compound 213 followed by functional group adjustment resulted to 5,7,8tris-epi-thioglycoside donor 219 (Figure 17). These configurational changes led to a change in the
conformation of the exocyclic bond from gauche,gauche (gg) in 213 to trans,gauche (tg) in 219.
Indeed, an inspection of 1H NMR spectrum revealed a 3J6,7 coupling constant of 10.5 Hz for the
H6, H7 spin system of the pseudaminic acid glycosyl donor 219 that confirmed the existence of a
tg conformation as the values were consistent with the reported literature values.
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Figure 17. Inversion of the configuration at C5, C7 and C8 of compound 213
Consistent with their predictions, it was observed that activation of the pseudaminic acid
donor 219 by the NIS/TfOH combination led to the stereoselective formation of equatorialsialosides. (Table 16).98
Table 16. The coupling reactions of compound 219 with selected acceptors

The conclusions arrived at were that in a tg conformation, the electron withdrawing eﬀect
of the C6−O6 bond is maximized thereby stabilizing the covalently bonded intermediate 224 with
an SN2-like character, resulting in the formation of the equatorial anomers (Scheme 17).
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Scheme 17. Mechanistic explanation of the role of tg conformation in the formation of βsialosides
1.8 Literature evidence on the existence of a tg side chain conformation in KDO residues
In 1980, Unger and co-workers synthesized the methyl α- and β-KDO pyranosides 226 and
227 and an inspection of the 1H NMR spectrum of the compounds revealed a 3JH6, H7 coupling
constant of 9.7 Hz for the H6, H7 spin system, suggesting the predominance of the tg conformation
(Figure 18).99 Most recently, computational work by Kiessling and co-workers has also pointed
KDO adopting the tg side chain conformation.100

Figure 18. Investigation of the 3JH6, H7 coupling constants of KDO anomers
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1.9 Goals
The unique bicyclic chemical structure of bradyrhizose poses a synthetic challenge and
indeed presents an opportunity for the development of efficient methods for its synthesis before
its biological application is investigated. Both the Yu and Lowary syntheses above employ several
steps with purification challenges encountered along the way. Moreover, the two approaches
involved fusion of a pyranose ring onto a preformed inositol skeleton. In view of these problems,
the research described in this thesis set out to develop a simple and a shorter method for accessing
bradyrhizose from D-glucose. This protocol is based on the fusion of the bicyclic ring onto an
existing pyranose framework as opposed to the fusion of a pyranose ring onto a preformed inositol
skeleton.
As discussed above, there exists fewer methods for accessing β-KDO glycosides and only
a few cases display high level of β-selectivity. Inspired by the pseudo-enantiomeric relationship
between pseudaminic acid 228 and 3-deoxy-D-manno-oct-2-ulosonic acid 102 (KDO) (Figure
19), and building upon the work by Unger and co-workers as well as the majority of the 3-deoxyD-manno-oct-2-ulosonic acid thioglycoside donors synthesized and employed in this study as

models have a tg conformation about their exocyclic bond.

Figure 19. Pseudo-enantiomeric relationship of pseudaminic acid 228 and KDO 102
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CHAPTER 2 SYNTHESIS OF BRADYRHIZOSE FROM D-GLUCOSE
2.1 Results and discussion
2.1.1 Retrosynthetic analysis of bradyrhizose
Bradyrhizose 20 can be obtained from the benzyl protected tetraol 242 through
hydrogenolysis. The tetraol 242 can be straightforwardly obtained from methallyl derivative 237
via a sequence of transformations involving ring closing metathesis, regioselective allylic
oxidation, regio- and stereoselective reduction on the enone, stereoselective epoxidation and acidcatalyzed regio- and stereoselective epoxide ring opening. As a key intermediate, compound 237
can be synthesized from a reaction involving the ketone compound 236 and the vinyl Grignard
422. Oxidation of the C4-OH on compound 235 is expected to yield to ketone derivative 236. As
a key intermediate, the methallylated compound 235 can be obtained via a side chain elongation
at the glucopyranoside 6-position of compound 234 under radical initiated methallyllation
conditions using the iodo compound 234 and the sulfone 257 as precursors. Compound 234 can
be obtained from compound 232 via a sequence of reactions involving the selective cleavage of
the benzylidene group in compound 232 and conversion of the C6 hydroxy group in compound
233 to the iodo group. Finally, the benzyl protected intermediate 232 can be obtained from Dglucose 229 via a sequence of reactions involving the Fischer glycosylation on compound 229
leading to compound 230, selective benzylidene protection of the O4 and O6 hydroxy groups on
compound 230 leading to compound 231 and benzylation on the α-anomer of compound 231.
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Scheme 18. Retrosynthesis of a planned bradyrhizose 20
2.1.2 Synthesis of bradyrhizose from methyl α-D-glucopyranoside
2.1.2.1 Derivatization of compound 247
The initial planned synthesis of bradyrhizose was based on using a single anomer of a
glucopyranoside in order to avoid unnecessary complications in the NMR spectra. Following the
retrosynthetic analysis, methyl α-D-glucopyranoside 243 was chosen as the starting material
(Scheme 19): the preliminary steps involved selective installation of a benzylidene acetal101 on the
C4 and C6 hydroxyl groups of 243 followed by benzylation102 of the free C2 and C3 hydroxyl
groups, which led to compound 245 in 89% yield. Liberation of the C4 and C6 hydroxyl groups
was achieved by cleavage of the benzylidene acetal under acid-catalyzed conditions;103 this paved
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the way for selective installation of the iodo group on the free primary hydroxyl group under Appel
conditions104 resulting in compound 247.

Scheme 19. Synthesis of the iodo compound from methyl α-D-glucopyranoside
2.1.2.2 Exploration of various C-C bond formation reactions for side chain elongation at the
glucopyranoside 6-position of compound 247
Methallylation of 247 under thermal conditions using lauroyl peroxide as the initiator, as
well methallylation using methallyl Grignard reagents and metal catalysts were investigated.
2.1.2.2.1 Methallylation via the cross-coupling reaction of methallylmagesium chloride with
the iodo sugar derivative
Metal-catalyzed allylation or methallyllation reactions of alkyl halides with allyl or
methallyl Grignard reagents have been demonstrated to be an effective way of forming C-C bonds
(Scheme 20). The most commonly employed transition-metal catalysts in such transformations
include copper (I) iodide, (Pd(PPh3)4),105 Li2CuCl4,106 [NiCl2(dppp)],107 [CoCl2(dppp)],108
Cu(OTf)2109 and AgNO3.110
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Scheme 20. Example of metal catalyzed C-C bond construction using Grignard reagent
Therefore, methallylation using methallyl Grignard reagent 252 in the presence of
(Pd(PPh3))4, CuI, or Li2CuCl4 were attempted (Table 17). However, starting materials were
recovered essentially unchanged under such conditions. It was reasoned that these failures in part
arose from the protonation of the hydroxy group at the C4 position of the substrate. This problem
could potentially have been overcome by the inclusion of an extra protecting group but, as would
have added two steps to the planned synthesis, attention was turned instead to C-C bond forming
reactions compatible with the presence of a free alcohol.
Table 17. Attempted methallylation by use of a Grignard reagent in the presence of a catalyst

2.1.2.2.2 C-C bond formation via radical methallylation using methallylsulfones
Attention was therefore focused on radical conditions with initiation by the readily
available stable peroxide lauroyl peroxide.111 Methallylsulfones 257, and 259 (Scheme 21) were
synthesized in good yields and employed in the radical coupling reactions.
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Scheme 21. Synthesis of methallylsulfones 257 and 259
Subjection of compound 247 to radical methallylation conditions yielded the desired 253
in 50% yield with the formation of the reduced substrate 260 in 40% yield (Scheme 22). In the
course of yield optimization, it was discovered that replacing 2-pyridyl methallylsulfone 257 by
4-toluyl methallylsulfone 259 gave a cyclized compound 261 in 57% yield (Scheme 23) as was
confirmed by 1H NMR studies.

Scheme 22. Lauroyl peroxide radical initiated reaction using 2-pyridyl methallylsulfone

Scheme 23. Lauroyl peroxide radical initiated reaction using 4-toluyl methallylsulfone
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The proposed mechanism for the radical methallylation leading to compound 261 is
illustrated in (Scheme 24). In the initiation step radical 263 is generated from the thermal
fragmentation/decarboxylation of lauroyl peroxide 262. This alkyl radical adds onto the 4-toluyl
methallylsulfone 259 to generate the 4-toluyl sulfonyl radical 265 with the generation of byproduct
264. Desulfonylation of 265 is considered unlikely since it would generate a high energy aryl
radical 268. The 4-toluly sulfonyl radical 265 abstracts iodine atom from the iodo glucopyranoside
247 to form the radical 267 with the liberation of the sulfonyl iodide 266. The reactive radical 267
then couples irreversibly to the 4-toluyl methallylsulfone 259 to form compound 253 with
regeneration of radical 265 that propagates the radical chain reaction.
The sulfonyl iodide 266 can be hydrolyzed to 4-toluenesulfonic acid 269 in the presence
of moisture thereby generating an acidic medium. Under such acidic conditions, compound 253 is
protonated generating the tertiary cation 270. Finally, the C4 hydroxy group in 270 being in
proximity with the carbocation attacks the tertiary center resulting to the formation of the bicyclic
compound 261. When the pyridyl methallylsulfone 257 was employed as reagent, the internal
base buffers the reaction conditions and suppresses this acid-catalyzed cyclization. Formation of
the reduction product 260 is presumably the product of hydrogen atom abstraction from the allylic
position of the reagent or from one of the many C-H bonds in the initiator.
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Scheme 24. Proposed mechanism for the formation of product 253 and byproducts 260 and 261
2.1.2.3 Synthesis of the key bicyclic intermediate 278
Compound 271 was obtained in moderate yields from oxidation of 253 under ParikhDoering conditions (Scheme 25). Parikh-Doering conditions, often known as the industrial Swern
conditions, were employed as they are relatively green and do not involve tedious workup
procedures.112

Scheme 25. Oxidation under Parikh-Doering conditions
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La Ferla and co-workers reported a stereo-controlled addition of Grignard reagents that led
to the isolation of compound 273 in 94% as a single diastereoisomer (Scheme 26).113

Scheme 26. Stereo-controlledGrignard addition reactions in related glucopyranoside systems
Considering La Ferla’s work, reaction of compound 271 with vinyl magnesium bromide
gave compound 274 as a single diastereoisomer in 76% yield (Scheme 27).

Scheme 27. Stereo-controlled formation of compound 274
The observed desired stereoselectivity was confirmed by NOE studies that revealed the
existence of NOE correlations between H4′ and H3 and, H4′ and H5 (Figure 20).

Figure 20. NOE correlations between H4’ and H3 and H5 in compound 274
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The stereo-controlled addition of the vinyl Grignard was proposed to be influenced by
formation of a Cram chelated intermediate 271 that allows the nucleophile to approach from the
less hindered side thus leading to compound 274 (Figure 21). 114

Figure 21. Hypothesized role of Cram chelation in the stereo-controlled addition of vinyl
Grignard reagent to compound 271
Plenio and co-workers demonstrated that trisubstituted cyclohexenes could be effectively
formed in excellent yields from methallyl type precursors in the presence of a Grubbs catalyst
(Scheme 28).115e

Scheme 28. Synthesis of trisubstituted cyclohexene as reported by Plenio and co-workers
Therefore, the bicyclic scaffold was constructed by the ring closing metathesis on
compound 274 using Grubbs cat. 2nd generation thus giving compound 278 in 84% yield (Scheme
29).115a-d
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Scheme 29. Construction of the bicyclic scaffold
2.1.2.4 Stereoselective synthesis of the epoxide 279
Subsequently, compound 278 was subjected to allylic oxidation conditions using SeO2 to
regioselectively give enone 279 as the major compound. The regioisomeric aldehyde 280 was
also isolated in 7% yield from this reaction (Scheme 30).

Scheme 30. Regioselective allylic oxidation on compound 279
The regioselectivity observed is consistent with Guillemonat’s rules and subsequent
work.116 According to Guillemonat’s rule, the selenium dioxide catalyzed allylic oxidation at the
endocyclic secondary (CH2) position is preferred over the exocyclic primary (CH3) position. This
is because the secondary C-H bonds are weaker than the primary ones in the methyl group. The
regioselective formation of enone 279 begins with a heteroene reaction, to give the seleninic acid
282, which undergoes a 1,3 sigmatropic rearrangement that results in 283.

Hydrolysis of 283

gives the alcohol 284 that reacts with another equivalent of selenium dioxide to generate
intermediate 285. Subsequent cleavage of the Se-O bond results to enone 279 (Scheme 31).
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Scheme 31. Proposed mechanism leading to enone 279
Regio- and stereoselective reduction of the enone 279 was performed under Luche’s
reduction conditions,117 resulting in compound 287 in 80% yield (Scheme 32). The observed
stereoselectivity is thought to arise by approach of the hydride to the carbonyl center from the
bottom face, which is less hindered in comparison to the top face. A hydrogen bond directed
epoxidation118 (Scheme 33) on enol 287 then stereoselectively gave the epoxide 288 in 78% yield
as a single diastereoisomer.

Scheme 32. Stereoselective synthesis of epoxide 288
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Scheme 33. Proposed mechanism for epoxidation leading to compound 288
The relative configuration of epoxide 288 was determined by the observation of strong
NOE correlations of H9 with the C8-methyl group, H3, H5 and H7 (Figure 22).

Figure 22. NOE correlations of H9, C8-methyl group, H3, H5 and H7 in compound 288
2.1.2.5 Regio- and stereoselective ring opening of the epoxide 288
The regio- and stereoselective opening of 288 was conducted using sulfuric acid as catalyst
in a 1,4-dioxane:water 1:2 mixture and yielded tetraol 291 in 37% yield alongside 35% of the
enone 279 that was recycled (Scheme 34).
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Scheme 34. Acid catalyzed regio- and stereoselective opening of epoxide 288
The regiochemical and stereochemical outcome of this ring opening observed derives from
the well-known anti attack of nucleophiles at the more substituted position of trisubstituted
epoxides under acidic conditions (Scheme 35).119 This observation deviates from the FürstPlattner rule120 that involves attack of nucleophiles at the less substituted position of a trisubstituted
epoxide thereby directly leading to tetraol 293 with wrong stereochemistry at both C8 and C9
positions.

Scheme 35. Proposed mechanism leading to tetraol 291
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The relative configuration of 291 was established by the NOE studies that revealed the
proximity of H9 with H3, H5 and H7. Similarly, a strong NOE correlation of the axial C8 methyl
group to H6axial was observed and supported the assigned structure (Figure 23).

Figure 23. NOE correlations between H9, H3, H5 and H7 in compound 291
The formation of compound 279 is suggested to have occurred as a result of a 1,2-hydride
shift followed by β-elimination (Scheme 36).

Scheme 36. Proposed mechanism for the regeneration of enone 279
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An attempt to hydrolyze the glycosidic bond in 291 under acidic conditions were
complicated by apparent decomposition of tetraol 291 as was judged by thin layer chromatography
and mass spectrometry of the crude reaction mixtures (Scheme 37).

Scheme 37. Attempted hydrolysis of the glycosidic bond
These complications lead to a redesign of the synthesis to incorporate a benzyl glycoside,
cleavable by hydrogenolysis, rather than a methyl glycoside.
2.1.3.1 Preparation of benzyl 2,3-di-O-benzyl-6-deoxy-6-iodo-α-D-glucopyranoside from Dglucose
As outlined in (Scheme 38), the synthesis of 234 from D-glucose 229 was achieved in five
steps with the first step involving subjection of 229 to Fischer glycosylation121 in benzyl alcohol
at reflux resulting in 230. Subsequently, the benzylidene group was selectively installed on O4 and
O6 under acidic conditions furnishing 231 in 31g scale, 91% yield as a mixture of two anomers
with a ratio of 14:1 α:β.101 In order to minimize complications in purifications of the anomeric
mixtures in later stages of synthesis, and simplify NMR spectral analysis, the pure α-anomer of
231 was isolated in 85% yield and subjected to benzylation with benzyl bromide and sodium
hydride to afford compound 232.102 Acid-catalyzed removal of the benzylidene acetal,103 followed
by selective Appel104 iodination of the primary hydroxyl group resulted in compound 234. All of
these steps proceeded with excellent yields
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Scheme 38. A five-step synthesis of compound 234 from D-glucose
2.1.3.2 Exploration of various C-C bond formation reactions for side chain elongation at the
glucopyranoside 6-position of benzyl 2,3-di-O-benzyl-6-deoxy-6-iodo-α-D-glucopyranoside
2.1.3.2.1 C-C bond formation via radical methallylations using methallylsulfones or
methallyltri-n-butylstannane
In an attempt to improve the yield of the radical methallylation step, further methallyl
sulfones were prepared as outlined in (Scheme 39). As previously, the methallylation reactions
were conducted under thermal conditions with initiation by lauroyl peroxide or azoisiobutyronitrile
as summarized in (Table 18).

Scheme 39. Synthesis of methallylsulfones 301 and 304
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Table 18. Methallylation under various radical initiated conditions using methallylsulfones or
methallyltri-n-butylstannane

The radical methallylation reactions on iodo glucopyranoside 234 with 2-pyridyl
methallylsulfone 257 under thermal initiation by lauroyl peroxide gave compound 235 in 54%
yield while replacement of the 2-pyridyl methallylsulfone with the regioisomeric 3-pyridyl
methallylsulfone122 301 gave the corresponding methallylated product 235 in 50% yield albeit with
the formation of the reduced compound 306 (Table 18, entries 1 and 2). Based on these
observations, it was concluded that a change of nitrogen position in the pyridine ring did not have
a major impact in yield optimization as the yield obtained in methallylation reactions involving 2pyridyl methallyl sulfone were similar to those of 3-pyridyl methallylsulfone. The construction of
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the C-C bond via thermal initiation by AIBN using 2-pyridyl methallylsulfone 257 (Table 1 entry
3) equally resulted in low yields of the desired compound.
Attention was therefore focused on investigating radical methallylation using
triethylborane as an initiator. Precedent by Brown and co-workers on reaction of organoboranes
with alkyl, benzylic and allylic iodides in the presence of oxygen123 to generate radicals revealed
that organoboranes are excellent sources of free radicals for use in chain reactions in the presence
of oxygen (Scheme 40). Subsequently, these initiation conditions were developed by Oshima and
coworkers and have been very widely employed in subsequent years.124

Scheme 40. Et3B-induced radical reaction by Brown and co-workers
Most recently, Crich and co-workers demonstrated in their synthesis of the 4′-C-alkyl
paromomycin derivative 312, that the key C−C bond forming step was possible by employing allyl
phenylsulfone 311 and the iodo derivative 310 in α,α,α trifluorotoluene with initiation by
triethylborane and air (Scheme 41).125 α,α,α-Trifluorotoluene was selected as an environmentally
friendly radical-compatible solvent for such transformation and the reaction was successfully
conducted on scales of up to 100 g.126
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Scheme 41. Et3B-induced radical transformation by Crich and co-workers
Therefore, methallylation using 2-pyridyl methallylsulfone 257 and triethylborane127 as
initiator in the presence of oxygen at room temperature was attempted (Table 18, entry 4).
However, the construction of the C-C bond under such conditions proved inefficient and resulted
in the formation of significant quantities of the simple reduction product 306. Subsequently,
chemical initiation with AIBN was investigated with the methallyltri-n-butylstannane derivative
305 (Table 18, entry 5).128 However, the methallylated compound 235 proved rather difficult to
obtain in pure form.
2.1.3.2.2

Visible-light

mediated

C-C

bond

formation

using

(fac-Ir(ppy)3)

and

methallylsulfone
Stephenson and co-workers reported a visible-light mediated reductive dehalogenation of
unactivated carbon–iodide bonds using photocatalyst fac-Ir(ppy)3 having a strong reduction
potential of -2.19 V (versus SCE) under mild conditions. Such photocatalytic transformations
required the use of tributylamine as a sacrificial electron donor and either the Hantzsch ester or
formic acid as hydrogen atom donor (Scheme 42).130
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Scheme 42. Visible-light mediated reductive dehalogenation of unactivated alkyl, alkenyl or aryl
iodides
In the light of Stephenson’s work, visible-light mediated methallylation using (facIr(ppy)3), 2-pyridyl methallylsulfone 257 and tributylamine in acetonitrile was attempted and gave
compound 235 with an optimum yield of 68% (Table 18 entry 7).
The proposed mechanism for this photocatalyzed transformation is shown in (Scheme 43).
Thus, visible-light-excitation of fac-Ir(ppy)3 results in the radical cleavage of carbon–iodide bond
on compound 234 through a single electron transfer (SET) process. The glucopyranoside radical
315 generated then directly adds onto the 2-pyridyl methallylsulfone 257 thereby generating
compound 235 and 2-pyridyl sulfonyl radical 316. Subsequently, the excited fac-Ir(ppy)3 form of
the catalyst is reduced to its ground state by a sacriﬁcial electron donor such as tributylamine. The
carbon radical 315 generated can as well undergo hydrogen atom abstraction probably from the
methallysulfone 257 to give the reduced product 306.
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Scheme 43. Proposed mechanism for the visible-light mediated formation of compound 235
using fac-Ir(ppy)3 as a catalyst
2.1.3.3 Construction of the bicyclic scaffold
The oxidation of 235 under Parikh-Doering conditions112 gave ketone 236, which on
treatment with vinyl magnesium bromide afforded allylic alcohol 236 as a single diastereoisomer.
The generation of compound 236 as a single diastereoisomer was consistent with the earlier
observation on the corresponding methyl glycoside (Scheme 44).113

Scheme 44. Synthesis of the bicyclic intermediate 238
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As previously, the configuration of compound 237 was confirmed by NOE studies that
revealed the existence of NOE correlations between H4′ and H3 and, H9 and H5 (Figure 24).

Figure 24. NOE correlations between H4′ and H3 and H5 in compound 237
The requisite bicyclic scaffold was then obtained by ring closing methathesis in excellent
yield and it functioned as with the methyl glycoside (Scheme 29)
2.1.3.4. Stereoselective synthesis of oxiranes 241 and 317

Scheme 45. Derivatization of 241 and 317 from intermediate 240
As previously observed with the methyl glycoside, the regioselective allylic oxidation of
238 with SeO2 in 1,4-dioxane at 80 oC gave enone 239 in 70% yield.116 Subsequently, the regioand stereoselective reduction of the enone derivative 239 under Luche’s conditions,117 resulted in
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the isolation of the allylic alcohol 240 in 86% yield as a single diastereoisomer as previously
observed with the methyl glycoside (Scheme 32).
Functionalization of the alkene group in compound 240 was then attempted next to access
the epoxide derivative 312. Thus, benzylation followed by epoxidation on compound 240 using
m-CPBA118 at room temperature in 1,2 di-chloromethane furnished oxirane 315 in 86% yield
(Scheme 45). Mechanistically, the observed stereochemical outcome of this reaction suggests that
in the indicated half-chair conformation, the epoxidation preferentially occurs from the bottom
face of the alkene which is less sterically hindered (Scheme 46).

Scheme 46. Proposed mechanism for epoxidation leading to compound 317
The assigned structure of 317 is consistent with the NOE studies that revealed the existence
of the NOE correlations between H9 and the axial C8-methyl group as well as the benzylic
methylene resonances of the 4-O-benzyl ether. Similarly, an NOE correlation of the axial C8
methyl group to the benzylic methylene resonances of the 7-O-benzyl ether was observed (Figure
25).
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Figure 25. NOE correlations between H9, C8-methyl group and the benzylic methylene
hydrogens in compound 317
The regio- and stereoselective epoxide ring opening of 317 was then investigated under
various conditions intended to involve SN2-attack of the external nucleophile at the secondary site.
As summarized in (Table 19), subjection of the epoxide 317 under mild conditions or
thermal/microwave conditions proved unsuccessful as they led to recovery of starting materials or
decomposition of the epoxide.
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Table 19. Attempted regioselective epoxide ring opening under various conditions

Reverting to the H-bonded directed epoxidation achieved with the methyl glycoside
(Scheme 33), epoxide 241 was obtained in 83% yield as a single diastereoisomer, via treatment of
compound 240 with m-CPBA at room temperature in 1,2 di-chloromethane (Scheme 45).118
Similar to the observations made with the methyl glycoside, the relative configuration of epoxide
241 was confirmed by the observation of strong NOE correlations of H9 with the C8-methyl group,
H3, H5 and H7 (Figure 26).

80

Figure 26. NOE correlations of H9, C8-methyl group, H3, H5 and H7 in compound 241
Regioselective opening of 241 was attempted under a variety of acidic conditions (Table
20). Thus, in dry solvents (Table 20, entry 2) the enone 239 was isolated as the only product.
Reactions conducted under aqueous acidic conditions without excessive heating proved
unsuccessful due to the insolubility of epoxide 241 (Table 20, entries 6 and 7). Finally, consistent
with the studies on the methyl glycoside (Scheme 34) regio- and stereoselective access to the
desired tetraol 242 was realized by employing sulfuric acid as catalyst in a homogeneous solution
mixture of 1,4-dioxane:water 1:3 at 65 oC (Table 3, entry 5). Thus, tetraol 242 was obtained in
50% yield alongside 45% of the enone 239.
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Table 20. Regioselective epoxide ring opening under various acidic conditions

Consistent with the previous observations made in the establishment of the relative
configuration of the methyl tetraol 289, NOE studies on tetraol 242 revealed the presence of strong
NOE correlations of H9 with H3, H5 and H7. Moreover, NOE correlation of the axial C8 methyl
group to H6axial was also observed (Figure 27).
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Figure 27. NOE correlations between H9, H3, H5 and H7 in compound 242
2.1.3.5 Deprotection of 242 to give 20
The synthesis of bradyrhizose 20 was completed by hydrogenolysis of the benzyl ethers
over 10% Pd/C in methanol in quantitative yield (Scheme 47).48

Scheme 47. Completion of synthesis
2.1.4 Comparison of 1H and 13C spectral data of bradyrhizose
Upon completion of the synthesis of compound 20, a comparison of the NMR spectral data
with the reported literature data was carried out as outlined in (Table 21).
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Table 21. Comparison of 1H and 13C spectral data of bradyrhizose synthesis with literature
syntheses

The spectral data of the synthesized bradyrhizose were consistent with the literature data
from Yu and Lowary syntheses

48,50

as an inspection of the 1H NMR spectra of 20 in D2O with

HOD as an internal standard revealed that the structure of bradyrhizose give rise in solution to an
equilibrium mixture consisting of two different pyranose forms a and b, the regioisomer c, and the
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furanose forms d and e (Table 21). The anomeric signals of H-1 at δH 4.61 and 5.21 ppm
corresponds to the - and -anomers of pyranose forms a and b with 3JH1,H2 coupling constants of
8.1 and 4.3 Hz, respectively. The H-1 anomeric signals observed at δH 5.05 and 5.25 ppm
corresponds to the - and -anomers of furanose forms d and e, respectively, while the anomeric
signal observed at 5.04 ppm is attributed to the regioisomeric form c. As was previously
highlighted in Chapter 1, the deviations in both the 1H and

13

C NMR spectra chemical shifts

observed in (Table 21) results from the use of different internal standards.
2.2

Conclusions
In summary, an effective synthesis of bradyrhizose has been developed from D-glucose in

14 steps and 6% overall yield (Scheme 48). This synthesis differs from the known literature
methods as it involves the fusion of the bicyclic ring onto an existing pyranose framework as
opposed to the fusion of a pyranose ring onto a preformed inositol skeleton. It is worth noting that
this synthesis also involves fewer steps with minimal usage of protecting groups in comparison to
the literature syntheses described in Chapter 1.

85

Scheme 48. Synthesis of bradyrhizose 20 from D-glucose 229
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CHAPTER 3 STEREOSELECTIVE SYNTHESIS OF THE EQUATORIAL
GLYCOSIDES OF 3-DEOXY-D-MANNO-OCT-2-ULOSONIC ACID
3.1

Background
As a virulence factor, the bacterial capsule is an important factor in the propagation of

bacterial infections by Gram-negative in humans. KDO, a constituent of the bacterial capsule, has
been found to commonly form (2→3) or (2→6) equatorial glycosidic linkages with other sugar
residues.71-76 Therefore, the development of stereocontrolled synthetic methods for accessing
equatorial KDO glycosides in high yields and selectivity as well as use of such pure glycosides as
candidates in the development of antibacterial vaccines is of importance. As discussed in chapter
1, very few selective glycosylation methods have been reported for synthesizing β-KDO
glycosides, with only few cases demonstrating high selectivity, hence there is a need to develop
an efficient method.
Crich and co-workers demonstrated that excellent equatorial selectivity was attainable in
the pseudaminic acid series with donor 219, that was shown to take up the least reactive and most
equatorially selective conformation about its C6-C7 bond (Figure 28).98

Figure 28. Pseudaminic donor 219 with a predominant tg conformation about its exocyclic C6C7 bond
Recognition of the pseudo-enantiomeric relationship between pseudaminic acid 228 and 3deoxy-D-manno-oct-2-ulosonic acid (KDO) 102 (Figure 19), leads to the prediction that KDO
donors will populate the tg conformation about their exocyclic 6,7-bond and will display excellent
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equatorial selectivity under the standard conditions used by Crich and co-workers.98 Accordingly,
the synthesis of KDO donors with strategic protecting groups and their use in the stereocontrolled
synthesis of KDO glycosides are the focus of this chapter.

Figure 19. Pseudo-enantiomeric relationship of pseudaminic acid 228 and KDO 102
3.2

Results and discussion

3.2.1 Synthesis of a key KDO acetonide intermediate
The synthesis of KDO in general is relatively trivial and many syntheses have been
reported in the literature. The synthesis of KDO derivative 326 from D-mannose 323 as reported
by Chai and co-workers was adopted for these studies as it provides the targeted KDO derivative
in a minimum number of steps that use practical chemistry.131 Thus, isopropylidenation of 323
with 2,2-dimethoxypropane in the presence of a catalytic amount of p-TsOH monohydrate gave
324 in 95% yield (Scheme 50). The TBS protected phosphonate ester131 322 was prepared
according to (Scheme 49) and utilized in the HWE condensation with 324 in the presence of tBuOLi in THF yielding 325 in 84% yield. TBAF mediated cleavage of the silyl ether followed by
cyclization afforded compound 326 in 76% yield.131 Subsequently, acetylation on 326 in the
presence of pyridine and acetic anhydride gave 327 in good yield (Scheme 50).
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Scheme 49. Preparation of phosphonate ester 322

Scheme 50. Preparation of KDO key intermediate 327 from D-mannose
3.2.2 Synthesis of KDO thioglycosyl donors
Attention was then turned to the synthesis of KDO thioglycosyl donors using compound
327 as the precursor, and to establishing the conformation about their exocyclic bond by
measurement of the 3J6,7 coupling constant. Thus, thioglycoside 328 was obtained in 84% yield
from compound 327 by treatment with 1-adamantanethiol in the presence of BF3·Et2O (Scheme
51). Adamantanethiol was selected for this reaction because it presents less odor problems and
most importantly, it poses good electron donating properties.132
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Scheme 51. Preparation of thioglycoside 328 and its H6,H7 coupling constant
Inspection of the 1H NMR spectrum of compound 328 revealed a 3J6,7 coupling constant
of 8.3 Hz (Scheme 51). This value was comparable to those obtained previously by Unger and coworkers in ammoniated KDO salts 99 as well as in the pseudaminic acid series by Crich and coworkers.98 This observation confirmed the existence of a predominant tg conformation about the
exocyclic bond in the thioglycoside 328. Thioglycosyl donor 330 was obtained by a two-step
reaction sequence involving cleavage of the acetonide groups with aqueous trifluoracetic to give
tetraol 329 and acetylation of 329 with an overall 96% yield (Scheme 52).

Scheme 52. Preparation of KDO thioglycosyl donor 330 from the acetonide derivative 328
The 1H NMR spectrum of compound 330 also revealed a 3J6,7 coupling constant of 8.6 Hz,
thus confirming the predominant tg conformation of its exocyclic bond.
Next, thioglycoside 331 was obtained in excellent yield by treating tetraol 329 with benzyl
bromide and sodium hydride in dimethylformamide (Scheme 53). A 3J6,7 coupling constant of 10.0
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Hz observed in the 1H NMR spectrum of compound 331 demonstrated the predominant tg
conformation about its exocyclic bond.

Scheme 53. Synthesis of benzylated thioglycoside 331 from tetraol 329
Subsequently, KDO thioglycosyl donor 334 was obtained from tetraol 329 via selective
silylation of the primary alcohol to give 332, followed by installation of the di-tert-butylsilylene
acetal in compound 333, and eventually benzoylation, all in excellent yields (Scheme 54). As
expected, the 3 JH6,H7 coupling constant of 0.7 Hz in the 1H NMR spectrum of 334 confirmed that
the 6,7-bond in the bicyclic donor 334 is locked in an approximate gg conformation.

Scheme 54. Synthesis of a silyl protected KDO donor 334
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3.2.3 Preparation of acceptors
Turning to acceptor preparation, the selection of acceptors 338, 341, 346, 351, 360 and 368
as models having free hydroxyl group at either C-3 or C-6 positions was based on their presence
in various bacterial KDO equatorial glycosides as discussed in chapter 1. Methyl glycosyl acceptor
338 was obtained from methyl α-D-glucopyranoside 335 via installation of a benzylidene acetal in
336 followed by benzylation and finally selective cleavage of the benzylidene acetal, with modest
yields observed in all the steps (Scheme 55).133

Scheme 55. Preparation of the methyl glucosyl acceptor 338
As previously reported in the literature, methyl α-D-mannoside 339 was converted to
benzylidene acetal derivative 340. Reaction of 340 with tetrabutylammonium hydrogen sulfate,
benzyl bromide and aqueous sodium hydroxide in dichloromethane at reflux selectively afforded
the 2-O-benzyl ether 341 in 89% yield (Scheme 56).134

Scheme 56. Synthesis of mannosyl acceptor 341 from D-mannoside
Ribofuranosyl acceptor 346 was obtained in four steps from methyl β-D-ribofuranoside
342.

Thus,

treatment

of

methyl

β-D-ribofuranoside

342

with

1,3-dichloro-1,1,3,3-

tetraisopropyldisiloxane led to selective protection of C3-OH and C5-OH resulting in compound
343. Subsequent benzylation of compound 343 followed by cleavage of the silyl protecting group
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with TBAF gave diol 345. Selective silylation of the primary C5-OH with TBSCl then gave
acceptor 346 in 87% yield.135

Scheme 57. Synthesis of the methyl ribofuranosyl acceptor 346
Methyl α-L-rhamnosyl acceptor 351 was obtained by a reaction sequence involving
treatment of methyl rhamnoside 347 with triethyl orthoacetate in the presence of 10camphorsulfonic acid to yield to the 2,3-ortho ester 349 as a mixture of diastereoisomers.
Benzylation at the C4-OH position and acid-catalyzed regioselective ring opening of the ortho
ester then afforded the desired acceptor 351 in 93% yield (Scheme 58).136

Scheme 58. Preparation of acceptor 351
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Starting from D-glucosamine hydrochloride 352, methyl 2-deoxy-2-azido-4,6-Obenzylidene-α-D-glucopyranoside 360 was synthesized using a known literature protocol.137 Thus,
D-glucosamine hydrochloride was treated with methyl chloroformate 353 in the presence of

potassium carbonate to give carbamate 354, which was dissolved in methanolic hydrogen chloride
solution and heated under reflux to give 355. Installation of the benzylidene acetal followed by
cleavage of the carbamate protecting group gave 358. Azidation in the presence of triflyl azide
with subsequent selective cleavage of the benzylidene acetal gave the desired acceptor 360 in 83%
yield (Scheme 59).

Scheme 59. Synthesis of acceptor 360
The galactosyl 368 was obtained in 81% yield from intermediate 367 by adopting the
synthetic protocol used in the synthesis of acceptor 360 (Scheme 60).

94

Scheme 60. Preparation of galactosyl acceptor 368
3.3 Glycosylation reactions of KDO thioglycosyl donors
Glycosylation reactions were conducted under the standard conditions employed by Crich
and co-workers97-98 for ease of comparison. Thus, activation of the donors was done in a 2/1
dichloromethane/acetonitrile solvent system at -78

o

C using N-iodosuccinimide and

trifluoromethanesulfonic acid in the presence of acid-washed 4 Å molecular sieves. Acid-washed
molecular sieves were used to improve on yield and selectivity. Reaction mixtures were quenched
by the addition of triethylamine at −78 °C before warming to room temperature and workup. All
the coupling reactions afforded equatorial KDO glycosides in excellent yields and selectivity as
outlined in (Figure 29).
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Figure 29. Synthesis of equatorially linked KDO glycosides
3.3.1 Assignment of configuration for coupled KDO glycosides
The assignment of anomeric configuration of KDO glycosides can be achieved by
measurement of the 3JC-1/H-3ax heteronuclear coupling constant, as long as the KDO pyranose ring
exists in the 5C2 chair conformation.99,138 The configurational assignment using a 3JC-1/H-3ax
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heteronuclear coupling constant is based on the correlation of coupling constants with torsional
angle.139 As such, KDO glycosides with equatorial linkages have a 3JC-1/H-3ax value of 5.0−7.0 Hz,
while the axially linked KDO glycosides have a value of ≤1.0 Hz. This difference observed for the
3

JC-1/H-3ax coupling constants can be rationalized by a Karplus relationship140 in which the dihedral

angle of C1-C2-C3-H3ax of the equatorial KDO anomer 378 is 180o while that of the axial KDO
anomer 379 is 60º (Figure 30).

Figure 30. Karplus relationship showing the dihedral angle of equatorial and axial KDO
glycosides and their corresponding coupling constants
The 3JC-1/H-3ax values of KDO glycosides were determined using HSQMBC experiments as
illustrated in Figure 31. Thus, two complementary in-phase (IP) and anti-phase (AP) spectra were
acquired from the HSQMBC experiments using data set points of 4096 x 512 with the inter-pulse
delay optimized to 8 Hz, and then the difference spectrum was obtained to provide spin-state
HSQMBC spectra from which the 3JC-1/H-3ax values were measured by comparing the relative
displacement of a given cross-peak in both spectra (Figure 31).141

97

98

Figure 31. Determination of the configuration of KDO glycosides using the IPAP-HSQMBC
experiment
Consistent with the literature findings, analysis of 3JH,H coupling constants around the
pyranoside ring of the synthesized KDO thioglycosyl donors employed in this study revealed that
donors 330, 331, and 334 adopted the 5C2 chair conformation. However, minor distortion in the
chair conformation of compound 328 and its glycosides caused by the cis-fused 4,5-O-acetonide
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group was evident from a 2JH3eq,H3ax geminal coupling constant of 15.6 Hz, which contrasted with
that of ~12.0 Hz seen in all other thioglycoside donors and their glycosides (Table 22 and 23).
Table 22. Chemical shifts of the synthesized KDO thioglycosyl donors

100

Table 23. 2JH,H and 3JH,H coupling constants around the pyranoside ring of the synthesized KDO
thioglycosyl donors

Glycosylation of the peracetylated thioglycoside donor 330 with the methyl 2,3,4-tri-Obenzyl-α-D-glucopyranoside 338 afforded the desired equatorial glycoside 369 in 89% yield as a
single anomer with a 3JC‑1/H‑3ax value of 6.8 Hz (Figure 29). In the same manner, coupling of donor
338 with mannopyranosyl acceptor 341, ribofuranosyl acceptor 346, rhamnopyranosyl accceptor
351, glucopyranosyl acceptor 360, and galactopyranosyl acceptor 368 afforded the expected
equatorial glycosides 370-374 each as single equatorial anomers in excellent isolated yield. All
products were found to display 3JC-1/H-3ax coupling constants ranging from 6.7 to 7.0 Hz. The glycal
ester 378 was also isolated in minor amounts from these coupling reactions.
Of note is that the glycosylation reaction involving use of peracetylated thioglycoside
donor 330 with the ribofuranosyl acceptor 346 was accompanied by cleavage of the primary silyl
ether with no competing glycosylation at the primary position of the acceptor 346 observed. This
observation suggested that the silyl cleavage occurred during workup and not in the course of the
glycosylation.
Coupling of 4,5;7,8-di-O-isopropylidene-protected donor 328 to the mannosyl acceptor
341 resulted in the formation of the equatorial glycoside 375β in 86% isolated yield with a
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JC‑1/H‑3ax coupling constant of 6.3 Hz. The α-anomer of 375 was also isolated in 10% yield with a

3

JC‑1/H‑3ax coupling constant of <1.0 Hz. Since the tg conformation predominates in the side chain

of donors 328, 330 and 331 (Figure 29), it would be expected that all the three systems display
high equatorial selectivity in the coupling reactions. The reduced selectivity observed with donor
328 is likely the result of the distortion of the pyranoside ring imposed by the presence of the cisfused 4,5-O-acetonide group. This distortion is evident by a change in the 2JH3ax, H3eq coupling
constant outlined in (Table 22). Indeed, the distortion of the 5C2 chair conformation of related
KDO glycosyl donors by cyclic isopropylidene at O-4/O-5 positions has been shown in the
literature as an effective means of achieving α-selectivity in glycosylation reactions (Scheme
61).76, 142

Scheme 61. Enhancement of α-selectivity by distortion of the 5C2 chair conformation of donor
380
Gratifyingly, coupling of the perbenzylated donor 331 to the glucosyl acceptor 360 gave
the desired equatorial glycoside 376 in 83% isolated yield. It was characterized by a 3JC-1/H-3ax
value of 6.9 Hz. Both the peracetylated donor 328 and the perbenzylated donor 331 show excellent
equatorial selectivity, suggesting that other donors containing different combinations of benzyl
ether and acetate esters will also be good precursors for the selective synthesis of equatorial
glycosides of KDO from bacterial capsular polysaccharides.
Yang and co-workers demonstrated that the closely related 5,7‐O-silylene‐protected KDO
thioglycosides are excellent donors for the formation of axial glycosides (Scheme 62).143 They
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hypothesized that this selectivity arose from steric shielding of the β-face of the donor imposed by
the bulky 5,7-di-O-tert-butylsilylene substituent.

Scheme 62. Synthesis of axial KDO glycosides using 5,7-di-O-tert-butylsilylene protected donor
383
Consistent with the Yang findings, coupling of 5,7-di-O-tert-butylsilyl donor 334 with the
acceptor 360 gave the axial glycoside 377, which had a 3JC‑1/H‑3ax value of <1 Hz, in 87% isolated
yield. In addition to the steric shielding of the β-face suggested by Yang and coworkers, the αselectivity of donor 334 is likely a result of imposition of the gg conformation of the side chain by
the 5,7-O-silylene acetal. Moreover, cleavage of the silyl group was consistent with the
observation made during the formation of glycoside 371.
The β-selectivity observed in the coupling reactions of KDO donors 328, 330 and 331
results from the protecting groups ability to favor the tg conformation of the KDO side chain in
which the electron withdrawing eﬀect of the C6−O6 bond is maximized. This conformation
stabilizes the covalent axial glycosyl triflate or its functional equivalent the contact ion pair 386,
or the glycosyl nitrilium ion 387, and so the β-face attack of the covalent axial glycosyl triflate by
the acceptor results in formation of the equatorial KDO glycosides.
On the other hand, when the protecting group imposes the gg conformation on the side
chain, a looser solvent separated ion pair 388 is populated to a greater extent, which results in α-
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selectivity, because the acceptor approaches the SSIP from the α-face to form the
thermodynamically stable axial KDO glycosides (Scheme 63).

Scheme 63. Mechanistic hypothesis outlining the importance of side chain conformation on
reactivity and selectivity of KDO glycosyl donors
3.4

Conclusions
In conclusion, the vital lessons learnt from recent work by Crich and co-workers on studies

involving the role of configuration and conformation on the reactivity and selectivity of
pseudaminic acid glycosyl donor led to the prediction that KDO donors would be highly
equatorially selective in glycosylation reactions conducted under standard conditions as long as
the KDO protecting group favors the predominant tg conformation of the KDO side chain. These
predictions were borne out by the experimental findings that revealed excellent equatorial
selectivity with the peracetyl and perbenzyl-protected KDO donors 330 and 331, and to a lesser
degree by the 4,5;7,8-di-O-isopropylidene-protected donor 328. As would be expected, a change
in the side conformation to the gg conformation in donor 334 led to a reversal in selectivity. This
concept provides an effective and selective method for the synthesis of KDO equatorial glycosides
similar to those found in numerous pathogenic bacteria.
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CHAPTER 4 PROGRESS TOWARDS A STEREOCONTROLLED CONVERGENT
SYNTHESIS OF A PENTASACCHARIDE CONTAINING THE TETRASACCHARIDE
REPEATING UNIT OF K. kingae TYPE C CAPSULAR POLYSACCHARIDE
4.1

Background
Isolated in 1960, Kingella kingae is a Gram-negative bacterium belonging to the

Neisseriaceae family. It is commonly known to cause pediatric bacteremia, osteomyelitis and
septic arthritis in children aged 6 to 36 months. This pathogen is carried asymptomatically in the
oropharynx and spreads by close interpersonal contact. The colonization of the human mucosae
by the bacterium occurs via its attachment to the respiratory epithelium using surface factors such
as the type 4 pili, the trimeric autotransporter protein (Knh), and the polysaccharide capsule. The
attachment enables the bacterium to penetrate into the host blood stream where its replication and
spread to other sites in the human body occurs.144, 71, 72 Currently, the containment of K. kingae
infections is through the administration of a wide array of antimicrobial drugs including β-lactam
antibiotics that have been developed for treating infections caused by other bacterial pathogens.145
As previously discussed in chapter 1, three structurally distinct K. kingae polysaccharide capsules
have been identified in which 3-deoxy-D-manno-oct-2-ulosonic acid forms β-(2→3)-linkages with
2-acetamido-2-deoxygalactose and D-ribose in capsules a and c respectively, while in capsule b,
it forms β-(2→6)-linkages with 2-acetamido-2-deoxyglucose.71-72
There is a continuous need for the development of capsular polysaccharide-based vaccines
against infections caused by bacterial pathogens; such efforts are often limited by the scarcity of
pure bacterial isolates as well as the complexity of the bacterial glycan structures. As a result,
selective chemical syntheses have been developed as an alternative solution for synthesis of such
vaccine candidates.75 In continuation of this quest, a stereocontrolled chemical synthesis of a
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pentasaccharide containing the K. kingae type c capsular polysaccharide repeating unit capped by
a suitable linker for conjugation was planned. The polymer of Rib-β-D-(1→2)-Rib-β-D-(1→2)Rib-β-D-(1→4)-KDO-β-D-(2→O)-linker containing a hydrophobic linker equipped with a
terminal primary amine group 403 was targeted (Figure 32).

Figure 32. K. kingae capsule c repeating unit 119 and its derivative 403 containing a linker
Building on the results presented in chapter three, a similar trend in selectivity outcome
was predicted to be observed for the construction of the (2→O-linker) equatorial glycosidic
linkage present in 403 by employing the equatorially selective peracetylated KDO donor 330
(Figure 33).

Figure 33. Equatorially selective peracetylated donor 330
Similarly, the stereocontrolled construction of β-(1→2) and β-(1→4) glycosidic linkages
in compound 403 (Figure 32) can be straightforwardly achieved using ribofuranosyl donors

106

possessing acyl-protecting group on O2. 1,2 trans-β-Glycosidic linkages in pyranose or furanose
systems are known to be stereoselectively formed with the help of stereodirecting participation by
C2 acyloxy groups in such systems.146 For example, Gorin and co-workers demonstrated that
coupling of β-D-ribofuranosyl bromide 405 and acceptor 406 under the mediation of silver oxide
resulted in the formation of ribofuranoside 407 (Scheme 64).147

Scheme 64. Synthesis of a β-ribofuranoside via neighboring participation of the p-nitrobenzoyl
group
Therefore, it is anticipated that the neighboring group participation by an acyl group can
be used to facilitate the formation of a predominant 1,2 trans-β-glycosidic linkage. Progress
towards a stereocontrolled convergent synthesis of the pentasaccharide 404 is described in this
chapter.
4.2 Results and discussion
4.2.1 Retrosynthesis of compound 404
Rather than targeting the exact repeating unit, which is a tetrasaccharide, an extended
pentasaccharide 404 was targeted (Scheme 65). This pentasaccharide was selected as the target
for synthesis because it contained two KDO equatorial linkages, one from a primary alcohol
(linker) and one from a secondary alcohol (ribose); it is therefore a better test of the synthetic
methodology developed for synthesis of equatorial KDO linkages.
Pentasaccharide 404 can be obtained from the protected derivative 399 via a sequence of
reactions involving desilylation, benzylidene acetal cleavage, deacetylation and debenzylation
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(Scheme 65). Compound 399 can be formed from a stereoselective convergent 3+2 glycosylation
approach by employing trisaccharide acceptor 398 and the ribofuranosyl imidate donor 392.
Acceptor 398 can be obtained from 397 under Zemplén deacetylation conditions. As a key
intermediate, masked acceptor 397 can be obtained by first performing the assembly of the β(1→4)-linkage using benzylidene protected KDO acceptor 394 and ribofuranosyl imidate donor
393, followed by elongation at O2′ of 396 using donor 393 (Scheme 66).
The formation of imidate donor 392 can be realized by first forming the β-(2→3)-linkage
using the equatorially selective peracetylated KDO donor 330 and ribofuranosyl acceptor 389
under well-established standard glycosylation conditions. Subsequent selective cleavage of the
allyl ether followed by installation of the imidate group should result in the desired donor 392
(Scheme 66).
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Scheme 65. Retrosynthetic analysis of the convergent 3 + 2 synthesis of pentasaccharide 404

Scheme 66. Retrosynthetic analysis of the synthesis of trisaccharide acceptor 398 and
ribofuranosyl donor 392.
4.2.2 Preparation of KDO donor 330 and acceptor 398
The synthesis of pentasaccharide 404 began with preparation of key KDO donor 330,
which was achieved as described in chapter three. The preparation of acceptor 398 from 330
required the use of 5-azido-1-pentanol 409 as an acceptor. This acceptor was readily made in 73%
yield by treatment of the commercial amino alcohol 408 with triflyl azide and copper sulfate
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(Scheme 67).148 As would be expected, excellent equatorial selectivity and a 3JC-1/H-3ax value of 6.7
Hz observed for the glycoside in the glycosylation step were consistent with the observations
described in chapter three. Deacetylation and subsequent selective protection of the C6 hydroxyl
with tert-butyldimethylsilyl chloride afforded compound 412 in good yield. Regioselective
installation of the benzylidene group on O4 and O6 under acidic conditions then furnished the
targeted KDO acceptor 398 in 71% yield (Scheme 67).

Scheme 67. Preparation of KDO acceptor 398 from donor 330
4.2.3 Preparation of the ribofuranosyl imidate donor 393 and the ribosyl acceptor 389
Attention was then focused on the synthesis of ribofuranosyl derivative 393 and acceptor
389. Starting from D-ribose, compound 417 was obtained in four steps (Scheme 68). Thus, Fischer
glycosylation of allyl alcohol with D-ribose 413 followed by selective silylation on C3-OH and
C5-OH of 414 with a cyclic disiloxane group gave 415. Subsequent acetylation at C2-OH followed
by cleavage of the silyl protecting group with TBAF gave diol 417. Treatment of diol 417 with
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sodium hydride and benzyl bromide yielded to an inseparable mixture of 418 and 419 that were
carried to the next step, which involved selective cleavage of the allyl ether using palladium
chloride149 yielding to 421 and 420 in a ratio of 9:1 as determined from the reaction mixture. The
verification of the intramolecular acetyl group migration to C3 position of 417 at the benzylation
step was confirmed by 1D and 2D spectral analysis of the inseparable mixture of 421 and 420.
Thus, a comparison of the proton and carbon chemical shifts observed in the mixture in relation to
the 1D and 2D spectra of 417, revealed acetyl migration leading to compound 421 (Table 23).
Unfortunately, the separation of 420 and 421 could not be achieved in a timely manner due to the
COVID-19 outbreak. Hypothetically, treatment of form of 420 with trichloroacetonitrile and DBU
would furnish the desired imidate donor 393. In parallel, ribofuranosyl acceptor 389 was obtained
in 80% yield via treatment of diol 417 with tert-butyldimethylsilyl chloride and imidazole.

Scheme 68. Synthesis of acceptor 389 from diol 417 and the proposed preparation of imidate
donor 393 from 420
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Table 24. Comparison of 1H and 13C chemical shifts of a mixture of compounds 420 and
421 in relation to compound 417

4.3 Intended completion of syntheses
Unfortunately, the intended syntheses had to be curtailed because of the shutdown
following the COVID-19 outbreak. The intended route is described here in the hope that it may be
of use to a later worker.
4.3.1 Preparation of key trisaccharide acceptor 398
Future directions will involve preparation of acceptor 398 from donor 393 and acceptor
394 (Scheme 69). It is predicted that BF3.Et2O mediated coupling of donor 393 with acceptor 394
will lead to the stereoselective formation of the β-(1→4)-linkage in compound 395. It is reasoned
that the stereoselective formation of the β-linkage will be facilitated by neighboring group
participation of the C2 acetyl group in donor 393. Deacetylation using sodium methoxide in
methanol will furnish acceptor 396, which then will be coupled to imidate donor 393 under the
mediation of BF3.Et2O resulting in disaccharide 397. Again, stereodirecting participation by the
C2 acetyl group in donor 393 is expected to aid in the stereoselective formation of the β-(1→2)-
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linkage in compound 397. Subsequent cleavage of the acetyl group will furnish the desired
trisaccharide acceptor 398.

Scheme 69. Proposed preparation of trisaccharide acceptor 398
4.3.2 Preparation of key imidate donor 392
Based on the work described in chapter three, it is envisioned that the masked donor 390
containing a β-(2→3)-linkage would be stereoselectively achieved through the glycosylation of an
equatorially selective peracetylated KDO thioglycosyl donor 330 with ribofuranosyl acceptor 389
under the mediation of NIS/TfOH at -78 oC in a 2/1 CH2Cl2/CH3CN solvent system (Scheme 70).
Cleavage of the allyl ether in the presence of palladium chloride149 followed by installation of the
imidate group at the anomeric position using DBU and trichloroacetonitrile will furnish the desired
donor 392.
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Scheme 70. Proposed stereoselective synthesis of 390 and preparation of imidate donor 392
4.3.3 Stereocontrolled construction of the β-(1→2)-linkage via a convergent 3+2
glycosylation approach
Stereoselective convergent 3+2 glycosylation of ribofuranosyl donor 392 and trisaccharide
acceptor 398 under the activation of BF3.Et2O in dichloromethane is expected to lead to the
formation of pentasaccharide 399 containing the new β-D-Rib-(1→2)-β-Rib linkage. Subsequent
global deprotection (desilylation, benzylidene cleavage, removal of the acetyl-protecting groups
under Zemplén conditions and debenzylation) would be expected to successfully yield to the
compound 404 containing the tetrasaccharide repeating unit of K. kingae type c capsular
polysaccharide (Scheme 71).
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Scheme 71. Proposed preparation of the pentasaccharide via a stereocontrolled convergent 3+2
glycosylation approach
4.5 Conclusion
In summary, convergent synthesis of the pentasaccharide 404 containing the
tetrasaccharide repeating unit of the capsular polysaccharide of K. kingae type c has been designed
and partially accomplished. Thus, the use of peracetylated thioglycoside donor in glycosylation to
furnish the desired β-KDO linkage, applying the concept of the side chain control of reactivity
discussed in chapter three, yielded to an equatorially-linked KDO glycoside in good selectivity
and yield. Additionally, key donors and acceptors were synthesized in good yields by employing
practical chemistry. Such results clearly demonstrate that with the right trisaccharide acceptor and
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donor at hand, a stereocontrolled convergent 3 + 2 glycosylation mediated by a Lewis acid at low
temperature, followed by global deprotection would be anticipated to furnish the desired
pentasaccharide.
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CHAPTER 5. CONCLUSIONS
The unusual structure of bradyrhizose coupled with its immunologically silent nature
stimulated an interest in its chemical synthesis. An effective and short synthesis was developed in
which bradyrhizose was synthesized in 14 steps and 6% overall yield from D-glucose. The
synthesis involved the elaboration of a trans-fused carbocyclic ring onto the pre-exisiting
glucopyranose framework with key steps involving photocatalyzed radical extension of the
glucopyranose side chain, construction of the bicyclic framework via ring closing metathesis,
regioselective allylic oxidation, regio- and stereoselective Luche reduction, hydroxy-directed
epoxidation and regio- and stereoselective acid-catalyzed epoxide opening at the more substituted
position. The final step involved global deprotection through hydrogenolysis. This synthesis is
significantly shorter than the two previous syntheses.
The widespread occurrence of equatorial glycosides of KDO in the capsular
polysaccharides of numerous pathogenic bacteria, coupled with the challenges encountered in
isolation of such glycosides in pure form, necessitates the need to synthesize them in a
stereocontrolled fashion. However, there exists few methods for accessing β-KDO glycosides and
only a few examples display high level of β-selectivity. Conformational analysis of the likely side
chain conformation of KDO, and analogy with the pseudoenantiomeric pseudaminic acid,
predicted the equatorially selective coupling of peracetyl KDO donor to typical acceptors at low
temperature. This hypothesis was borne out by experiment and confirms the important role of side
chain conformation in regulating glycosyl donor reactivity and selectivity.
The successful demonstration of synthesis of equatorial KDO glycosides as a function of
side chain conformation provides an effective and alternative route for selective synthesis of KDO
equatorial glycosides commonly found in numerous pathogenic bacteria.
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CHAPTER 6. EXPERIMENTAL SECTION
General Experimental: All reactions were carried out under argon unless otherwise
stated. Solvents used for column chromatography were analytical grade and were purchased from
commercial suppliers. Thin-layer chromatography was carried out with 250 μm glass backed silica
(XHL) plates. Detection of compounds was achieved by UV absorption (254 nm) and by staining
with 10% sulfuric acid in ethanol. Purification of crude residues was performed over silica gel
chromatography using 230–400 mesh grade 60 silica unless otherwise stated. Specific rotations
were measured in chloroform on an automatic polarimeter with a path length of 10 cm. NMR
spectra were recorded in acetonitrile-d3, CDCl3, D2O or CD3OD using a 400 or 600 MHz Varian
spectrometers, a 900 MHz Bruker Avance spectrometer and EZC500 JEOL instrument (500 MHz).
High-resolution (HRMS) mass spectra were recorded in the electrospray mode using a time of
flight mass analyzer (ESI-TOF). Heating of reaction mixtures were carried out on an aluminum
heating block of appropriate size. volumetric glass. The chemical shifts (δ) were recorded in ppm
and the multiplicity were abbreviated as follows: s (singlet), m (multiplet), br (broad), d (doublet),
t (triplet) and q (quartet).
Methyl 2,3-di-O-benzyl-6-deoxy-6-iodo-α-D-glucopyranoside (247). This compound
was prepared according to the literature method in (20 g, 83% yield) as a colorless syrup. [α]D23 =
+19.4 (c = 1.0, CHCl3), 1H NMR (400 MHz, CDCl3) δ 7.47 – 7.29 (m, 10H), 5.03 (d, J = 11.5 Hz,
1H), 4.77 (d, J = 12.0 Hz, 1H), 4.69 (s, 1H), 4.67-4.64 (m, 3H), 3.78 (t, J = 9.1 Hz, 1H), 3.57 –
3.50 (m, 2H), 3.48 – 3.37 (m, 4H), 3.34 – 3.19 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 138.5,
137.9, 128.7, 128.6, 128.11, 128.07, 128.0, 98.1, 80.7, 79.9, 75.4, 73.7, 73.2, 69.8, 55.6, 7.1. ESIHRMS: m/z calcd for C21H25O5INa [M + Na] 507.0645, found 507.0644.
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2-pyridyl methallyl sulfone (257). To a solution of 2-mercaptopyridine (6.31 g, 56.8
mmol) and 3-chloro-2-methylpropene (25.7 g, 283.8 mmol) in CH3CN (81 mL) was Et3N (23 mL).
The mixture was stirred at rt till completion. The solvent was then removed at reduced pressure
and the residual crude dissolved in diethyl ether (100 mL) and washed with 5% sodium hydroxide
(30 mL) and sodium chloride. The combined organic layer was dried in MgSO4, filtered, and
concentrated under reduced pressure. The residual crude (8.5 g, 51.4 mmol) was dissolved in
CH2Cl2 (200 mL). The solution was treated with m-Chloroperoxybenzoic acid (17.8 g, 102.9
mmol) and stirred at 0 oC till completion. After completion, the reaction mixture was concentrated
under reduced pressure, diluted with CH2Cl2 (20 mL) and neutralized with 0.2 M aqueous sodium
bicarbonate (15 mL). The aqueous layer was extracted with CH2Cl2 twice and the combined
organic layer was dried over anhydrous MgSO4, filtered, and concentrated. The crude was purified
by silica gel column chromatography (hexane:ethyl acetate 5:1) to give (7.7 g, 76%) as a colorless
liquid. 1H NMR (400 MHz, CDCl3) δ 8.67 (dd, J = 7.8, 7.7, 1H), 7.96 (dd, J = 7.9, 7.9 Hz, 1H),
7.88 (dd, J = 7.7, 7.7 Hz, 1H), 7.49 (dd, J = 7.6, 7.7 Hz, 1H), 4.93 (s, 1H), 4.68 (s, 1H), 3.99 (s,
2H), 1.78 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 156.5, 150.1, 138.1, 132.8, 127.5, 122.8, 120.9,
59.8, 22.8. ESI-HRMS: m/z calcd for C9H11O2NSNa [M + H] 198.0363, found 198.0358.
Methyl 2,3-di-O-benzyl-6,7,8,9-tetradeoxy-8-methyl-α-D-non-8-enoglucopyranoside
(253). Compound 247 (3.0 g, 6.2 mmol) was dissolved in dry α,α,α-Trifluorotoluene (31 mL) and
treated with 2-pyridyl methallylsulfone (1.2 g, 6.2 mmol). Lauroyl peroxide (5.0 g, 12.4 mmol)
was added to the reaction mixture in two portions at 80 oC. The reaction mixture was stirred at 80
o

C for 2 h with monitoring by TLC (hexane:ethyl acetate 6:1, Rf =0.6). After completion, the

reaction mixture was concentrated under reduced pressure and the residue was purified by silica
gel column chromatography (hexane:ethyl acetate 15:1 to 10:1 to 6:1) to give 253 (1.2 g, 50%) as
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a colorless syrup and 260 (0.9 g, 40%) also as a colorless syrup. [α]D23 = +58 (c = 0.4, CHCl3), 1H
NMR (400 MHz, CDCl3), 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.20 (m, 10H), 5.02 (d, J = 11.5
Hz, 1H), 4.82 – 4.51 (m, 6H), 3.73 (t, J = 9.3 Hz, 1H), 3.55 – 3.46 (m, 2H), 3.36 (s, 3H), 3.23 (t, J
= 9.2 Hz, 1H), 2.26 – 2.17 (m, 1H), 2.02-1.94 (m, 1H), 1.61 – 1.45 (m, 2H). 13C NMR (101 MHz,
CDCl3) δ 145.4, 138.7, 138.0, 128.6, 128.5, 128.1, 128.0, 127.96, 127.9, 110.0, 97.9, 81.5, 79.98,
75.4, 73.7, 72.99, 70.1, 55.1, 33.5, 29.8. ESI-HRMS: m/z calcd for C25H32O5Na [M + Na]
435.1764, found 435.1762.
4-toluyl methallyl sulfone (259). To a solution of 4-toluene sulfinate (10 g, 56.1 mmol) in
DMF (40 mL) was added 3-Chloro-2-methylpropene (2.7 mL, 27.6 mmol). The mixture was
stirred at reflux till completion. The solvent was then removed at reduced pressure and the residual
crude dissolved in ethyl acetate (50 mL) and washed with saturated sodium bicarbonate (2 × 20
mL). The aqueous layer was extracted twice with ethyl acetate and the combined organic layer
dried in MgSO4, filtered, and concentrated under reduced pressure. The residual crude was purified
by silica gel column chromatography (hexane:ethyl acetate 5:1) to give 259 (10.9 g 92%) as white
solid. 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 8.2 Hz, 2H), 7.32 (d, J = 8.4 Hz, 2H), 5.02 (br,
1H), 4.68 (br, 1H), 3.74 (br, 2H), 2.43 (s, 3H), 1.85 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 144.6,
135.5, 133.5, 129.6, 128.5, 120.6, 64.5, 22.7, 21.6. ESI-HRMS: m/z calcd for C11H14O2SNa [M +
Na] 233.0308, found 233.0304.
Methyl

2,3-di-O-benzyl-6,7-dideoxy-8,8-dimethyl-α-D-glucopyranoside

(261).

Compound 247 (2.95 g, 6.09 mmol) was dissolved in dry α,α,α-trifluorotoluene (30 mL) and
treated with 4-toluyl methallylsulfone (2.6 g, 12.18 mmol). Lauroyl peroxide (2.4 g, 6.09 mmol)
was added to the reaction mixture in two portions at 80 oC. The reaction was stirred at 80 oC for 4
h with monitoring by TLC (hexane:ethyl acetate 5:1, Rf =0.5). After completion, the reaction
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mixture was concentrated under reduced pressure and the residue was purified by silica gel column
chromatography (hexane:ethyl acetate 20:1 to 10:1 to 5:1) to give 261 (1.4 g, 57%) as a colorless
syrup. [α]D23 = +47.4 (c = 0.5, CHCl3), 1H NMR (400 MHz, CDCl3) δ 7.56 – 6.99 (m, 10H), 4.95
– 4.79 (m, 2H, 2PhCH2), 4.79 – 4.63 (m, 2H, 2PhCH2), 4.54 (d, J = 3.7 Hz, 1H, H-1), 3.79 (dd, J
= 9.5, 9.5 Hz, 1H, H-3), 3.53 – 3.18 (m, 6H, H-2, H-4, H-5, OCH3), 1.87-1.76 (m, 2H, H-6, H-7),
1.63-1.62 (m, 2H, H-6’, H-7’), 1.26 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 139.4, 138.5, 129.6,
128.4, 128.2, 128.1, 128.0, 127.7, 127.4, 99.1, 79.8, 79.1, 75.9, 75.2, 73.7, 72.0, 67.4, 55.2, 35.8,
31.1, 25.8, 22.3. ESI-HRMS: m/z calcd for C25H32O5Na [M + Na] 435.1464, found 435.1462.
Methyl

2,3-di-O-benzyl-6,7,8,9-tetradeoxy-8-methyl-4-keto-α-D-non-8-

enoglucopyranoside (271). Compound 253 (1.21 g, 2.9 mmol) was dried under vaccum overnight
and dissolved in anhydrous solution of DMSO:dichloromethane 2:1 (7 mL) under argon. The
mixture was cooled to 0 oC. A solution of sulfur trioxide pyridine complex (1.4 g, 8.8 mmol) in
DMSO (3 mL) was stirred at rt for 20 minutes then added dropwise to the sugar solution at 0 oC.
The reaction mixture was allowed to come to rt and stirred till completion with monitoring by TLC
(hexane:ethyl acetate 5:1, Rf =0.5). The reaction mixture was concentrated under reduced pressure
and the residue diluted with dichloromethane (30 mL) and water (20 mL). The aqueous layer was
extracted with dichloromethane twice and the combined organic layer was dried over anhydrous
MgSO4, filtered, and concentrated. The residue was purified by silica gel column chromatography
(hexane:ethyl acetate 5:1) to give 271 (0.93 g, 77%) as a colorless syrup. [α]D23 = +130 (c = 0.8,
CHCl3). 1H NMR (CDCl3, 400 MHz): δ 8.09 – 6.75 (m, 10H), 4.96 (d, J = 11.3 Hz, 1H), 4.87 (d,
J = 12.1 Hz, 1H), 4.75 – 4.69 (m, 3H), 4.67 (m, 1H), 4.43 (d, J = 10.1 Hz, 1H), 4.06 (dd, J = 8.5,
3.6 Hz, 1H), 3.75 (dd, J = 10.0, 3.6 Hz, 1H), 3.46 (s, 3H), 2.15 (m, 1H), 2.11 – 1.99 (m, 2H), 1.72
(s, 3H), 1.65 (m, 1H). 13C NMR (CDCl3) δ 203.24, 144.80, 128.47, 128.40, 128.13, 128.02, 127.97,
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127.81, 110.55, 98.40, 82.83, 80.27, 74.35, 73.92, 72.03, 55.99, 33.08, 26.21, 22.33. HRMS (ESI)
m/z calc. for C25H30O5Na [M+Na]+, 433.2004; found, 433.1991.
Methyl

2,3-di-O-benzyl-6,7,8,9-tetradeoxy-8-methyl-4-C-vinyl-α-D-non-8-

enogalactopyranoside (274). A solution of 271 (0.43 g, 1.0 mmol) in dry THF (10 mL) was cooled
to -78 oC under argon and treated with vinylmagnesium bromide (2.09 mL, 2.1 mmol). The
reaction mixture was stirred at -78 oC for 2 h with monitoring by TLC (hexane:ethyl acetate 5:1,
Rf = 0.5). After completion, the reaction mixture was concentrated and the residue purified by
silica gel column chromatography (hexane:ethyl acetate 5:1 ) to give 274 (0.35 g, 76%) as a
colorless syrup. [α]D23 = +85 (c = 1.0, CHCl3), 1H NMR (400 MHz, CDCl3) δ 7.44 – 7.10 (m,
10H), 5.75 (dd, J = 17.2, 10.7 Hz, 1H), 5.47 (dd, J = 17.2, 1.4 Hz, 1H), 5.33 (d, J = 10.6, 1H), 4.80
(d, 11.3 Hz, 2H), 4.71 – 4.61 (m, 4H), 3.80 (s, 2H), 3.40 (s, 3H), 2.28-2.20 (m, 1H), 2.04 – 1.90
(m, 1H), 1.74 – 1.64 (m, 4H), 1.30-1.21(m, 1H). 13C NMR (101 MHz, CDCl3) δ 145.5, 139.6,
138.3, 138.1, 128.4, 128.31, 128.27, 128.1, 127.9, 127.8, 116.5, 110.1, 98.2, 80.1, 77.7, 77.2, 76.0,
73.3, 70.7, 55.3, 34.5, 25.5, 22.4. HRMS (ESI) m/z calc. for C27H34O5Na [M+Na]+, 461.2306;
found, 461.2304.
Methyl

2,3-di-O-benzyl-6,7,8,9-tetradeoxy-8-methyl-α-D-non-8-

enogalactopyranoside (278). A solution of 274 (2 g, 4.6 mmol) in dry dichloromethane (11 mL)
was treated with 2nd gen. Grubbs catalyst (29 mg, 0.5 mmol). The reaction mixture was heated at
40 oC till completion with monitoring by TLC (hexane:ethyl acetate 4:1, Rf = 0.5). After
completion, the reaction mixture was concentrated and the concentrate purified by silica gel
column chromatography (hexane:ethyl acetate 4:1 ) to give 278 (1.57 g, 84%) as a light brown
syrup. [α]D23 = +60 (c = 0.6, CHCl3), 1H NMR (400 MHz, CDCl3) δ 7.48 – 7.18 (m, 10H), 5.50 (s,
1H), 5.04 (d, J = 11.2 Hz, 1H), 4.77 (d, J = 12.0 Hz, 1H), 4.72 – 4.60 (m, 3H), 4.00 (dd, J = 9.4,

122

3.9 Hz, 1H), 3.68 (dd, J = 12.3, 3.7 Hz, 1H), 3.61 (d, J = 9.4 Hz, 1H), 3.39 (s, 3H), 2.13 – 1.98 (m,
3H), 1.70-1.64 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 139.2, 138.5, 138.3, 128.43, 128.40,
128.23, 128.21, 127.9, 127.8, 122.0, 98.8, 80.0, 75.97, 73.4, 70.7, 68.9, 55.3, 30.3, 23.2, 21.7.
HRMS (ESI) m/z calc. for C25H30O5Na [M+Na]+, 433.1997; found, 433.1991.
Methyl

2,3-di-O-benzyl-6,8,9-trideoxy-8-methyl-7-keto-α-D-non-8-

enogalactopyranoside (279). A solution of 278 (94.4 mg, 0.2 mmol) in dry 1.4 dioxane (10 mL)
was treated with selenium dioxide (10 mg, 0.1 mmol) added in four portions over the period of the
reaction. The reaction mixture was heated at 80 oC till completion with monitoring by TLC
(hexane:ethyl acetate 2:1, Rf = 0.4). After completion, the reaction mixture was concentrated and
the residue purified by silica gel column chromatography (hexane:ethyl acetate 2:1) to give first,
279 (55 mg, 65%) as a white form then, 280 (6 mg, 7%) as a colorless syrup. 279: [α]D23 = +59 (c
= 0.53, CHCl3), 1H NMR (400 MHz, CDCl3) δ 7.56 – 7.08 (m, 10H), 6.42 (s, 1H), 5.09 (d, J =
11.4 Hz, 1H), 4.85 – 4.51 (m, 4H), 4.14 – 3.91 (m, 2H), 3.72 (d, J = 9.3 Hz, 1H), 3.37 (s, 3H), 3.00
– 2.83 (m, 1H), 2.57 – 2.52 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 197.5, 141.1, 137.9, 128.62,
128.55, 128.4, 128.2, 128.1, 98.9, 78.5, 78.2, 75.9, 73.4, 70.5, 66.6, 55.6, 38.0, 15.6. HRMS (ESI)
m/z calc. for C25H28O6Na [M+Na]+, 447.1196; found, 447.1193.
Methyl 2,3-di-O-benzyl-6,7,8,9-tetradeoxy-α-D-non-8-enogalactopyranoside (280). 1H
NMR (400 MHz, CDCl3) δ 9.22 (s, 1H), 7.56 – 7.15 (m, 10H), 5.09 (d, J = 11.5 Hz, 1H), 4.88 –
4.55 (m, 4H), 4.14 – 3.91 (m, 1H), 3.68 – 3.59 (m, 1H), 2.62 – 2.38 (m, 2H), 2.22 – 2.05 (m, 1H),
2.05 – 1.88 (m, 1H), 1.85 – 1.65 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 196.4, 141.0, 137.9,
128.6, 128.5, 128.4, 128.2, 128.1, 98.9, 78.6, 78.3, 75.9, 73.5, 70.4, 66.6, 55.7, 38.1, 15.5. HRMS
(ESI) m/z calc. for C25H28O6Na [M+Na]+, 447.1300; found, 447.1296.
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Benzyl 2,3-di-O-benzyl-6,8,9-trideoxy -8-methyl-α-D-non-8-enogalactopyranoside
(287). A solution of 279 (58 g, 0.1 mmol) in dry methanol (1.4 mL) was treated with cerium (III)
chloride heptahydrate (61 mg, 0.2 mmol) and stirred at rt for 1 h. The reaction mixture was cooled
to -78 oC and sodium borohydride (8 mg, 0.2 mmol) was added, with monitoring by TLC
(hexane:ethyl acetate 1:1, Rf = 0.2). After completion, the reaction mixture was concentrated and
the crude diluted with ethyl acetate (10 mL) and washed with water (10 mL). The aqueous layer
was extracted with ethyl acetate and the combined organic layer dried over anhydrous MgSO4,
filtered, and concentrated. The residue was purified by silica gel column chromatography
(hexane:ethyl acetate 1:1 ) to give 287 (47 mg, 80%) as a colorless liquid. [α]D23 = +50.1 (c = 0.67,
CHCl3), 1H NMR (400 MHz, CDCl3) δ 7.41 – 7.28 (m, 10H), 5.50 (s, 1H), 5.04 (d, J = 11.3 Hz,
1H), 4.76 (d, J = 11.9 Hz, 1H), 4.70 – 4.52 (m, 3H), 4.11 (t, J = 8.3 Hz, 1H), 3.97 (dd, J = 9.4, 3.8
Hz, 1H), 3.63 (dd, J = 12.9, 3.5 Hz, 1H), 3.58 (d, J = 9.4 Hz, 1H), 3.38 (s, 3H), 2.19-2.13 (m, 1H),
2.05-1.97 (m, 1H), 1.71 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 141.4, 138.3, 128.5, 128.3, 128.2,
127.95, 127.9, 123.99, 98.9, 79.4, 78.5, 75.9, 73.4, 70.9, 70.1, 66.7, 55.5, 32.2, 19.1. HRMS (ESI)
m/z calc. for C25H30O6Na [M+Na]+, 449.1948; found, 449.1940.
Methyl 8,9-anhydro-2,3-di-O-benzyl-6-deoxy-8-methyl-α-D-nonagalactopyranoside
(288). A solution of 287 (32 mg, 0.1 mmol) in dry THF (0.75 mL) was treated with mchloroperoxybenzoic acid (13 mg, 0.1 mmol) and stirred at rt, with monitoring by TLC
(hexane:ethyl acetate:methanol 1:1:0.1, Rf = 0.2). After completion, the reaction mixture was
concentrated under reduced pressure, diluted with ethyl acetate (15 mL) and neutralized with 0.2
M aqueous sodium bicarbonate (30 mL). The aqueous layer was extracted with ethyl acetate twice
and the combined organic layer was dried over anhydrous MgSO4, filtered, and concentrated. The
crude product was purified by silica gel column chromatography (hexane:ethyl acetate:methanol
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1:1:0.1) to give 288 (26 mg, 78%) as a syrup. [α]D23 = +25.7 (c = 0.4, CHCl3), 1H NMR (400 MHz,
CDCl3) δ 7.41 – 7.26 (m, 10H), 5.05 (d, J = 11.7 Hz, 1H), 4.79 (d, J = 11.9 Hz, 1H), 4.69 (d, J =
11.8 Hz, 1H), 4.64 (d, J = 11.9 Hz, 1H), 4.56 (d, J = 3.8 Hz, 1H), 4.06 (dd, J = 9.5, 3.8 Hz, 1H),
3.91 – 3.81 (m, 2H), 3.62 (d, J = 9.5 Hz, 1H), 3.33 (s, 3H), 3.18 (dd, J = 12.7, 2.5 Hz, 1H), 2.70
(s, 1H), 1.76 - 1.70 (m, J = 12.4, 6.3, 2.7 Hz, 1H), 1.60 – 1.48 (m, 1H), 1.22 (s, 3H). 13C NMR
(101 MHz, CDCL3) δ 162.7, 138.1, 137.98, 128.9, 128.6, 128.51, 128.48, 128.5, 128.2, 128.0,
127.97, 98.9, 78.2, 77.3, 75.3, 73.54, 70.50, 67.2, 62.6, 55.6, 28.5, 19.1. HRMS (ESI) m/z calc. for
C25H30O7Na [M+Na]+, 465.1891; found, 465.1889.
Methyl 2,3-di-O-benzyl-8-α-D-bradyrhizopyranoside (291). A solution of 288 (0.17 g,
0.4 mmol) in 1,4 dioxane:water 2:1 (4 mL), was treated with concentrated sulphuric acid (4 µL,
0.1 mmol) added dropwise in three portions at 65 oC. The reaction was monitored by TLC
(hexane:ethyl acetate:methanol 1:1:0.1, Rf =0.1). After completion, the mixture was diluted with
ethyl acetate (10 mL) and neutralized with saturated aqueous sodium bicarbonate (5 mL). The
aqueous layer was extracted with ethyl acetate twice and the combined organic layer was dried
over anhydrous MgSO4, filtered, and concentrated. The crude product was purified by silica gel
column chromatography (hexane:ethyl acetate:methanol 1:1:0.1) to give first, 279 (58.6 mg, 35%)
then, 291 (67.2 mg, 37%) as a white form. [α]D23 = +64 (c = 0.5, CHCl3),1H NMR (400 MHz,
CDCl3) δ 7.43 – 7.20 (m, 11H), 5.09 (d, J = 10.7 Hz, 1H), 4.75 – 4.59 (m, 4H), 4.03 (dd, J = 9.4,
3.7 Hz, 1H), 3.91 (d, J = 9.4 Hz, 1H), 3.73 (br, 1H), 3.66 – 3.55 (m, 2H), 3.51 (br, 1H), 3.38 (s,
3H), 2.76 (s, 1H), 1.94 – 1.80 (m, 2H), 1.26 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 137.7, 137.2,
128.9, 128.6, 128.52, 128.46, 128.3, 128.2, 98.2, 82.9, 78.8, 78.3, 77.5, 75.8, 73.7, 73.1, 72.2, 66.3,
55.6, 30.3, 15.5. HRMS (ESI) m/z calc. for C25H32O8Na [M+Na]+, 483.1995; found, 483.1990.
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Benzyl α,β-D-glucopyranoside (230). This compound was prepared according to the
literature method in 89% yield as a white solid (26.7g) in the form of a 12.5:1 α:β mixture. 1H
NMR (400 MHz, CD3OD) δ 7.47 – 7.16 (m, 10H), 4.94-4.90 (m, 2H), 4.76 (d, J = 11.9 Hz, 1H),
4.66 (d, J = 11.9 Hz, 1H), 4.55 (d, J = 12.0 Hz, 1H), 4.36 (d, J = 7.8 Hz, 1H), 3.93 – 3.88 (m, 1H),
3.82 – 3.77 (m, 1H), 3.75 – 3.58 (m, 5H), 3.42 (dd, J = 9.7, 3.8 Hz, 1H), 3.41 – 3.21 (m, 5H). 13C
NMR (101 MHz, CD3OD) δ 140.4, 137.6, 128.4, 127.92, 127.88, 127.86, 127.8, 127.3, 125.6,
101.9, 97.8, 76.7, 76.6, 73.71, 73.68, 72.5, 72.1, 70.4, 70.34, 70.27, 68.8, 61.4, 61.2. HRMS (ESI):
m/z calcd for C13H18O6Na [M + Na] 293.0957, found 293.0952.
Benzyl 4,6-O-benzylidene-α,β-D-glucopyranoside (231). To a solution of 230 (25 g, 92.5
mmol) in DMF (500 mL) was added benzaldehyde dimethyl acetal (17.3 mL, 111.0 mmol) and pTsOH monohydrate (3.5 g, 18.0 mmol). The mixture was stirred at rt till completion. The solvent
was then removed at reduced pressure and the residual crude dissolved in ethyl acetate (100 mL)
and washed with saturated sodium bicarbonate (2 × 30 mL). The aqueous layer was extracted twice
with ethyl acetate and the combined organic layer dried in MgSO4, filtered, and concentrated under
reduced pressure. The residual crude was purified by silica gel column chromatography
(hexane:ethyl acetate 3:1) to give first compound 231β as a white solid (2.1 g, 6%) and then 231α
as a white solid (28 g, 85%). 231α. Mp 155 -162 oC [α]D23 = +103 (c = 0.98, CHCl3) 1H NMR (400
MHz, CDCl3) δ 8.05 – 7.16 (m, 10H), 5.48 (s, 1H, benzylidene), 4.95 (d, J = 3.9 Hz, 1H, H-1),
4.73 (d, J = 11.8 Hz, 1H, PhCH2), 4.53 (d, J = 11.8 Hz, 1H, PhCH2), 4.19 (dd, J = 10.1, 4.8 Hz,
1H, H-6eq), 3.94 (t, J = 9.3 Hz, 1H, H-3), 3.82 (td, J = 9.9, 4.8 Hz, 1H, H-5), 3.69 (q, J = 10.4 Hz,
1H, H-6ax), 3.60 (dd, J = 9.2, 3.9 Hz, 1H, H-2), 3.46 (t, J = 9.4 Hz, 1H, H-4). 13C NMR (101 MHz,
CDCl3) δ 162.7, 137.1, 136.8, 129.1, 128.5, 128.2, 128.12, 128.08, 126.3, 101.8, 98.3, 81.0, 72.9,
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71.4, 70.0, 68.9, 62.7. HRMS (ESI): m/z calcd for C20H22O6Na [M + Na] 381.1314, found
381.1316.
231β. Mp 120 -125 oC [α]D23 = +98 (c = 1.0, CHCl3) 1H NMR (400 MHz, CDCl3) δ 7.57 –
7.30 (m, 10H), 5.50 (s, 1H, benzylidene), 4.91 (d, J = 11.6 Hz, 1H, , PhCH2 ), 4.61 (d, J = 11.6
Hz, 1H, PhCH2), 4.45 (d, J = 7.7 Hz, 1H, H-1), 4.34 (dd, J = 10.5, 5.0 Hz, 1H, H-6eq), 3.84 – 3.70
(m, 2H, H-6ax, H-3), 3.60 – 3.47 (m, 2H, H-2, H-4), 3.39 (td, J = 9.7, 4.9 Hz, 1H, H-5). 13C NMR
(101 MHz, CDCl3) δ 137.0, 136.7, 129.3, 128.6, 128.4, 128.18, 128.16, 126.3, 102.1, 101.9, 80.5,
74.5, 73.1, 71.4, 68.7, 66.4. HRMS (ESI): m/z calcd for C20H22O6Na [M + Na] 381.1314, found
381.1319.
Benzyl 2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranoside (232). A solution of
231 (8 g, 22.2 mmol) in dry DMF (222 mL) was placed in an ice bath at 0 oC under argon. Sodium
hydride (2.7 g, 66.7 mmol) and benzyl bromide were then added. The reaction mixture was stirred
at 0 oC for 3 h then at ambient temperature for 4 h, with monitoring by TLC (hexane:ethyl acetate
6:1, Rf = 0.6). After completion, the reaction mixture was quenched with methanol (10 mL)
followed by water (100 mL) and extracted with ethyl acetate (100 mL). The aqueous layer was
extracted with ethyl acetate thrice and the combined organic layer dried over anhydrous MgSO4,
filtered, and concentrated. The residue was purified by silica gel column chromatography
(hexane:ethyl acetate 6:1 ) to give 232 as a white amorphous solid (11.3 g, 94%). Mp 114 -117 oC.
[α]D23 = +21.9 (c = 0.54, CHCl3), 1H NMR (400 MHz, CDCl3) δ 7.76 – 6.96 (m, 20H), 5.56 (s,
1H, benzylidene), 4.94 (d, J = 11.2 Hz, 1H, PhCH2), 4.86 (d, J = 11.4 Hz, 1H, PhCH2), 4.84 (d, J
= 3.8 Hz, 1H, H-1 ), 4.77 (d, J = 12.0 Hz, 1H, PhCH2 ), 4.74 (d, J = 12.3 Hz, 1H, PhCH2 ), 4.60
(d, J = 12.2 Hz, 2H, 2PhCH2), 4.21 (dd, J = 10.2, 4.9 Hz, 1H, H-6eq), 4.12 (t, J = 9.3 Hz, 1H, H3), 3.92 (dt, J = 9.9, 4.8 Hz, 1H, H-5), 3.70 (t, J = 10.3 Hz, 1H, H-6ax), 3.63 (t, J = 9.4 Hz, 1H, H-
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4), 3.57 (dd, J = 9.3, 3.8 Hz, 1H, H-2). 13C NMR (101 MHz, CDCl3) δ 138.8, 138.1, 137.4, 136.9,
128.9, 128.5, 128.41, 128.36, 128.3, 128.2, 127.97, 127.9, 127.8, 127.6, 126.0, 101.2, 96.5, 82.2,
79.2, 78.7, 75.4, 73.5, 69.3, 69.0, 62.6. HRMS (ESI): m/z calcd for C 34H34O6Na [M + Na]
561.2253, found 561.2258.
Benzyl 2,3-di-O-benzyl-α-D-glucopyranoside (233). A solution of 232 (19.0 g, 35.2
mmol) in methanol:chloroform 2:1 (300 mL), was treated with p-TsOH monohydrate (2.7 g, 14.07
mmol) at rt. The reaction was monitored by TLC (hexane:ethyl acetate 2:1, Rf =0.3). After
completion, the reaction mixture was concentrated under reduced pressure, diluted with ethyl
acetate (250 mL) and neutralized with saturated aqueous sodium bicarbonate (100 mL). The
aqueous layer was extracted with ethyl acetate twice and the combined organic layer was dried
over anhydrous MgSO4, filtered, and concentrated. The residual syrup was purified by silica gel
column chromatography (hexane:ethyl acetate 2:1) to give 233 (13.3 g, 84%) as white amorphous
solid. Mp 95-98 oC. [α]D23 = +53.6 (c = 0.64, CHCl3), 1H NMR (400 MHz, CDCl3) δ 7.75 – 6.96
(m, 15H), 5.05 (d, J = 11.4 Hz, 1H, PhCH2), 4.85 (d, J = 3.6 Hz, 1H, H-1), 4.75 (d, J = 11.4 Hz,
1H, PhCH2), 4.72 (d, J = 12.3 Hz, 1H, PhCH2 ), 4.64 (d, J = 11.9 Hz, 1H, PhCH2), 4.57 (d, J =
12.3 Hz, 1H, PhCH2), 4.54 (d, J = 11.9 Hz, 1H, PhCH2), 3.89 (t, J = 9.2 Hz, 1H, H-3), 3.75-3.73
(m, 2H, H-6, H-6’), 3.72 – 3.66 (m, 1H, H-5), 3.57 (t, J = 9.2 Hz, 1H, H-4), 3.51 (dd, J = 9.5, 3.6
Hz, 1H, H-2). 13C NMR (101 MHz, CDCl3) δ 138.8, 138.0, 137.1, 128.6, 128.5, 128.43, 128.39,
127.8, 127.91, 127.85, 95.5, 81.4, 79.8, 75.4, 72.7, 71.1, 70.3, 69.2, 62.2. HRMS (ESI): m/z calcd
for C27H30O6Na [M + Na] 473.1940, found 473.1947.
Benzyl 2,3-di-O-benzyl-6-deoxy-6-iodo-α-D-glucopyranoside (234). A solution of 233
(8.6 g, 19.0 mmol) in toluene:acetonitrile 1:1 (190 mL), was treated with triphenyl phosphine (5.5
g, 20.9 mmol), iodine (5.3 g, 20.9 mmol), and imidazole (3.9 g, 57.1 mmol). The mixture was
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heated at 40 oC and monitored by TLC (hexane:ethyl acetate 6:1, Rf =0.6). After completion, the
reaction mixture was concentrated under reduced pressure. The residual syrup was purified by
silica gel column chromatography (hexane:ethyl acetate 6:1) to give 234 (9.3 g, 87%) as a colorless
syrup. [α]D23 = +46.6 (c = 0.98, CHCl3), 1H NMR (400 MHz, CDCl3) δ 7.64 – 7.03 (m, 15H), 5.06
(d, J = 11.5 Hz, 1H, PhCH2), 4.87 (d, J = 3.6 Hz, 1H, H-1), 4.81 (d, J = 12.1 Hz, 1H, PhCH2), 4.69
(d, J = 11.5 Hz, 1H, PhCH2 ), 4.63 (d, J = 12.7 Hz, 2H, 2PhCH2), 4.55 (d, J = 11.9 Hz, 1H, PhCH2
), 3.87 (t, J = 9.2 Hz, 1H, H-3), 3.57 – 3.46 (m, 3H, H-2, H-4, H-6), 3.33 (td, J = 9.2, 2.5 Hz, 1H,
H-5), 3.26 (dd, J = 10.9, 7.5 Hz, 1H, H-6’). 13C NMR (101 MHz, CDCl3) δ 138.6, 137.8, 136.8,
128.70, 128.65, 128.5, 128.04, 128.01, 128.0, 127.9, 94.97, 80.8, 79.8, 75.4, 73.7, 72.6, 70.1,
68.99, 7.3. HRMS (ESI): m/z calcd for C27H29IO5Na [M + Na] 583.0957, found 583.0953.
Benzyl 2,3-di-O-benzyl-6,7,8,9-tetradeoxy-8-methyl-α-D-non-8-enoglucopyranoside
(235). Compound 234 (5.89 g, 10.5 mmol) was dissolved in dry α,α,α-Trifluorotoluene (117 mL)
and treated with 2-pyridyl methallylsulfone (7.3 g, 36.8 mmol). Lauroyl peroxide (20.9 g, 52.6
mmol) was added to the reaction mixture in two portions at 80 oC. The reaction mixture was stirred
at 80 oC for 2 h with monitoring by TLC (hexane:ethyl acetate 6:1, Rf =0.6). After completion, the
reaction mixture was concentrated under reduced pressure and the residue was purified by silica
gel column chromatography (hexane:ethyl acetate 15:1 to 10:1 to 6:1) to give 235 (2.7 g, 54%) as
a colorless syrup and 306 (1.6g, 36%) also as a colorless syrup. [α]D23 = +60.1 (c = 0.57, CHCl3),
1

H NMR (400 MHz, CDCl3 ) δ 7.46 – 7.22 (m, 15H), 5.06 (d, J = 11.5 Hz, 1H, PhCH2), 4.81 (d, J

= 3.6 Hz, 1H, H-1), 4.76 – 4.68 (m, 4H, 2PhCH2, 2H-vinyl ), 4.62 (d, J = 11.9 Hz, 1H, PhCH2 ),
4.53 - 48 (m, 2H, 2PhCH2 ), 3.83 (t, J = 9.3 Hz, 1H, H-3), 3.65 (t, J = 8.8 Hz, 1H, H-5), 3.52 (dd,
J = 9.5, 3.6 Hz, 1H, H-2), 3.27 (t, J = 9.3 Hz, 1H, H-4), 2.26 – 2.18 (m, 1H, H-7), 2.07 – 1.98 (m,
2H, H-7’, H-6), 1.74 (s, 3H, methyl), 1.56 – 1.46 (m, 1H, H-6’). 13C NMR (101 MHz, CDCl3) δ
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145.5, 138.8, 138.0, 137.1, 128.6, 128.42, 128.39, 127.93, 127.89, 127.8, 110.1, 94.8, 81.5, 79.9,
75.3, 73.8, 72.5, 70.4, 68.7, 33.5, 29.9, 22.5. HRMS (ESI): m/z calcd for C31H36O5Na [M + Na]
511.2460, found 511.2459.
Benzyl 2,3-di-O-benzyl-6-deoxy-α-D-glucopyranoside (306). α]D23 = +19.5 (c = 1.1,
CHCl3)1H NMR (500 MHz, CDCl3) δ 7.37 – 7.25 (m, 15H), 5.05 (d, J = 11.5 Hz, 1H, PhCH2),
4.80 (d, J = 3.6 Hz, 1H, H-1), 4.71 (dd, J = 11.9, 5.5 Hz, 2H, PhCH2), 4.62 (d, J = 11.9 Hz, 1H,
1PhCH2), 4.55 (d, J = 12.0 Hz, 2H), 3.81 (t, J = 9.2 Hz, 1H, H-3), 3.76 – 3.68 (m, 1H, H-5), 3.52
(dd, J = 9.5, 3.7 Hz, 1H, H-2), 3.18 (t, J = 9.2 Hz, 1H, H-4), 1.21 (d, J = 6.3 Hz, 3H, CH3). 13C
NMR (126 MHz, CDCl3) δ 138.9, 138.2, 137.4, 128.7, 128.50, 128.45, 128.0, 95.4, 81.5, 80.2,
75.5, 75.4, 72.7, 69.1, 67.3, 17.8. HRMS (ESI): m/z calcd for C27H30O5Na [M + Na] 457.1963,
found 457.1968.
Photocatalyzed allylation using fac-Ir(ppy)3 catalyst
Benzyl 2,3-di-O-benzyl-6,7,8,9-tetradeoxy-8-methyl-α-D-non-8-enoglucopyranoside
(235). To an oven-dried 100 mL Pyrex volumetric flask was added compound 234 (0.23 g, 0.4
mmol), 2-pyridyl methallylsulfone (0.16 g, 0.8 mmol) and tributylamine (0.2 mL, 0.8 mmol)
.Ir(ppy)3 catalyst (5 mol%, 14 mg, 0.02 mmol), purified according to the literature protocol2and
anhydrous acetonitrile (41 mL) were then added, and the mixture degassed with argon for 30
minutes. The flask was then placed in a 600 mL beaker lined with 12V blue LED strips and covered
with aluminum foil. The reaction mixture was irradiated with a blue LED light till completion with
monitoring by TLC (hexane:ethyl acetate 5:1, Rf =0.5). The mixture was then diluted with
acetonitrile, concentrated at reduced pressure and the residue purified via silica gel
chromatography (5:1) to give 235 (0.14 g, 68%) as a colorless syrup and 306 (23 mg, 13%). The
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spectral data were consistent with the data acquired from allylation procedure utilizing lauroyl
peroxide as the initiator.
Procedure for preparation of 3-pyridyl methallylsulfone (301)
3-pyridyl sulfonyl chloride (1.21 g, 6.8 mmol,) and Na2SO3 (1.7 g, 13.6 mmol,) were
dissolved H2O (10 mL and heated to 80 °C. NaHCO3 (1.2 g, 13.6 mmol) was then added
portionwise over 1 hr. The reaction was stirred at 80 °C till completion and was then removed
from the heating bath and allowed to reach ambient temperature. The reaction was concentrated
under reduced pressure and the residual water was co-evaporated with toluene to give a white solid
that was directly dissolved in DMF (20 mL) at room temperature and 3- chloro-2-methylpropene
(0.9 mL) was added. The reaction was heated to 70 °C till completion. the reaction was diluted
with EtOAc and H2O was added. The layers were separated and the aqueous layer was extracted
with EtOAc. The organic layer was, dried with Na2SO4, filtered and concentrated at reduced
pressure. The residue was purified via silica gel chromatography (3:1) to give 301 (0.85 g, 62%)
as a colorless liquid.
Procedure for allylation reaction using 3-pyridyl methallylsulfone (301)
Benzyl 2,3-di-O-benzyl-6,7,8,9-tetradeoxy-8-methyl-α-D-non-8-enoglucopyranoside
(235). Compound 234 (100 mg, 0.2 mmol) was dissolved in dry α,α,α-Trifluorotoluene (10 mL)
and treated with 3-pyridyl methallylsulfone (0.1 g, 0.5 mmol). Lauroyl peroxide (0.36 g, 0.9 mmol)
was added to the reaction mixture in two portions at 80 oC. The reaction mixture was stirred at 80
o

C for 2 h with monitoring by TLC (hexane:ethyl acetate 6:1, Rf =0.6). After completion, the

reaction mixture was concentrated under reduced pressure and the residue was purified by silica
gel column chromatography (hexane:ethyl acetate 15:1 to 10:1 to 6:1) to give 235 (43 mg, 50%)
as a colorless syrup and 306 (29.3 mg, 38%) also as a colorless syrup. The spectral data were
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consistent with the data acquired from allylation procedure utilizing 2-pyridyl methallylsulfone as
the allyl source.
Procedure for preparation of methyallyl ethylsulfone (304)
A solution of ethanethiol (5 ml, 67.6 mmol) in DMF (5 mL) was cooled to 0 oC, then
sodium hydride (2.7 g, 67.6 mmol) was added portionwise over 15 minutes. 3-chloro-2methylpropene (6.6 g, 67.6 mmol) was added and the mixture was stirred at 0 oC for 1 h then at
ambient temperature for 2 h. After completion, the reaction mixture was quenched with methanol
(5 mL) followed by water (15 mL) and extracted with ethyl acetate (30 mL). The aqueous layer
was extracted with ethyl acetate thrice and the combined organic layer dried over anhydrous
MgSO4, filtered, and concentrated. The residual crude (7.86 g, 67.6 mmol) was dissolved in
CH2Cl2 (150 mL). The solution was treated with m-Chloroperoxybenzoic acid (23 g, 135.2 mmol)
and stirred at 0 oC till completion. After completion, the reaction mixture was concentrated under
reduced pressure, diluted with CH2Cl2 (20 mL) and neutralized with 0.2 M aqueous sodium
bicarbonate (100 mL). The aqueous layer was extracted with CH2Cl2 twice and the combined
organic layer was dried over anhydrous MgSO4, filtered, and concentrated. The crude was purified
by silica gel column chromatography (hexane:ethyl acetate 4:1) to give 304 (8.1 g, 81%) as a
colorless liquid.1H NMR (400 MHz, CDCl3) δ 5.08 (s, 1H), 4.97 (s, 1H), 3.55 (s, 2H), 2.94-2.88
(m, 2H), 1.84 (s, 3H), 1.26-1.22 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 134.0, 120.2, 60.1, 45.6,
22.6, 6.4. HRMS (ESI): m/z calcd for C6H12O2SNa [M + Na] 171.0278, found 171.0270.
Procedure for allylation reaction using methallyl ethylsulfone (304)
Benzyl 2,3-di-O-benzyl-6,7,8,9-tetradeoxy-8-methyl-α-D-non-8-enoglucopyranoside
(235). Compound 234 (50 mg, 0.1 mmol) was dissolved in a solvent mixture of heptane:PhCl 1:1
(2 mL) and treated with ethyl methallylsulfone (26 mg, 0.2 mmol). AIBN (3 mg, 0.02 mmol) was
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then added. The reaction mixture was stirred at 80 oC for 2 h with monitoring by TLC (hexane:ethyl
acetate 3:1, Rf =0.6). After completion, the reaction mixture was concentrated under reduced
pressure and the residue was purified by silica gel column chromatography (hexane:ethyl acetate
3:1) to give 7 (4 mg, 10%) as a colorless syrup and 306 (2.6 mg, 6%). The spectral data were
consistent with the data acquired from allylation procedure utilizing lauroyl peroxide as the
initiator.
Procedure for allylation reaction using triethylborane as the initiator
Benzyl 2,3-di-O-benzyl-6,7,8,9-tetradeoxy-8-methyl-α-D-non-8-enoglucopyranoside
(235). Compound 234 (0.16 g, 0.3 mmol) and 2-pyridyl methallylsulfone (57 mg, 0.7 mmol) were
dissolved in dry α,α,α-Trifluorotoluene (3.2 mL) and the mixture cooled to 0 oC. Triethylborane
(1.45 mL, 1.5 mmol) was then added to the reaction mixture in a dropwise fashion via a syringe
pump. The reaction mixture was stirred at 0 oC for 2 h in an open air and gradually brought to rt
with monitoring by TLC (hexane:ethyl acetate 6:1, Rf =0.6). After completion, the reaction mixture
was concentrated under reduced pressure and the residue was purified by silica gel column
chromatography (hexane:ethyl acetate 6:1) to give 7 (57 mg, 40%) as a colorless syrup and 306
(64 mg, 51%) as a colorless syrup. The spectral data were consistent with the data acquired from
allylation procedure utilizing lauroyl peroxide as the initiator.
Benzyl

2,3-di-O-benzyl-6,7,8,9-tetradeoxy-8-methyl-4-keto-α-D-non-8-

enoglucopyranoside (236). Compound 235 (1.85 g, 3.8 mmol) was dried under vaccum overnight
and dissolved in anhydrous solution of DMSO:dichloromethane 2:1 (10.8 mL) under argon. The
mixture was cooled to 0 oC. A solution of sulfur trioxide pyridine complex (1.81 g, 11.4 mmol) in
DMSO (2 mL) was stirred at rt for 20 minutes then added dropwise to the sugar solution at 0 oC.
The reaction mixture was allowed to come to rt and stirred till completion with monitoring by TLC
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(hexane:ethyl acetate 4:1, Rf =0.5). The reaction mixture was concentrated under reduced pressure
and the residue diluted with dichloromethane (50 mL) and water (50 mL). The aqueous layer was
extracted with dichloromethane twice and the combined organic layer was dried over anhydrous
MgSO4, filtered, and concentrated. The residue was purified by silica gel column chromatography
(hexane:ethyl acetate 4:1) to give 236 (1.50 g, 81%) as a colorless syrup. [α]D23 = +135.1 (c = 1.2,
CHCl3), 1H NMR (400 MHz, CDCl3) δ 7.54 – 7.20 (m, 15H), 5.03 – 4.94 (m, 2H, PhCH2, H-1),
4.84 – 4.57 (m, 7H, 5PhCH2, 2Hgem), 4.52 (d, J = 10.1 Hz, 1H, H-3), 4.16 (dd, J = 8.4, 3.4 Hz, 1H,
H-5), 3.78 (dd, J = 10.1, 3.6 Hz, 1H, H-2), 2.21 – 2.01 (m, 3H, H-7, H-7’, H-6), 1.80 – 1.63 (m,
4H, H-6’, CH3). 13C NMR (101 MHz, CDCl3) δ 203.4, 144.9, 138.0, 137.9, 136.8, 128.5, 128.40,
128.38, 128.3, 128.2, 128.1, 128.0, 127.9, 127.83, 127.79, 110.6, 95.7, 82.98, 80.6, 74.4, 73.6,
72.5, 69.8, 33.2, 26.3, 22.4. HRMS (ESI): m/z calcd for C31H34O5Na [M + Na] 509.2304, found
509.2310.
Benzyl

2,3-di-O-benzyl-6,7,8,9-tetradeoxy-8-methyl-4-C-vinyl-α-D-non-8-

enogalactopyranoside (237). A solution of 236 (0.86 g, 1.8 mmol) in dry THF (18 mL) was cooled
to -78 oC under argon and treated with vinylmagnesium bromide (5.32 mL, 5.3 mmol). The
reaction mixture was stirred at -78 oC for 2 h with monitoring by TLC (hexane:ethyl acetate 6:1,
Rf = 0.6). After completion, the reaction mixture was concentrated and the residue purified by
silica gel column chromatography (hexane:ethyl acetate 6:1 ) to give 237 (0.86 g, 97%) as a
colorless syrup. [α]D23 = +89.3 (c = 1.35, CHCl3), 1H NMR (400 MHz, CDCl3) δ 7.54 – 7.22 (m,
15H), 5.82 (dd, J = 17.2, 10.6 Hz, 1H, H-vinyl), 5.52 (dd, J = 17.2, 1.1 Hz, 1H, H-vinyl), 5.38 (dd,
J = 10.7, 1.0 Hz, 1H, H-vinyl), 4.94 (d, J = 3.6 Hz, 1H, H-1), 4.88 (d, J = 10.4 Hz, 1H, PhCH2),
4.80 (d, J = 12.3 Hz, 1H, PhCH2), 4.77 – 4.73 (m, 2H), 4.69 (d, J = 11.9 Hz, 1H, PhCH2), 4.66 (d,
J = 10.4 Hz, 1H, PhCH2), 4.59 (d, J = 12.3 Hz, 1H, PhCH2), 4.56 (d, J = 11.9 Hz, 1H, PhCH2),

134

3.92 (d, J = 9.6 Hz, 1H, H-3), 3.85 (dd, J = 9.6, 3.7 Hz, 1H, H-2), 3.78 (dt, J = 9.8, 3.51 Hz, 1H,
H-5), 2.63 (s, 1H, OH), 2.35 – 2.28 (m, 1H), 2.07 – 2.00 (m, 1H), 1.83 – 1.65 (m, 5H). 13C NMR
(101 MHz, CDCl3) δ 145.5, 139.7, 138.3, 138.2, 137.2, 128.5, 128.4, 128.3, 128.24, 128.17,
127.93, 127.87, 127.8, 127.7, 116.6, 110.3, 95.1, 80.1, 72.9, 71.0, 68.7, 34.6, 25.6, 22.5. HRMS
(ESI): m/z calcd for C33H38O5Na [M + Na] 537.2617, found 537.2622.
Benzyl

2,3-di-O-benzyl-6,7,8,9-tetradeoxy-8-methyl-α-D-non-8-

enogalactopyranoside (238). A solution of 237 (0.76 g, 1.5 mmol) in dry dichloromethane (4 mL)
was treated with 2nd gen. Grubbs catalyst (0.1 g, 0.2 mmol). The reaction mixture was heated at 40
o

C till completion with monitoring by TLC (hexane:ethyl acetate 3:1, Rf = 0.5). After completion,

the reaction mixture was concentrated and the concentrate purified by silica gel column
chromatography (hexane:ethyl acetate 3:1 ) to give 238 (0.62 g, 85%) as a light brown syrup. [α]D23
= +65.6 (c = 0.8, CHCl3), 1H NMR (400 MHz, CDCl3) δ 7.66 – 7.04 (m, 15H), 5.55 (s, 1H), 5.08
(d, J = 11.2 Hz, 1H), 4.93 (d, J = 3.9 Hz, 1H, H-1), 4.71 (d, J = 12.2 Hz, 2H, PhCH2), 4.69 – 4.60
(m, 2H, PhCH2), 4.55 (d, J = 11.8 Hz, 1H, PhCH2), 4.01 (dd, J = 9.4, 4.0 Hz, 1H, H-2), 3.74 (dd,
J = 11.9, 3.7 Hz, 1H, H-5), 3.68 (d, J = 9.4 Hz, 1H, H-3), 2.15 – 1.94 (m, 3H, H-7, H-7’, H-6),
1.74 – 1.53 (m, 4H, CH3, H-6’). 13C NMR (101 MHz, CDCl3) δ 139.2, 138.6, 138.3, 137.5, 128.5,
128.39, 128.35, 128.1, 128.0, 127.80, 127.75, 127.7, 122.1, 96.2, 80.2, 78.6, 75.96, 72.9, 70.7,
69.3, 69.3, 30.3, 23.3, 21.7. HRMS (ESI): m/z calcd for C31H34O5Na [M + Na] 509.2304, found
509.2316.
Benzyl

2,3-di-O-benzyl-6,8,9-trideoxy-8-methyl-7-keto-α-D-non-8-

enogalactopyranoside (239). A solution of 238 (0.48 g, 1.0 mmol) in dry 1.4 dioxane (10 mL)
was treated with selenium dioxide (0.11 g, 1.0 mmol) added in four portions over the period of the
reaction. The reaction mixture was heated at 80 oC till completion with monitoring by TLC
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(hexane:ethyl acetate 4:1, Rf = 0.3). After completion, the reaction mixture was concentrated and
the residue purified by silica gel column chromatography (hexane:ethyl acetate 4:1 to 2:1) to give
239 (0.34 g, 70%) as an off white crystalline solid. Mp 117-120 oC. [α]D23 = +64.6 (c = 0.35,
CHCl3), 1H NMR (400 MHz, CDCl3 ) δ 7.50 – 7.20 (m, 15H), 6.47 (s, 1H), 5.12 (d, J = 11.3 Hz,
1H, PhCH2), 4.94 (d, J = 3.8 Hz, 1H, H-1), 4.74 (d, J = 11.4 Hz, 1H, PhCH2), 4.68 (d, J = 12.2 Hz,
1H, PhCH2), 4.63 (d, J = 11.7 Hz, 1H, PhCH2 ), 4.57 (d, J = 12.2 Hz, 1H, PhCH2), 4.54 (d, J =
11.7 Hz, 1H, PhCH2), 4.10 (dd, J = 12.8, 4.9 Hz, 1H, H-5 ), 4.03 (dd, J = 9.3, 3.9 Hz, 1H, H-2),
3.78 (d, J = 9.3 Hz, 1H, H-3), 2.91 (dd, J = 16.5, 12.8 Hz, 1H, H-6ax), 2.48 (dd, J = 16.5, 4.9 Hz,
1H, H-6eq), 1.70 (s, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 197.5, 141.2, 137.9, 137.8, 136.9,
128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 96.2, 78.4, 78.3, 75.9, 72.9, 70.5,
69.6, 67.0, 37.99, 15.6. HRMS (ESI): m/z calcd for C31H32O6Na [M + Na] 523.2097, found
523.2096.
Benzyl 2,3-di-O-benzyl-6,8,9-trideoxy -8-methyl-α-D-non-8-enogalactopyranoside
(240). A solution of 239 (0.39 g, 0.8 mmol) in dry methanol (7 mL) was treated with cerium (III)
chloride heptahydrate (0.44 g, 1.2 mmol) and stirred at rt for 1 h. The reaction mixture was cooled
to -78 oC and sodium borohydride (50 mg, 1.3 mmol) was added, with monitoring by TLC
(hexane:ethyl acetate 1:1, Rf = 0.3). After completion, the reaction mixture was concentrated and
the crude diluted with ethyl acetate (50 mL) and washed with water (20 mL). The aqueous layer
was extracted with ethyl acetate and the combined organic layer dried over anhydrous MgSO4,
filtered, and concentrated. The residue was purified by silica gel column chromatography
(hexane:ethyl acetate 1:1 ) to give 240 (0.34 g, 86%) as a colorless liquid. [α]D23 = +55.5 (c = 0.95,
CHCl3), 1H NMR (400 MHz, CD3OD) δ 7.51 – 7.13 (m, 15H), 5.50 (s, 1H, H-9), 5.01 – 4.92 (m,
2H, PhCH2, H-1), 4.69 – 4.63 (m, 2H, 2PhCH2), 4.63 – 4.52 (m, 3H, 3PhCH2), 4.05 – 3.94 (m, 2H,
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H-2, H-7), 3.62 (dd, J = 12.2, 4.1 Hz, 1H, H-5), 3.54 (d, J = 9.6 Hz, 1H, H-3), 2.02 – 1.86 (m, 2H,
H-6, H-6’), 1.66 (s, 3H, CH3). 13C NMR (101 MHz, CD3OD) δ 141.4, 138.6, 138.3, 137.6, 128.2,
128.1, 128.0, 127.96, 127.9, 127.8, 127.5, 127.4, 127.3, 122.9, 96.5, 79.7, 78.4, 75.3, 72.4, 70.5,
69.1, 69.0, 67.7, 31.4, 17.96. HRMS (ESI): m/z calcd for C31H34O6Na [M + Na] 525.2253, found
525.2252.
Benzyl-2,3,4,7-tetra-O-benzyl-8,9-epoxy-α-D-bradyrhizopyranoside (317). A solution
of 240 (42 mg, 0.08 mmol) in dry DMF (0.8 mL) was placed in an ice bath at 0 oC under argon.
Sodium hydride (3 mg, 0.08 mmol) and benzyl bromide (10 µL, 0.08 mmol) were added. The
reaction mixture was stirred at 0 oC for 1 h then at ambient temperature for 2 h, with monitoring
by TLC (hexane:ethyl acetate 20:1, Rf = 0.5). After completion, the reaction mixture was quenched
with methanol (2 mL) followed by water (5 mL) at 0 oC and extracted with ethyl acetate (10 mL).
The aqueous layer was extracted with ethyl acetate thrice and the combined organic layer dried
over anhydrous MgSO4, filtered, and concentrated. The unreacted benzyl bromide was removed
via flash column chromatography yielding 52 mg of desired intermediate by weight. A solution of
intermediate (52 mg, 0.08 mmol) in dry THF (0.6 mL) was treated with m-Chloroperoxybenzoic
acid (0.03 mg, 0.15 mmol) and stirred at RT, with monitoring by TLC (hexane:ethyl acetate 10:1,
Rf = 0.6). After completion, the reaction mixture was concentrated under reduced pressure, diluted
with ethyl acetate (5 mL) and neutralized with 0.2 M aqueous sodium bicarbonate (3 mL). The
aqueous layer was extracted with ethyl acetate twice and the combined organic layer was dried
over anhydrous MgSO4, filtered, and concentrated. The crude was purified by silica gel column
chromatography (hexane:ethyl acetate 10:1) to give 317 (51 mg, 86%) as a syrup. [α]D23 = +30.9
(c = 0.25, CHCl3) 1H NMR (900 MHz, Acetonitrile-d3) δ 7.42 – 7.31 (m, 25H), 5.08 – 5.01 (m,
3H), 4.85 (d, J = 10.7 Hz, 1H), 4.76 (d, J = 11.3 Hz, 1H), 4.69 – 4.65 (m, 4H, H-1, 3PhCH2), 4.54
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(d, J = 11.7 Hz, 1H), 4.52 (d, J = 12 Hz, 1H), 4.06 (dd, J = 9.9, 3.8 Hz, 1H, H-2), 3.93 (d, J = 9.9
Hz, 1H, H-3), 3.84 – 3.78 (m, 2H, H-5, H-7), 3.63 (s, 1H, H-9), 1.94-1.93 (m, 1H, H-6), 1.84 –
1.81 (m, 1H, H-6’), 1.36 (s, 3H).
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C NMR (226 MHz, CD3CN) δ 139.7, 139.0, 138.7, 138.2,

128.4, 128.3, 128.3, 128.3, 128.2, 127.99, 127.9, 127.8, 127.7, 127.7, 127.6, 127.6, 127.5, 127.4,
96., 80.3, 77.7, 75.8, 75.1, 74.1, 72.1, 71.5, 69.3, 67.8, 65.1, 61.5, 60.7, 28.8, 18.7. ESI-HRMS:
m/z calcd for C45H46O7Na [M + Na] 721.3141, found 721.3143.
Benzyl

8,9-anhydro-2,3-di-O-benzyl-6-deoxy-8-methyl-α-D-nonagalactopyranoside

(241). A solution of 240 (0.34 g, 0.7 mmol) in dry THF (6.7 mL) was treated with mchloroperoxybenzoic acid (72 mg, 0.4 mmol) and stirred at rt, with monitoring by TLC
(hexane:ethyl acetate:methanol 1:1:0.1, Rf = 0.3). After completion, the reaction mixture was
concentrated under reduced pressure, diluted with ethyl acetate (50 mL) and neutralized with 0.2
M aqueous sodium bicarbonate (100 mL). The aqueous layer was extracted with ethyl acetate
twice and the combined organic layer was dried over anhydrous MgSO4, filtered, and concentrated.
The crude product was purified by silica gel column chromatography (hexane:ethyl
acetate:methanol 1:1:0.1) to give 241 (0.29 g, 83%) as a syrup. [α]D23 = +28.9 (c = 0.7, CHCl3),
1

H NMR (600 MHz, CDCl3) δ 7.51 – 7.16 (m, 15H), 5.09 (d, J = 11.7 Hz, 1H, PhCH2 ), 4.85 (d, J

= 3.9 Hz, 1H, H-1), 4.72 (d, J = 11.7 Hz, 1H, PhCH2), 4.69 (d, J = 11.8 Hz, 1H, PhCH2), 4.62 –
4.59 (m, 2H, 2PhCH2 ), 4.56 (d, J = 11.8 Hz, 1H, PhCH2), 4.07 (dd, J = 9.4, 3.9 Hz, 1H, H-2), 3.73
(dd, J = 10.4, 6.3 Hz, 1H, H-7), 3.69 (d, J = 9.4 Hz, 1H, H-3), 3.19 (dd, J = 12.7, 2.7 Hz, 1H, H5), 2.78 (s, 1H, H-9), 1.63 (ddd, J = 12.3, 6.3, 2.8 Hz, 1H, H-6eq), 1.48 (td, J = 12.6, 10.4 Hz, 1H,
H-6ax), 1.24 (s, 3H, methyl). 13C NMR (151 MHz, CDCl3) δ 138.0, 137.3, 128.7, 128.5, 128.41,
128.39, 127.99, 127.97, 127.8, 96.7, 78.3, 75.3, 73.1, 70.8, 69.9, 69.6, 67.4, 63.4, 62.95, 28.5, 19.1.
HRMS (ESI): m/z calcd for C31H34O7Na [M + Na] 541.2202, found 541.2210.
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Benzyl 2,3-di-O-benzyl-8-α-D-bradyrhizopyranoside (242). A solution of 241 (135 mg,
0.3 mmol) in 1,4 dioxane:water 05:1.5 (5 mL), was treated with concentrated sulphuric acid (30
µL, 0.6 mmol) added dropwise in three portions at 65 oC. The reaction was monitored by TLC
(hexane:ethyl acetate:methanol 1:1:0.2, Rf =0.2). After completion, the mixture was diluted with
ethyl acetate (20 mL) and neutralized with saturated aqueous sodium bicarbonate (50 mL). The
aqueous layer was extracted with ethyl acetate twice and the combined organic layer was dried
over anhydrous MgSO4, filtered, and concentrated. The crude product was purified by silica gel
column chromatography (hexane:ethyl acetate:methanol 1:1:0.2) to give 15 (70 mg, 50%) as a
white amorphous solid. Mp, 148-152 oC. [α]D23 = +66.3 (c = 0.75 , CHCl3), 1H NMR (600 MHz,
CD3OD) δ 7.49 – 7.11 (m, 15H), 4.95 – 4.92 (m, 2H, PhCH2, H-1), 4.78 (d, J = 10.4 Hz, 1H,
PhCH2 ), 4.66 (d, J = 12.2 Hz, 1H, PhCH2), 4.57 (d, J = 12.2 Hz, 1H, PhCH2 ), 4.55 (d, J = 11.5
Hz, 1H, PhCH2), 4.52 (d, J = 11.5 Hz, 1H, PhCH2 ), 3.93 (dd, J = 9.5, 3.7 Hz, 1H, H-2), 3.89 (d, J
= 9.6 Hz, 1H, H-3), 3.70 (dd, J = 12.4, 4.0 Hz, 1H, H-5), 3.48 (s, 1H, H-9), 3.43 (dd, J = 12.2, 4.3
Hz, 1H, H-7), 1.82 (q, J = 12.2 Hz, 1H, H-6ax), 1.64 (dt, J = 11.9, 4.2 Hz, 1H, H-6eq), 1.22 (s, 3H,
methyl). 13C NMR (151 MHz, CD3OD) δ 138.14, 138.08, 137.5, 128.14, 128.09, 128.0, 127.99,
127.96, 127.9, 127.8, 127.54, 127.47, 127.4, 95.97, 82.7, 78.8, 78.0, 77.2, 74.95, 73.8, 72.5, 72.3,
69.2, 66.6, 31.1, 14.0. HRMS (ESI): m/z calcd for C31H36O8Na [M + Na] 559.2308, found
559.2311.

α,β-D-Bradyrhizose (20). Compound 242 (45 mg, 0.08 mmol) was dissolved in dry
methanol (5 ml) then 10% Pd/C (79 mg, 0.1 mmol) was added and the mixture degassed with
argon. The reaction mixture was then purged with H2 gas then put under H2 gas at rt till completion.

139

The palladium on carbon was filtered and the filtrate concentrated at reduced pressure. The residual
crude was purified by reversed phase column chromatography ( on a C-18 silica gel) using H2O
as the eluent yielding compound 20 (21 mg, 100% , as an equilibrium mixture of α-D-bradyrhizose,
β-D-bradyrhizose, α,β-furanoses and a regioisomeric 1,9-pyranose) as a white foam with spectral
data consistent with the literature.3 1H NMR (900 MHz, D2O) δ 5.25 (d, J = 3.7 Hz, 0.08H, H-1e),
5.23 (d, J = 4.1 Hz, 0.08H), 5.21 (d, J = 4.3 Hz, 0.42H, H-1b), 5.05 (s, 0.03H, H-1d), 5.04 (s,
0.17H, H-1c), 4.61 (d, J = 8.1 Hz, 1H, H-1a), 4.37 – 4.25 (m, 0.28H), 4.18 – 4.08 (m, 0.24H), 4.06
– 3.96 (m, 0.53H), 3.94 - 3.91 (m, 0.57H), 3.85 – 3.77 (m, 3.14H), 3.78 – 3.67 (m, 4.83H), 3.50 –
3.42 (m, 0.98H), 2.02 – 1.92 (m, 0.17H), 1.92 – 1.82 (m, 0.40H), 1.34 – 1.30 (m, 0.55H), 1.25 1.21 (m, 3.09H), 1.19 – 1.15 (m, 0.80H). 13C NMR (151 MHz, D2O) δ 96.5, 92.2, 78.4, 78.2, 77.6,
77.3, 74.3, 73.3, 72.8, 72.5, 72.0, 70.4, 70.3, 69.0, 65.4, 30.9, 30.8, 14.0, 14.0. HRMS (ESI): m/z
calcd for C10H18O8Na [M + Na] 289.0899, found 289.0900. The chemical shifts for both 1H for
(20) were referenced to HOD (δH 4.79).
Methyl 2,3,4-tri-O-benzyl-α-D-glucopyranoside (338). This acceptor was prepared
according to the literature method in (1.4 g, 98%) yield as a colorless syrup. 1H NMR (400 MHz,
CDCl3) δ 7.41 – 7.25 (m, 15H), 5.00 (d, J = 10.9 Hz, 1H), 4.93 – 4.77 (m, 3H), 4.66 (dd, J = 11.6,
8.2 Hz, 2H), 4.58 (d, J = 3.6 Hz, 1H), 4.02 (t, J = 9.2 Hz, 1H), 3.78 (dd, J = 11.6, 2.5 Hz, 1H), 3.74
– 3.62 (m, 2H), 3.57 – 3.46 (m, 2H), 3.37 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 138.7, 138.14,
138.11, 128.5, 128.4, 128.1, 128.0, 127.94, 127.92, 127.9, 127.6, 98.2, 81.95, 79.99, 77.4, 75.7,
75.0, 73.4, 70.7, 61.9, 55.2. HRMS (ESI): m/z calcd for C28H32O6Na [M + Na] 487.2271, found
487.2265.
Methyl 2-O-benzyl-4,6-O-benzylidene-α-D-mannopyranoside (341). This acceptor was
prepared according to the literature method in (1.2 g, 89%) yield as a colorless syrup. 1H NMR
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(499 MHz, CDCl3) δ 7.53 – 7.49 (m, 2H), 7.43 – 7.30 (m, 8H), 5.57 (s, 1H), 4.77 – 4.75 (m, 1H),
4.74 – 4.66 (m, 2H), 4.27 (dd, J = 9.7, 4.3 Hz, 1H), 4.12 – 4.06 (m, 1H), 3.92 (t, J = 9.5 Hz, 1H),
3.87 – 3.73 (m, 3H), 3.37 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 137.7, 137.4, 129.1, 128.6, 128.3,
128.1, 127.96, 126.3, 102.1, 99.5, 79.5, 78.5, 73.8, 68.8, 68.7, 63.4, 54.99. HRMS (ESI): m/z calcd
for C21H24O6Na [M + Na] 395.1252, found 395.1248.
Methyl

2-O-benzyl-5-O-tert-butyldimethylsilyl-β-D-ribofuranoside

(346).

This

acceptor was prepared according to the literature method in (97 mg, 87%) yield as a colorless
syrup. 1H NMR (600 MHz, CDCl3) δ 7.39 – 7.18 (m, 5H), 4.81 (s, 1H, H-1), 4.72 (d, J = 11.9 Hz,
1H, PhCH2), 4.60 (d, J = 11.9 Hz, 1H, PhCH2 ), 4.34 (dd, J = 7.2, 4.6 Hz, 1H, H-3), 4.09 (dt, J =
7.4, 3.1 Hz, 1H, H-4), 3.79 (dt, J = 12.1, 2.6 Hz, 1H, H-5eq), 3.70 (d, J = 4.5 Hz, 1H, H-2), 3.54
(ddd, J = 11.9, 8.0, 3.5 Hz, 1H, H-5ax), 3.34 (s, 3H), 2.92 (s, 3H), 2.84 (s,3H), 0.87 (s, 9H).13C
NMR (151 MHz, CDCl3) δ 162.5, 137.97, 128.98, 128.3, 128.2, 127.8, 127.7, 106.7, 83.4, 82.3,
72.6, 71.1, 61.7, 55.5, 36.4, 31.4, 25.7, 18.1. HRMS (ESI): m/z calcd for C19H32O5Na [M + Na]
391.1960, found 391.1957.
Methyl 2-O-acetyl-4-O-benzyl-α-L-rhamnopyranoside (351). This acceptor was
prepared according to the literature method in (120 mg, 93%) yield as a colorless syrup. 1H NMR
(500 MHz, CDCl3) δ 7.37 – 7.30 (m, 5H), 5.07 (dd, J = 3.6, 1.6 Hz, 1H), 4.82 (d, J = 11.1 Hz, 1H),
4.68 (d, J = 11.1 Hz, 1H), 4.60 – 4.59 (m, 1H), 4.06 (dd, J = 9.4, 3.6 Hz, 1H), 3.70 (dq, J = 9.5,
6.2 Hz, 1H), 3.34 – 3.29 (m, 4H), 2.13 (s, 3H), 1.33 (d, J = 6.3 Hz, 3H). 13C NMR (126 MHz,
CDCl3) δ 171.0, 138.4, 128.6, 127.95, 98.5, 81.7, 75.2, 72.9, 70.2, 67.3, 54.96, 21.1, 18.1. HRMS
(ESI): m/z calcd for C16H22O6Na [M + Na] 333.1361, found 333.1356.
Methyl 2-azido-3,4-di-O-benzyl-2-deoxy-α-D-galactopyranoside (368). This compound
was prepared according to the literature method5 in (0.25 g, 81%) yield as a colorless syrup. 1H
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NMR (500 MHz, CDCl3) δ 7.39 – 7.31 (m, 10H), 4.95 – 4.89 (m, 1H), 4.82-4.80 (m, 1H), 4.80 –
4.67 (m, 3H), 4.57 (d, J = 11.6 Hz, 1H), 3.97 – 3.91 (m, 3H), 3.76-3.72 (m, 1H), 3.57 – 3.50 (m,
1H), 3.39 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 137.98, 137.6, 128.7, 128.7, 128.6, 128.22,
128.16, 128.0, 127.1, 99.2, 77.9, 74.6, 73.4, 72.8, 70.8, 62.3, 60.2, 55.5. HRMS (ESI): m/z calcd
for C21H25N3O5Na [M + Na] 422.1889, found 422.1878.
Methyl 2-azido-3,4-di-O-benzyl-2-deoxy-α-D-glucopyranoside (360). This compound
was prepared according to the literature method5 in (0.34 g, 83%) yield as a colorless syrup. 1H
NMR (500 MHz, CDCl3) δ 7.41-7.30 (m, 10H), 4.93-4.88 (m, 2H), 4.78 (d, J = 3.5 Hz, 1H), 4.72
– 4.65 (m, 2H), 4.02 (dd, J = 10.2, 8.6 Hz, 1H), 3.84-3.81 (m, 1H), 3.77 – 3.69 (m, 2H), 3.65 (t, J
= 9.3 Hz, 1H), 3.41 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 138.1, 138.0, 128.7, 128.6, 128.24,
128.20, 128.12, 128.08, 128.0, 127.99, 127.1, 98.9, 80.5, 78.1, 75.6, 75.2, 71.5, 63.8, 61.5, 55.3.
HRMS (ESI): m/z calcd for C21H25N3O5Na [M + Na] 422.1910, found 422.1901.
Ethyl

(2-O-acetyl-4,5,7,8-di-O-isopropylidene-3-deoxy-α-D-manno-oct-2-

ulopyranosyl) onate (327). This compound was prepared according to the literature method in
(2.6g, 91 %) yield as a white foam. 1H NMR (600 MHz, CDCl3) δ 4.52 (dt, J = 7.3, 3.5 Hz, 1H,
H-4), 4.37 (ddd, J = 8.4, 6.1, 3.7 Hz, 1H, H-7), 4.32 (dd, J = 7.8, 2.0 Hz, 1H, H-5), 4.24 – 4.19 (m,
2H), 4.08 (dd, J = 9.1, 6.1 Hz, 1H, H-8ax), 3.85 (dd, J = 9.1, 3.7 Hz, 1H, H-8eq), 3.59 (dd, J = 8.3,
2.0 Hz, 1H, H-6), 2.66 (dd, J = 15.6, 3.7 Hz, 1H, H-3eq), 2.07 – 2.03 (m, 4H, H-3ax, CH3), 1.47 (s,
3H), 1.40 (s, 3H), 1.34 (s, 3H), 1.30 (s, 3H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (151 MHz, CDCl3)
δ 168.9, 168.0, 109.8, 109.5, 96.9, 73.3, 72.9, 71.2, 69.5, 67.1, 62.0, 32.1, 27.0, 25.5, 25.1, 24.8,
21.0, 13.8. HRMS (ESI): m/z calcd for C18H28O9Na [M + Na] 411.1751, found 411.1743.
Ethyl (1-adamantanyl 4,5,7,8-di-O-isopropylidene-3-deoxy-2-thio-α-D-manno-oct-2ulopyranosid) onate (328). To a stirred mixture of the Kdo donor 327 (0.23 g, 0.6 mmol), and 1-
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adamantanethiol (0.15 g，0.9 mmol) in anhydrous CH2Cl2 (2 mL) at 0 °C, was added dropwise
boron trifluoride etherate (0.2 mL) under argon. The reaction mixture was stirred at 0 °C for 30
min with monitoring by TLC (hexane:ethyl acetate 2:1, Rf = 0.3). After completion, the reaction
mixture was diluted with CH2Cl2, and neutralized with saturated aqueous sodium bicarbonate (10
mL). The aqueous layer was extracted with CH2Cl2 twice and the combined organic layer was
dried over anhydrous Na2SO4, filtered, and concentrated at reduced pressure. The residual crude
was purified by silica gel column chromatography (hexane/EtOAc: 2/1) to provide 328 (0.26 g,
84%) as a colorless syrup. [α]D23 = +20 (c = 0.6, CHCl3) 1H NMR (600 MHz, CDCl3) δ 4.45-4.43
(m, 1H), 4.35 – 4.25 (m, 3H), 4.16 – 4.06 (m, 3H), 3.71 (dd, J = 7.9, 1.9 Hz, 1H), 2.87 (dd, J =
15.2, 3.9 Hz, 1H), 2.01 – 1.94 (m, 6H), 1.88-1.85 (m, 3H), 1.79 (dd, J = 15.2, 2.6 Hz, 1H), 1.631.62 (m, 6H), 1.42 (s, 3H), 1.39 (s, 3H), 1.36 (s, 3H), 1.32 (t, J = 7.1 Hz, 3H), 1.28 (s, 3H). 13C
NMR (151 MHz, CDCl3) δ 171.2, 109.6, 109.1, 84.5, 73.8, 72.1, 71.5, 70.3, 67.7, 61.7, 49.99,
43.6, 36.1, 34.3, 29.8, 26.9, 25.5, 25.3, 24.9, 14.0. HRMS (ESI): m/z calcd for C26H40O7SNa [M
+ Na] 519.2647, found 519.2640.
Ethyl (1-adamantanyl-3-deoxy-2-thio-α-D-manno-oct-2-ulopyranosid) onate (329). A
solution of 328 (0.89 g, 1.8 mmol) in CH2Cl2 (5 mL), was treated with a solution mixture of
trifluoroacetic acid:water 1:1 (1 mL) at 0 oC. The reaction mixture was stirred at 0 oC till
completion with monitoring by TLC (hexane:ethyl acetate:methanol 1:1:0.5, Rf =0.1). After
completion, the mixture was diluted with CH2Cl2 (10 mL) and neutralized with saturated aqueous
sodium bicarbonate (20 mL). The aqueous layer was extracted with ethyl acetate three times and
the combined organic layer was dried over anhydrous Na2SO4, filtered, and concentrated. The
residual crude was purified by silica gel column chromatography (hexane:ethyl acetate:methanol
1:1:0.5) to give 329 (0.35 g, 94%) as a light yellow syrup [α]D23 = +98 (c = 0.4, CD3OD) 1H NMR
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(500 MHz, CD3OD) δ 4.34-4.29 (m, 1H), 4.23-4.16 (m, 2H), 4.04 – 3.96 (m, 3H), 3.78 (dd, J =
11.3, 5.5 Hz, 1H), 3.63 (dd, J = 11.1, 6.6 Hz, 1H), 2.05 – 1.93 (m, 8H), 1.91 – 1.86 (m, 3H), 1.701.63 (m, 6H), 1.32 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CD3OD) δ 172.5, 86.4, 78.2, 72.4,
71.6, 67.17, 7.91, 63.1, 62.0, 49.3, 43.5, 36.5, 35.9, 29.9, 13.1. HRMS (ESI): m/z calcd for
C20H32O7SNa [M + Na] 439.1757, found 439.1710.
Ethyl

(1-adamantanyl

4,5,7,8-tetra-O-acetyl-3-deoxy-2-thio-α-D-manno-oct-2-

ulopyranosid) onate (330). A solution of 329 (0.18 g, 0.4 mmol) in pyridine (5 mL), was cooled
to 0 oC. 4-dimethylaminopyridine (26 mg, 0.2 mmol) was added followed by the addition of acetic
anhydride (0.2 mL, 2.2 mmol) The reaction mixture was stirred at 0 oC till completion with
monitoring by TLC (hexane:ethyl acetate 3:1, Rf = 0.3). After completion, the reaction mixture
was concentrated under reduced pressure and the residue purified by silica gel column
chromatography (hexane:ethyl acetate 3:1) to give 330 (0.24 g, 96%) as an off white form. [α]D23
= +136 (c = 0.3, CHCl3) 1H NMR (600 MHz, CD3CN) δ 5.32 – 5.28 (m, 1H, H-5), 5.23 (ddd, J =
12.1, 5.3, 3.1 Hz, 1H, H-4), 5.15 (ddd, J = 8.6, 5.9, 2.7 Hz, 1H, H-7), 4.65 (dd, J = 8.6, 1.5 Hz,
1H, H-6), 4.54 (dd, J = 12.2, 2.8 Hz, 1H, H-8eq), 4.31 (dq, J = 10.8, 7.1 Hz, 1H, OCH2CH3), 4.21
(dq, J = 10.8, 7.1 Hz, 1H, OCH2CH3), 4.01 (dd, J = 12.2, 5.9 Hz, 1H, H-8ax), 2.22 – 2.17 (m, 1H),
2.16 – 2.13 (m, 1H), 2.06 – 1.94 (m, 15H), 1.93 – 1.89 (m, 5H), 1.71-1.65 (m, 6H), 1.32 (t, J = 7.1
Hz, 3H).13C NMR (151 MHz, CD3CN) δ 170.4, 170.1, 169.6, 169.4, 86.2, 69.3, 68.3, 66.6, 64.8,
62.2, 61.9, 49.9, 43.1, 35.7, 34.1, 29.8, 19.98, 19.96, 19.92, 19.85, 13.3. HRMS (ESI): m/z calcd
for C28H40O11SNa [M + Na] 607.2206, found 607.2189.
Ethyl (1-adamantanyl 8-O-tert-butyldimethylsilyl-3-deoxy-2-thio-α-D-manno-oct-2ulopyranosid) onate (332). To a solution mixture of thioglycoside 329 (0.15 g, 0.4 mmol) in DMF
(3.7 mL) was added imidazole (50 mg, 0.7 mmol) and TBSCl (55 mg, 0.4 mmol) at 0 °C. The
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reaction mixture was gradually warmed to rt and stirred for 1 h while monitoring by TLC
(hexane:ethyl acetate 1:1, Rf = 0.2). The reaction was then quenched by addition of saturated
aqueous NH4Cl, and then diluted with ethyl acetate. The organic layer was washed with water and
brine, dried over anhydrous Na2SO4, filtered and concentrated at reduced pressure. The residual
syrup was purified by silica gel column chromatography (hexane:ethyl acetate 1:1) to give 332
(0.17 g, 89%) as an off white foam. [α]D23 = +105 (c = 1.4, CH3OH) 1H NMR (500 MHz, CD3CN)
δ 4.27 – 4.17 (m, 1H), 4.17 – 4.08 (m, 2H), 3.94-3.92 (m, 1H), 3.89-3.85 (m, 2H), 3.81 (dd, J =
10.3, 5.5 Hz, 1H), 3.62 – 3.58 (m, 1H), 1.99 – 1.89 (m, 8H), 1.88 – 1.81 (m, 3H), 1.66 – 1.62 (m,
5H), 1.27 (t, J = 7.1 Hz, 3H), 0.91-0.82 (m, 9H), 0.06 (s, 6H). 13C NMR (126 MHz, CD3CN) δ
170.9, 86.5, 72.0, 71.6, 66.9, 66.0, 64.9, 61.6, 49.3, 43.4, 37.1, 35.9, 29.9, 25.5, 18.1, 13.5, 0.9,
0.7, 0.6, 0.4, 0.2, 0.07. HRMS (ESI): m/z calcd for C26H46O7SSiNa [M + Na] 553.2632, found
553.2626.
Ethyl (1-adamantanyl 5,7-di-O-tert-butylsilyl-8-O-tert-butyldimethylsilyl-3-deoxy-2thio-α-D-manno-oct-2-ulopyranosid) onate (333). A solution of 332 (60 mg, 0.1 mmol) in
pyridine (1.1 mL) was cooled to 0 oC. 4-dimethylaminopyridine (7 mg, 0.06 mmol) was added
followed by the addition of di-tert-butylsilyl bis(trifluoromethanesulfonate) (37 μL). The reaction
mixture was stirred at 0 oC till completion with monitoring by TLC (hexane:ethyl acetate 4:1, Rf
= 0.5). The reaction was then quenched by addition of saturated aqueous NH4Cl, and then diluted
with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous
Na2SO4, filtered and concentrated under reduced pressure. The residual crude was purified by
silica gel column chromatography (hexane:ethyl acetate 4:1) to give 333 (62 mg, 82%) as a
colorless syrup. [α]D23 = +82 (c = 0.3, CHCl3) 1H NMR (500 MHz, C6D6) δ 4.68 (br, 1H, H-6),
4.45 (t, J = 5.7 Hz, 1H, H-7), 4.34 (, J = 3.0 Hz, 1H, H-5), 4.26 – 4.12 (m, 1H, H-4), 4.02-3.99 (
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2H, 2CH2), 3.79 – 3.71 (m, 2H, H-8ax, H-8eq), 2.59 (dd, J = 13.5, 4.8 Hz, 1H, H-3ax), 2.26 – 2.10
(m, 2H), 2.00 (d, J = 12.0 Hz, 3H), 1.83 (br, 4H), 1.59-1.56 (m, 5H), 1.46 (d, J = 12.4 Hz, 4H),
1.14 (s, 9H), 1.03 (s, 6H), 1.00 (s, 9H), 0.88 (s, 9H). 13C NMR (126 MHz, C6D6) δ 170.1, 86.6,
77.4, 77.0, 70.6, 69.1, 66.6, 66.0, 61.0, 49.6, 43.4, 38.2, 36.1, 30.0, 27.9, 27.8, 27.4, 27.3, 25.9,
21.96, 21.5, 20.5, 18.4, 13.8. HRMS (ESI): m/z calcd for C34H62O7SSi2Na [M + Na] 694.3673,
found 694.3665.
Ethyl

(1-adamantanyl

4-O-benzoyl-5,7-di-O-tert-butylsilyl-8-O-tert-

butyldimethylsilyl-3-deoxy-2-thio-α-D-manno-oct-2-ulopyranosid) onate (334). To a solution
of 333 (70.7 mg, 0.1 mmol) in pyridine (1.1 mL) was added 4-dimethylaminopyridine (6 mg, 0.05
mmol) and benzoyl chloride (12 μL, 0.3 mmol) at 0 oC. The reaction mixture was stirred at 0 oC
till completion with monitoring by TLC (hexane:ethyl acetate 6:1, Rf = 0.5). The reaction was then
quenched by addition of methanol. The resulting mixture was concentrated under reduced
pressure. The obtained residue was purified by silica gel column chromatography (hexane:ethyl
acetate 6:1) to afford 334 (75 mg, 86%) as a colorless syrup. [α]D23 = +63 (c = 0.1, CHCl3) 1H
NMR (900 MHz, C6D6) δ 8.13 – 8.08 (m, 2H), 7.02 – 6.98 (m, 1H), 6.96 – 6.92 (m, 2H), 5.70
(ddd, J = 12.2, 4.7, 2.7 Hz, 1H, H-4), 4.92 (d, J = 2.8 Hz, 1H, H-5), 4.86 (t, J = 0.7 Hz 1H, H-6),
4.53 (ddd, J = 6.5, 4.8, 0.7 Hz, 1H, H-7), 4.07 – 3.99 (m, 2H, 2OCH2CH3), 3.86 – 3.81 (m, 2H, H8ax, H-8eq), 2.85 (t, J = 12.7 Hz, 1H, H-3ax), 2.67 (dd, J = 13.1, 4.6 Hz, 1H, H-3eq), 2.23 (d, J =
11.8 Hz, 3H), 2.07 (d, J = 11.9 Hz, 3H), 1.85 (s, 3H), 1.60 (d, J = 11.8 Hz, 3H), 1.48 (d, J = 12.1
Hz, 3H), 1.22 (s, 11H), 1.03 (s, 11H), 0.97 (d, J = 7.1 Hz, 3H), 0.94 (s, 11H). 13C NMR (226 MHz,
C6D6) δ 169.9, 165.4, 132.6, 130.6, 129.6, 128.2, 127.98, 127.96, 127.9, 127.8, 127.74, 127.69,
127.63, 127.59, 127.4, 86.6, 77.2, 70.7, 66.6, 66.1, 61.1, 49.8, 43.4, 36.1, 34.0, 29.99, 29.9, 27.95,
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27.2, 25.98, 21.96, 21.4, 18.5, 13.8. HRMS (ESI): m/z calcd for C41H66O8SSi2Na [M + Na]
797.3909, found 797.3889.
Ethyl

(1-adamantanyl

4,5,7,8-tetra-O-benzyl-3-deoxy-2-thio-α-D-manno-oct-2-

ulopyranosid) onate (331). To a solution of 329 (0.12 g, 0.3 mmol) in dry DMF (2.9 mL) were
added sodium hydride (46.1 mg, 1.2 mmol) and BnBr (138 μL, 1.2 mmol) at 0 °C. The reaction
mixture was gradually warmed to room temperature and stirred till completion with monitoring by
TLC (hexane:ethyl acetate 10:1, Rf = 0.6).The reaction was quenched by the addition methanol,
then was diluted with ethyl acetate. The organic layer was washed with water and brine, dried over
anhydrous Na2SO4, filtered and concentrated in at reduced pressure. The residual syrup was
purified by silica gel column chromatography (hexane:ethyl acetate 10:1) to afford 331 (0.2 g,
91%) as a colorless syrup. . [α]D23 = +138 (c = 0.8, CHCl3). 1H NMR (500 MHz, C6D6) δ 7.337.31 (m, 4H), 7.29 – 7.26 (m, 3H), 7.14-7.08 ( 7H), 7.04 – 7.01 (m, 6H), 5.09 (dd, J = 11.4, 3.7
Hz, 1H), 4.99 (d, J = 12.5 Hz, 1H), 4.92 (d, J = 12.4 Hz, 1H), 4.85 – 4.81 (m, 1H), 4.62 (ddd, J =
10.0, 8.2, 1.4 Hz, 1H, H-7), 4.56 – 4.53 (m, 1H), 4.41 – 4.37 (m, 2H), 4.34-.30 (m, 2H), 4.22-4.16
(m, 3H), 4.10 – 4.07 (m, 1H), 3.96 – 3.91 (m, 2H), 2.74 – 2.68 (m, 2H), 2.14 – 2.00 (m, 6H), 1.82
– 1.75 (m, 3H), 1.48 – 1.42 (m, 6H), 0.87 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, C6D6) δ 169.97,
169.9, 139.54, 139.48, 139.1, 138.8, 138.7, 129.0, 128.37, 128.35, 128.23, 128.20, 128.0, 127.95,
127.9, 127.8, 127.7, 127.6, 127.5, 127.4, 127.31, 127.25, 127.23, 127.16, 87.2, 87.1, 77.5, 77.4,
76.3, 74.7, 74.6, 73.4, 73.0, 72.97, 72.7, 72.6, 72.23, 72.17, 70.43, 70.40, 70.2, 70.0, 66.9, 61.1,
49.6, 49.5, 43.5, 36.2, 36.1, 35.7, 30.09, 30.06, 13.7. HRMS (ESI): m/z calcd for C48H56O7SNa
[M + Na] 800.3672, found 800.3671.
Ethyl (4,5,7,8-tetra-O-acetyl-3-deoxy-β-D-manno-oct-2-ulopyranosyl) onate-(2→6)methyl 2,3,4-tri-O-benzyl-α-D-glucopyranoside (369). A mixture of donor 330 (59 mg, 0.1
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mmol) acceptor 338 (70.3 mg, 0.2 mmol) and activated 4Å acid-washed powdered molecular
sieves (59 mg) in CH2Cl2:CH3CN 2:1 (0.5 mL, 0.2M) was stirred for 30 min at rt under argon,
then cooled to -78 oC. The reaction mixture was then treated with N-iodosuccinimide (25 mg, 0.1
mmol) and TfOH (9 μL, 0.1 mmol) and stirred at -78 oC till completion, then quenched with
triethylamine (10 μL) at -78 oC and gradually stirred to rt. The reaction mixture was diluted with
CH2Cl2 (5 mL) filtered through celite and washed with 20% aqueous Na2S2O3 (5 mL). The aqueous
layer was extracted with CH2Cl2 (3 mL) twice and the combined organic layer was dried over
Na2SO4 and concentrated at reduced pressure. The residual crude was purified via silica gel column
chromatography eluting with (hexane/ethyl acetate 4:1) yielding 369 (79 mg, 89%) as a colorless
syrup. [α]D23 = +33 (c = 0.8, CHCl3) 1H NMR (500 MHz, C6D6) δ 7.45 (m, 1H), 7.29 (m, 2H), 7.21
(d, J = 7.6 Hz, 2H), 7.10 – 7.02 (m, 10H), 5.54 – 5.52 (m, 1H), 5.49 (ddd, J = 9.4, 5.4, 2.0 Hz,
1H), 5.13 – 5.09 (m, 1H), 5.07 (d, J = 11.1 Hz, 1H), 4.90 (d, J = 11.4 Hz, 1H), 4.72 (d, J = 11.1
Hz, 1H), 4.63 (d, J = 11.8, 1H), 4.61 (d, J = 12.0, 1H), 4.55 – 4.49 (m, 2H), 4.36 (dd, J = 12.3, 5.6
Hz, 1H), 4.19 (dd, J = 9.8, 5.4 Hz, 1H), 4.16 (d, J = 7.6 Hz, 1H), 4.11 – 4.07 (m, 1H), 4.03-3.98
(m, 2H), 3.89-3.84 (m, 1H), 3.80 – 3.75 (m, 2H), 3.45 (t, J = 5.9 Hz, 1H), 3.34-3.31 (m, 4H), 2.73
(dd, J = 12.3, 4.1 Hz, 1H), 2.39 (t, J = 12.7 Hz, 1H), 1.74 (s, 3H), 1.73 (s, 3H), 1.69 (s, 3H), 1.56
(s, 3H), 0.86 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, C6D6) δ 169.99, 169.8, 169.3, 169.1, 167.4,
139.6, 139.2, 139.1, 128.3, 128.13, 128.06, 128.0, 127.9, 127.84, 127.75, 127.7, 127.6, 127.5,
127.44, 127.41, 127.2, 105.1, 99.8, 82.2, 79.8, 75.1, 74.92, 74.86, 73.5, 72.9, 71.4, 68.1, 67.3, 64.3,
64.1, 62.7, 61.9, 56.2, 32.8, 20.2, 20.1, 19.98, 13.7. HRMS (ESI): m/z calcd for C46H56O17Na [M
+ Na] 903.3417, found 903.3407.
Ethyl (4,5,7,8-tetra-O-acetyl-3-deoxy-β-D-manno-oct-2-ulopyranosyl) onate-(2→3)methyl 2-O-benzyl-4,6-O-benzylidene-α-D-mannopyranoside (370). A mixture of donor 330
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(110 mg, 0.2 mmol) acceptor 341 (110 mg, 0.3 mmol) and activated 4Å acid-washed powdered
molecular sieves (110 mg) in CH2Cl2:CH3CN 2:1 (0.95 mL, 0.2M) was stirred for 30 min at rt
under argon, then cooled to -78 oC. The reaction mixture was then treated with N-iodosuccinimide
(47 mg, 0.2 mmol) and TfOH (17 μL, 0.2 mmol) and stirred at -78 oC till completion, then
quenched with triethylamine (20 μL) at -78 oC and gradually stirred to rt. The reaction mixture
was diluted with CH2Cl2 (5 mL) filtered through celite and washed with 20% aqueous Na2S2O3 (5
mL). The aqueous layer was extracted with CH2Cl2 (5 mL) twice and the combined organic layer
was dried over Na2SO4 and concentrated at reduced pressure. The residual crude was purified via
silica gel column chromatography eluting with (hexane/ethyl acetate 3:1) yielding 370 in (0.13 g,
89%) as a colorless syrup and 378 in (4.7 mg, 6%) as an off-white foam. [α]D23 = +56 (c = 0.9,
CHCl3) 1H NMR (600 MHz, CD3CN) δ 7.48 – 7.46 (m, 2H), 7.45 – 7.35 (m, 8H), 5.63 (m, 1H),
5.23 (m, 1H), 5.02 (m, 2H), 4.87 (d, J = 11.6 Hz, 1H), 4.73 (d, J = 1.6 Hz ,1H), 4.70 (d, J = 11.6
Hz, 1H), 4.53 (dd, J = 10.3, 3.3 Hz, 1H), 4.34 (dd, J = 12.2, 2.3 Hz, 1H), 4.26 – 4.15 (m, 4H),
4.05-4.02 (m, 1H), 4.00 – 3.96 (m, 1H), 3.81 – 3.75 (m, 3H), 3.36 (s, 3H), 2.37 (dd, J = 13.0, 5.1
Hz, 1H), 2.24 (t, J = 12.8 Hz, 1H), 2.03 (s, 3H), 2.00 (s, 3H), 1.96 (s, 3H), 1.92 (s, 3H), 1.25 (t, J
= 7.1 Hz, 3H). 13C NMR (151 MHz, CD3CN) δ 170.3, 170.1, 169.6, 167.7, 138.8, 138.1, 128.7,
128.3, 128.1, 127.9, 127.6, 125.96, 100.98, 100.7, 99.7, 78.8, 76.5, 73.9, 71.6, 70.9, 68.3, 67.9,
67.4, 64.4, 63.97, 62.4, 62.2, 54.2, 30.5, 19.95, 13.3. HRMS (ESI): m/z calcd for C39H48O17Na [M
+ Na] 811.2775, found 811.2784.
Ethyl (4,5,7,8-tetra-O-acetyl-3-deoxy-β-D-manno-oct-2-ulo pyranosyl) onate-(2→3)methyl 2-O-benzyl-β-D-ribofuranoside (371). A mixture of donor 330 (30 mg, 0.1 mmol)
acceptor 346 (28 mg, 0.1 mmol) and activated 4Å acid-washed powdered molecular sieves (30
mg) in CH2Cl2:CH3CN 2:1 (0.3 mL, 0.2M) was stirred for 30 min at rt under argon, then cooled
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to -78 oC. The reaction mixture was then treated with N-iodosuccinimide (14 mg, 0.1 mmol) and
TfOH (45 μL, 0.1 mmol) and stirred at -78 oC till completion, then quenched with triethylamine
(5 μL) at -78 oC and gradually stirred to rt. The reaction mixture was diluted with CH2Cl2 (5 mL)
filtered through celite and washed with 20% aqueous Na2S2O3 (5 mL). The aqueous layer was
extracted with CH2Cl2 (4 mL) twice and the combined organic layer was dried over Na2SO4 and
concentrated at reduced pressure. The residual crude was purified via silica gel column
chromatography eluting with (hexane/ethyl acetate 1:1) yielding 371 in (29 mg, 84%) as a colorless
syrup and 378 in (1.1 mg, 5%) as an off-white foam. [α]D23 = +41 (c = 0.9, CHCl3). 1H NMR (600
MHz, C6D6) δ 7.13-7.03 (m, 5H), 5.56 – 5.48 (m, 2H), 5.10 (ddd, J = 13.2, 4.6, 2.9 Hz, 1H), 4.84
(br, 1H), 4.56 (dd, J = 12.3, 2.2 Hz, 1H), 4.45 (dd, J = 12.3, 5.5 Hz, 1H), 4.39 – 4.34 (m, 1H), 4.32
– 4.16 (m, 5H), 3.91 – 3.80 (m, 2H), 3.76 (d, J = 4.8 Hz, 1H), 3.69 (dd, J = 10.1, 4.9 Hz, 1H), 3.19
(s, 3H), 2.66 (dd, J = 12.4, 4.4 Hz, 1H), 2.40 (t, J = 12.8 Hz, 1H), 1.78 – 1.53 (m, 12H), 0.90 (t, J
= 7.1 Hz, 3H). 13C NMR (151 MHz, C6D6) δ 169.9, 169.2, 169.0, 167.6, 137.7, 127.8, 127.6, 127.5,
105.6, 99.7, 82.96, 82.2, 72.3, 71.4, 68.1, 67.2, 65.7, 64.1, 62.7, 61.6, 54.4, 32.6, 20.1, 13.6. HRMS
(ESI): m/z calcd for C31H42O16Na [M + Na] 693.2376, found 693.2369.
Ethyl (4,5,7,8-tetra-O-acetyl-3-deoxy-β-D-manno-oct-2-ulopyranosyl) onate-(2→3)methyl 2-O-acetyl-4-O-benzyl-α-L-rhamnopyranoside (372). A mixture of donor 330 (69 mg,
0.1 mmol) acceptor 351 (55 mg, 0.2 mmol) and activated 4Å acid-washed powdered molecular
sieves (69 mg) in CH2Cl2:CH3CN 2:1 (0.6 mL, 0.2M) was stirred for 30 min at rt under argon,
then cooled to -78 oC. The reaction mixture was then treated with N-iodosuccinimide (29 mg, 0.1
mmol) and TfOH (10 μL, 0.1 mmol) and stirred at -78 oC till completion, then quenched with
triethylamine (5 μL) at -78 oC and gradually stirred to rt. The reaction mixture was diluted with
CH2Cl2 (5 mL) filtered through celite and washed with 20% aqueous Na2S2O3 (5 mL). The aqueous
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layer was extracted with CH2Cl2 (3 mL) twice and the combined organic layer was dried over
Na2SO4 and concentrated at reduced pressure. The residual crude was purified via silica gel column
chromatography eluting with (hexane/ethyl acetate 3:1) yielding 372 in (73 mg, 84%) as a colorless
syrup and 378 in (3.5 mg, 7%) as an off-white foam. [α]D23 = +65 (c = 0.8, CHCl3) 1H NMR (499
MHz, C6D6) δ 7.56 (d, J = 7.1 Hz, 2H), 7.22 (t, J = 7.8 Hz, 2H), 7.01 (t, J = 7.5 Hz, 1H), 5.65-5.60
(m, 1H), 5.50-5.46 (m, 1H), 5.36 – 5.33 (m, 1H), 5.27-5.25 (m, 1H), 4.82 – 4.77 (m, 2H), 4.76 –
4.70 (m, 2H), 4.69 (br, 1H), 4.51 (d, J = 10.7 Hz, 1H), 4.23 – 4.18 (m, 1H), 4.18 – 4.12 (m, 1H),
4.01 (dq, J = 10.8, 7.1 Hz, 1H), 3.91 (dq, J = 9.2, 6.2 Hz, 1H), 3.66 (t, J = 9.7 Hz, 1H), 3.00 (s,
3H), 2.60 (dd, J = 12.7, 4.5 Hz, 1H), 2.32 (t, J = 12.8 Hz, 1H), 1.80 (s, 3H), 1.71 (s, 3H), 1.67 (s,
3H), 1.64 (s, 3H), 1.63 (s, 3H), 1.30 (d, J = 6.3 Hz, 3H), 0.99 (t, J = 7.1 Hz, 3H). 13C NMR (126
MHz, C6D6) δ 169.9, 169.7, 169.5, 169.2, 169.0, 167.4, 137.5, 128.5, 127.90, 127.85, 127.7, 127.5,
98.2, 96.9, 80.1, 75.8, 70.6, 70.4, 69.0, 68.4, 67.57, 66.63, 64.3, 62.9, 62.2, 54.3, 32.6, 20.3, 20.0,
18.0, 13.3. HRMS (ESI): m/z calcd for C34H46O17Na [M + Na] 749.2628, found 749.2627.
Ethyl (4,5,7,8-tetra-O-acetyl-3-deoxy-β-D-manno-oct-2-ulopyranosyl) onate-(2→6)methyl 2-azido-3,4-di-O-benzyl-2-deoxy-α-D-galactopyranoside (373). A mixture of donor 330
(50 mg, 0.1 mmol) acceptor 368 (51 mg, 0.1 mmol) and activated 4Å acid-washed powdered
molecular sieves (50 mg) in CH2Cl2:CH3CN 2:1 (0.43 mL, 0.2M) was stirred for 30 min at rt under
argon, then cooled to -78 oC. The reaction mixture was then treated with N-iodosuccinimide (21.3
mg, 0.1 mmol) and TfOH (8 μL, 0.1 mmol) and stirred at -78 oC till completion, then quenched
with triethylamine (5 μL) at -78 oC and gradually stirred to rt. The reaction mixture was diluted
with CH2Cl2 (5 mL) filtered through celite and washed with 20% aqueous Na2S2O3 (5 mL). The
aqueous layer was extracted with CH2Cl2 (3 mL) twice and the combined organic layer was dried
over Na2SO4 and concentrated at reduced pressure. The residual crude was purified via silica gel
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column chromatography eluting with (hexane/ethyl acetate 1:1) yielding 373 in (61 mg, 87%) as
a colorless syrup and 378 in (1.1 mg, 3%) as an off-white foam. [α]D23 = +37 (c = 0.5, CHCl3) 1H
NMR (500 MHz, C6D6) δ 7.38 (d, J = 7.7 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.19 (t, J = 7.5 Hz,
3H), 7.14-7.10 (m, 3H), 5.56 – 5.49 (m, 2H), 5.10 (dt, J = 13.2, 3.6 Hz, 1H), 4.92 (d, J = 10.9 Hz,
1H), 4.63 (d, J = 11.0 Hz, 1H), 4.53 (br, 1H), 4.47 (d, J = 3.7 Hz, 1H), 4.44 (br, 2H), 4.17 – 4.11
(m, 2H), 3.94 – 3.87 (m, 5H), 3.81 – 3.73 (m, 2H), 3.36 (d, J = 8.4 Hz, 1H), 3.08 (s, 3H), 2.71 (dd,
J = 12.3, 4.7 Hz, 1H), 2.39 (t, J = 12.7 Hz, 1H), 1.77 (s, 3H), 1.73 (s, 3H), 1.69 (s, 3H), 1.57 (s,
3H), 0.83 (t, J = 7.1 Hz, 3H).
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C NMR (126 MHz, C6D6) δ 169.9, 169.8, 169.3, 167.3, 138.8,

138.1, 99.7, 99.4, 77.3, 75.0, 74.3, 71.9, 71.4, 70.1, 68.2, 67.3, 64.6, 64.2, 62.6, 61.8, 60.1, 54.8,
32.97, 20.2, 20.1, 20.1, 19.98, 13.7. HRMS (ESI): m/z calcd for C39H49N3O16Na [M + Na]
838.3005, found 838.3000.
Ethyl (4,5,7,8-tetra-O-acetyl-3-deoxy-β-D-manno-oct-2-ulopyranosyl) onate-(2→6)methyl 2-azido-3,4-di-O-benzyl-2-deoxy-α-D-glucopyranoside (374). A mixture of donor 330
(50 mg, 0.1 mmol) acceptor 360 (51 mg, 0.1 mmol) and activated 4Å acid-washed powdered
molecular sieves (50 mg) in CH2Cl2:CH3CN 2:1 (0.43 mL, 0.2M) was stirred for 30 min at rt under
argon, then cooled to -78 oC. The reaction mixture was then treated with N-iodosuccinimide (21.3
mg, 0.1 mmol) and TfOH (8 μL, 0.1 mmol) and stirred at -78 oC till completion, then quenched
with triethylamine (5 μL) at -78 oC and gradually stirred to rt. The reaction mixture was diluted
with CH2Cl2 (5 mL) filtered through celite and washed with 20% aqueous Na2S2O3 (5 mL). The
aqueous layer was extracted with CH2Cl2 (3 mL) twice and the combined organic layer was dried
over Na2SO4 and concentrated at reduced pressure. The residual crude was purified via silica gel
column chromatography eluting with (hexane/ethyl acetate 1:1) yielding 374 in (62.4 mg, 89%) as
a colorless syrup and 378 in (1.0 mg, 2.7%) as an off-white foam. [α]D23 = +44 (c = 0.38, CHCl3)
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H NMR (500 MHz, C6D6) δ 7.27 (d, J = 7.2 Hz, 4H), 7.16 (d, J = 7.5 Hz, 3H), 7.09 (m, 3H), 5.52

– 5.50 (br, 1H), 5.49-5.45 (m, 1H), 5.08 (dt, J = 13.0, 3.8 Hz, 1H), 4.82 (d, J = 11.3 Hz, 1H), 4.75
– 4.70 (m, 2H), 4.68-4.64 (m, 2H), 4.50 (dd, J = 12.2, 4.9 Hz, 1H), 4.45 – 4.41 (m, 1H), 4.37 (d, J
= 3.5 Hz, 1H), 4.25-4.23 (m, 1H), 4.14 (d, J = 11.7 Hz, 1H), 4.02 – 3.98 (m, 1H), 3.86-3.80 (m,
2H), 3.72 (dd, J = 10.4, 5.0 Hz, 1H), 3.66 (dd, J = 10.7, 7.1 Hz, 1H), 3.51 (t, J = 9.4 Hz, 1H), 3.03
(s, 3H), 2.94 (dd, J = 10.3, 3.5 Hz, 1H), 2.68 (dd, J = 12.3, 4.6 Hz, 1H), 2.42 (t, J = 12.7 Hz, 1H),
1.77 (s, 3H), 1.71 (s, 3H), 1.68 (s, 3H), 1.56 (s, 3H), 0.81 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz,
C6D6) δ 170.0, 169.7, 169.2, 169.1, 167.3, 138.8, 138.5, 127.9, 127.8, 127.6, 99.9, 98.8, 80.2, 78.3,
74.9, 74.4, 71.3, 70.1, 68.1, 67.3, 64.1, 63.6, 62.5, 61.8, 54.6, 32.8, 20.2, 20.1, 20.04, 19.97, 13.7.
HRMS (ESI): m/z calcd for C39H49N3O16Na [M + Na] 838.3005, found 838.2988.
Ethyl (4,5,7,8-di-O-isopropylidene-3-deoxy-α,β-D-manno-oct-2-ulopyranosyl) onate(2→3)-methyl 2-O-benzyl-4,6-O-benzylidene-α-D-mannopyranoside (375). A mixture of
donor 328 (79.3 mg, 0.1 mmol) acceptor 341 (89.3 mg, 0.2 mmol) and activated 4Å acid-washed
powdered molecular sieves (79 mg) in CH2Cl2:CH3CN 2:1 (0.8 mL, 0.2M) was stirred for 30 min
at rt under argon, then cooled to -78 oC. The reaction mixture was then treated with Niodosuccinimide (40 mg, 0.2 mmol) and TfOH (14.2 μL, 0.2 mmol) and stirred at -78 oC till
completion, then quenched with triethylamine (5 μL) at -78 oC and gradually stirred to rt. The
reaction mixture was diluted with CH2Cl2 (5 mL) filtered through celite and washed with 20%
aqueous Na2S2O3 (5 mL). The aqueous layer was extracted with CH2Cl2 (5 mL) twice and the
combined organic layer was dried over Na2SO4 and concentrated at reduced pressure. The residual
crude was purified via silica gel column chromatography eluting with (hexane/ethyl acetate 5:1)
to give first compound 375α (11 mg, 9.8%) as a colorless syrup and then 375β (96 mg, 86%) as a
colorless syrup.
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Ethyl (4,5,7,8-di-O-isopropylidene-3-deoxy-α-D-manno-oct-2-ulopyranosyl) onate(2→3)-methyl 2-O-benzyl-4,6-O-benzylidene -α-D-mannopyranoside (375α). [α]D23 = +25 (c
= 0.7, CHCl3). 1H NMR (500 MHz, CD3CN) δ 7.45-7.43 (m, 2H), 7.42 – 7.11 (m, 8H), 5.55 (s,
1H), 4.85 (d, J = 11.5 Hz, 1H), 4.71 (dd, J = 10.1, 3.4 Hz, 1H), 4.66 – 4.62 (m, 2H), 4.45 – 4.41
(m, 1H), 4.19 – 4.06 (m, 7H), 3.96 (dd, J = 8.2, 6.0 Hz, 1H), 3.86 (t, J = 9.6 Hz, 1H), 3.77 – 3.60
(m, 3H), 3.36 (dd, J = 7.5, 2.1 Hz, 1H), 3.26 (s, 3H), 2.41 (dd, J = 15.9, 5.5 Hz, 1H), 2.27 (dd, J =
15.9, 4.5 Hz, 1H), 1.45 (s, 3H), 1.32 (s, 3H), 1.27 (s, 3H), 1.26 (s, 3H), 1.18 (t, J = 7.1 Hz, 3H).
C NMR (126 MHz, CD3CN) δ 169.3, 139.1, 138.3, 128.9, 128.4, 128.2, 128.0, 127.6, 126.2,
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108.9, 108.5, 101.3, 100.99, 100.2, 79.1, 77.1, 74.0, 73.99, 73.6, 71.5, 70.6, 70.0, 68.5, 66.2, 64.2,
61.9, 53.9, 31.5, 26.3, 26.1, 24.6, 24.2, 13.4 HRMS (ESI): m/z calcd for C37H48O13Na [M + Na]
723.2987, found 723.2982.
Ethyl (4,5,7,8-di-O-isopropylidene-3-deoxy-β-D-manno-oct-2-ulopyranosyl) onate(2→3)-methyl 2-O-benzyl-4,6-O-benzylidene-α-D-mannopyranoside (375β). [α]D23 = +31 (c =
1.0, CHCl3) 1H NMR (499 MHz, CD3CN) δ 7.49 – 7.44 (m, 4H), 7.43 – 7.37 (m, 5H), 7.35 (d, J =
7.1, 1H), 5.53 (s, 1H), 4.80 (d, J = 11.6 Hz, 1H), 4.74 (d, J = 1.6 Hz, 1H), 4.69 (d, J = 11.6 Hz,
1H), 4.48 (dt, J = 8.1, 2.9 Hz, 1H), 4.38 (dd, J = 10.3, 3.4 Hz, 1H), 4.28 – 4.23 (m, 1H), 4.18 –
4.15 (m, 2H), 4.07 – 4.03 (m, 2H), 3.97 (dd, J = 8.6, 6.5 Hz, 1H), 3.94 – 3.89 (m, 1H), 3.74 (dd, J
= 7.2, 3.6 Hz, 1H), 3.70 (td, J = 6.0, 3.3 Hz, 3H), 3.36 (s, 3H), 3.31 (td, J = 7.0, 3.8 Hz, 1H), 3.00
(dd, J = 15.4, 3.4 Hz, 1H), 1.80 (dd, J = 15.4, 2.2 Hz, 1H), 1.44 (s, 3H), 1.34 (s, 3H), 1.24 (s, 3H),
1.22 (s, 3H), 0.85 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CD3CN) δ 167.2, 138.9, 138.1, 128.98,
128.3, 128.14, 128.06, 127.7, 126.7, 117.3, 108.8, 107.9, 102.1, 100.2, 97.7, 79.4, 77.4, 74.7, 73.8,
72.6, 70.8, 69.9, 69.5, 68.5, 64.98, 64.2, 60.7, 54.2, 31.7, 25.7, 24.5, 24.4, 23.9, 13.2. HRMS (ESI):
m/z calcd for C37H48O13Na [M + Na] 723.2987, found 723.2961.
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Ethyl (4,5,7,8-tetra-O-benzyl-3-β-D-manno-oct-2-ulopyranosyl) onate (2→6)-methyl
2-azido-3,4-di-O-benzyl-2-deoxy-α-D-glucopyranoside (376). A mixture of donor 331 (68.3 mg,
0.1 mmol) acceptor 360 (52.6 mg, 0.1 mmol) and activated 4Å acid-washed powdered molecular
sieves (68 mg) in CH2Cl2:CH3CN 2:1 (0.44 mL, 0.2M) was stirred for 30 min at rt under argon,
then cooled to -78 oC. The reaction mixture was then treated with N-iodosuccinimide (21.8 mg,
0.1 mmol) and TfOH (7.8 μL, 0.1 mmol) and stirred at -78 oC till completion, then quenched with
triethylamine (5 μL) at -78 oC and gradually stirred to rt. The reaction mixture was diluted with
CH2Cl2 (5 mL) filtered through celite and washed with 20% aqueous Na2S2O3 (5 mL). The aqueous
layer was extracted with CH2Cl2 (5 mL) twice and the combined organic layer was dried over
Na2SO4 and concentrated at reduced pressure. The residual crude was purified via silica gel column
chromatography eluting with (hexane/ethyl acetate 7:1) yielding 376 in (73 mg, 83%) as a colorless
syrup. [α]D23 = +86 (c = 0.98, CHCl3). 1H NMR (500 MHz, C6D6) δ 7.33 – 7.23 (m, 12H), 7.09 –
7.02 (m, 18H), 5.13 (d, J = 11.2 Hz, 1H), 4.85 (d, J = 11.5 Hz, 1H), 4.80 (br, 1H), 4.77 – 4.72 (m,
2H), 4.67 (d, J = 11.1 Hz, 1H), 4.55 (d, J = 11.4 Hz, 1H), 4.38 – 4.35 (m, 3H), 4.25 (br, 2H), 4.19
– 4.14 (m, 3H), 4.00 (ddd, J = 10.2, 5.0, 3.1 Hz, 2H), 3.86 – 3.81 (m, 4H), 3.77 – 3.70 (m, 1H),
3.62 – 3.57 (m, 1H), 3.51 (ddd, J = 12.2, 4.3, 2.3 Hz, 1H), 2.99 (s, 3H), 2.95 (dd, J = 10.3, 3.5 Hz,
1H), 2.77 (dd, J = 12.1, 4.0 Hz, 1H), 2.70 (t, J = 12.2 Hz, 1H), 0.76 (t, J = 7.1 Hz, 3H). 13C NMR
(126 MHz, C6D6) δ 168.4, 139.6, 139.3, 139.1, 138.9, 138.7, 138.6, 128.2, 127.9, 127.8, 127.6,
100.2, 98.8, 80.3, 78.5, 76.8, 74.6, 74.5, 74.3, 73.4, 72.3, 72.1, 70.8, 70.4, 70.2, 63.6, 62.8, 61.2,
54.6, 32.3, 13.8. HRMS (ESI): m/z calcd for C59H65N3O12Na [M + Na] 1030.4460, found
1030.4451.
Ethyl (4-O-benzoyl-5,7-di-O-tert-butylsilyl-3-deoxy-α-D-manno-oct-2-ulopyranosyl)
onate (2→6)-methyl 2-azido-3,4-di-O-benzyl-2-deoxy-α-D-glucopyranoside (377). A mixture
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of donor 334 (11 mg, 0.01 mmol) acceptor 360 (8.5 mg, 0.02 mmol) and activated 4Å acid-washed
powdered molecular sieves (5 mg) in CH2Cl2:CH3CN 2:1 (0.1 mL, 0.2M) was stirred for 30 min
at rt under argon, then cooled to -78 oC. The reaction mixture was then treated with Niodosuccinimide (3.5 mg, 0.02 mmol) and TfOH (2.1 μL, 0.01 mmol) and stirred at -78 oC till
completion, then quenched with triethylamine (2 μL) at -78 oC and gradually stirred to rt. The
reaction mixture was diluted with CH2Cl2 (5 mL) filtered through celite and washed with 20%
aqueous Na2S2O3 (3 mL). The aqueous layer was extracted with CH2Cl2 (3 mL) twice and the
combined organic layer was dried over Na2SO4 and concentrated at reduced pressure. The residual
crude was purified via silica gel column chromatography eluting with (hexane/ethyl acetate 3:1)
yielding 377 in (11 mg, 87%) as a colorless syrup. [α]D23 = +68 (c = 0.3, CHCl3). 1H NMR (600
MHz, C6D6) δ 8.14 (br, 1H), 7.28 – 7.25 (m, 4H), 7.05 – 6.93 (m, 10H), 5.65-5.61 (m, 1H), 4.75
(t, J = 11.3 Hz, 3H), 4.67 (d, J = 2.7 Hz, 1H), 4.63 (d, J = 11.1 Hz, 1H), 4.50 (d, J = 3.6 Hz, 1H),
4.44 – 4.37 (m, 2H), 4.22 (br, 1H), 4.10 (dd, J = 10.6, 1.8 Hz, 1H), 4.03 – 3.96 (m, 3H), 3.96 –
3.90 (m, 2H), 3.90 – 3.82 (m, 2H), 3.48 (dt, J = 10.6, 5.2 Hz, 1H), 3.42 – 3.36 (m, 1H), 3.26 (s,
3H), 3.15 (dd, J = 10.3, 8.6 Hz, 1H), 3.01 (dd, J = 10.3, 3.5 Hz, 1H), 2.75 (t, J = 12.1 Hz, 1H),
2.42 (dd, J = 12.3, 4.8 Hz, 1H), 1.28 (s, 11H), 1.03 (s, 7H), 0.93 (t, J = 7.1 Hz, 3H).
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C NMR

(151 MHz, C6D6) δ 167.0, 165.7, 141.2, 138.38, 138.36, 132.8, 130.5, 129.6, 127.9, 127.7, 127.5,
98.7, 98.6, 80.2, 79.3, 77.1, 74.95, 74.7, 70.8, 70.5, 69.9, 66.8, 64.9, 63.5, 63.3, 61.1, 54.8, 27.7,
26.96, 21.8, 21.7, 13.7. HRMS (ESI): m/z calcd for C46H61O13SiN3Na [M + Na] 915.2286, found
915.2282.
Ethyl (4,5,7,8-tetra-O-acetyl-2,3-dideoxy-D-manno-oct-2-ulopyranosyl) onate (378).
[α]D23 = +56 (c = 0.7, CHCl3). 1H NMR (500 MHz, CDCl3) δ 5.86 (d, J = 6.5 Hz, 1H), 5.69 (br,
1H), 5.46 (br, 1H), 5.27-5.23 (m, 1H), 4.62-4.58 (m,1H), 4.41 – 4.17 (m, 5H), 2.06 (br, 6H), 2.01
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(br, 6H), 1.30 (t, J = 6.7 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 170.6, 170.4, 170.1, 169.6, 161.1,
144.96, 107.3, 73.4, 67.4, 64.9, 61.97, 61.8, 60.9, 20.8, 20.7, 20.6, 14.2. HRMS (ESI): m/z calcd
for C18H24O11Na [M + Na] 439.1008, found 439.1000.
5-azido-1-pentanol (409). A solution of triflic anhydride (3 mL, 17.9 mmol) in dry MeCN
(10 mL) was cooled to 0 oC, then, sodium azide (2.3g, 35.7 mmol) was added and the reaction
mixture stirred at 0 oC for 2 h. A solution of 5-aminopentanol (0.2 g, 1.9 mmol) in methanol (5mL)
was added to reaction mixture followed by the dropwise addition of a solution mixture of
CuSO4.H2O (20 mg, 0.1 mmol) and K2CO3 (0.2 g, 1.6 mmol) in MeOH:H2O 1:5 (10 mL). The
resulting mixture was gradually brought to rt and stirred till completion with monitoring by TLC
(dichloromethane:ethyl acetate 1:1, Rf =0.4). The solvent was carefully concentrated under
reduced pressure and the residue taken up in ethyl acetate and washed with water and brine. The
aqueous layer was extracted with ethyl acetate and the combined organic layer was dried over
anhydrous Na2SO4, filtered, and concentrated at reduced pressure. The residual crude was purified
by silica gel column chromatography (dichloromethane:ethyl acetate 1:1) to give 2 in (0.18 g,
73%) yield as a colorless oil and the spectral data were consistent with the literature. 1H NMR (500
MHz, CD3OD) δ 3.53 (t, J = 6.4 Hz, 2H), 3.32 (t, J = 7.2 Hz, 2H), 1.63 – 1.43 (m, 4H), 1.41 – 1.19
(m, 2H). 13C NMR (126 MHz, CD3OD) δ 61.3, 42.2, 31.8, 27.5, 22.9. HRMS (ESI): m/z calcd for
C5H11ON3Na [M + Na] 152.0804, found 152.0800.
Ethyl

(4,5,7,8-tetra-O-acetyl-2,3-dideoxy-D-manno-oct-2-ulopyranosyl)

onate-

(2→O)-5-azido-pentane (410). A mixture of donor 330 (117 mg, 0.2 mmol), acceptor 409 (39
mg, 0.3 mmol) and activated 4Å acid-washed powdered molecular sieves (117 mg) in
CH2Cl2:CH3CN 2:1 (1 mL, 0.2M) was stirred for 30 min at rt under argon, then cooled to -78 oC.
The reaction mixture was then treated with N-iodosuccinimide (49.7 mg, 0.2 mmol) and TfOH
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(17.8 μL, 0.2 mmol) and stirred at -78 oC till completion, then quenched with triethylamine (7 μL)
at -78 oC and gradually stirred to rt. The reaction mixture was diluted with CH2Cl2 (10 mL), filtered
through celite and washed with 20% aqueous Na2S2O3 (5 mL). The aqueous layer was extracted
with CH2Cl2 (5 mL) twice and the combined organic layer was dried over Na2SO4 and concentrated
at reduced pressure. The residual crude was purified via silica gel column chromatography eluting
with (hexane/ethyl acetate 2:1) yielding 410 in (102 mg, 94%) as a colorless syrup. [α]D23 = +30
(c = 1.3, CHCl3), 1H NMR (500 MHz, C6D6) δ 5.57 – 5.50 (m, 2H), 5.08 (dt, J = 13.2, 4.2 Hz, 1H),
4.58 – 4.50 (m, 2H), 4.24 (d, J = 9.7 Hz, 1H), 3.89-3.81 (m, 3H), 3.30 (dt, J = 9.2, 6.3 Hz, 1H),
2.67 (dd, J = 12.3,4.3 Hz, 1H), 2.57 (t, J = 6.0 Hz, 2H), 2.40 (t, J = 12.7 Hz, 1H), 1.80 (s, 3H),
1.70 (s, 3H), 1.55 (s, 3H), 1.30-1.27 (m, 3H), 1.12 – 1.08 (m, 3H), 0.89 (d, J = 6.9 Hz, 3H). 13C
NMR (126 MHz, C6D6) δ 170.1, 169.8, 169.3, 169.2, 167.8, 99.6, 71.3, 68.3, 67.3, 64.3, 64.2, 62.8,
61.6, 50.9, 32.99, 29.0, 28.3, 23.1, 20.2, 20.13, 20.07, 19.99, 13.8. HRMS (ESI): m/z calcd for
C23H35O12Na [M + Na] 568.2113, found 568.2109.
Ethyl (8-O-tert-butyldimethylsilyl-3-deoxy-β-D-manno-oct-2-ulopyranosyl) onate(2→O)-5-azido-pentane (412). A solution of 410 (0.1 g, 0.2 mmol) in dry methanol (10 mL) was
treated with sodium methoxide (40 mg g, 0.7 mmol) added in four portions over the period of the
reaction. The reaction mixture was stirred at rt till completion. After completion, the reaction
mixture was neutralized with IR 120 resin and concentrated at reduced pressure. The residue was
dissolved in DMF (3 mL) and the solution mixture treated with imidazole (18 mg, 0.3 mmol) and
TBSCl (30 mg, 0.2 mmol) at 0 °C. The reaction mixture was gradually warmed to rt and stirred
till completion with monitoring by TLC (hexane:ethyl acetate 1:1, Rf = 0.2). The reaction was then
quenched by addition of saturated aqueous NH4Cl, and then diluted with ethyl acetate. The organic
layer was washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated at
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reduced pressure. The residual syrup was purified by silica gel column chromatography
(hexane:ethyl acetate 1:1) to give 412 (86.5 mg, 88%) as a colorless syrup. [α]D23 = +57 (c = 0.2,
CH3OH), 1H NMR (500 MHz, CD6CO) δ 4.30-4.26 (m, 2H), 4.02 (dd, J = 10.5, 3.3 Hz, 1H), 3.93
– 3.82 (m, 2H), 3.82 – 3.73 (m, 1H), 3.69 (dd, J = 10.5, 7.0 Hz, 1H), 3.65-3.61 (m, 1H), 3.53 (d, J
= 8.0 Hz, 1H), 3.45-3.40 (m, 1H), 3.37 (t, J = 6.9 Hz, 2H), 3.21 (d, J = 5.4 Hz, 1H), 3.17 – 3.07
(m, 2H), 2.29 (dd, J = 12.3, 4.6 Hz, 1H), 2.23 (s, 6H), 1.88 (t, J = 12.3 Hz, 1H), 1.69-1.58 (m, 4H),
1.51 – 1.43 (m, 2H), 1.36 (t, J = 7.0 Hz, 3H), 1.01 (s, 9H). 13C NMR (126 MHz, CD6CO) δ 168.9,
99.4, 74.6, 70.7, 67.1, 66.2, 65.4, 63.6, 61.5, 51.3, 34.97, 29.2, 28.4, 25.5, 23.2, 18.2, 13.7. HRMS
(ESI): m/z calcd for C21H41O8N3SiNa [M + Na] 514.1461, found 514.1457.
Ethyl

(5,7-O-benzylidene-8-O-tert-butyldimethylsilyl-3-deoxy-β-D-manno-oct-2-

ulopyranosyl) onate-(2→O)-5-azido-pentane (398). To a solution of 412 (31 mg, 0.1 mmol) in
DMF (0.3 mL) was added benzaldehyde dimethyl acetal (11.7 μL, 0.1 mmol) and CSA (3 mg, 0.01
mmol). The mixture was stirred at rt till completion. The solvent was then removed at reduced
pressure and the residual crude dissolved in ethyl acetate (10 mL) and washed with saturated
sodium bicarbonate (2 × 10 mL). The aqueous layer was extracted twice with ethyl acetate and the
combined organic layer dried in MgSO4, filtered, and concentrated under reduced pressure. The
residual crude was purified by silica gel column chromatography (hexane:ethyl acetate 2:1) to give
398 (41 mg, 71%) as a colorless syrup. [α]D23 = +61 (c = 0.6, CHCl3), 1H NMR (500 MHz, CD3CN)
δ 7.58-7.56 (m, 2H), 7.38 – 7.36 (m, 3H), 5.74 (s, 1H), 4.50 (dt, J = 8.0, 4.1 Hz, 1H), 4.33 (dd, J
= 7.8, 2.0 Hz, 1H), 4.20-4.13 (m, 2H), 4.05 (dd, J = 10.8, 2.6 Hz, 1H), 3.77 – 3.67 (m, 3H), 3.60
(dd, J = 10.7, 7.4 Hz, 1H), 3.51 (dd, J = 8.7, 2.0 Hz, 1H), 3.26 (dt, J = 9.3, 6.7 Hz, 1H), 3.20-3.17
(m, 3H), 3.04 (d, J = 5.2 Hz, 1H), 1.50 – 1.44 (m, 4H), 1.27 – 1.24 (m, 5H), 0.88 (s, 14H). 13C
NMR (126 MHz, CD3CN) δ 169.9, 137.9, 129.5, 128.2, 127.4, 103.2, 98.6, 72.3, 72.1, 71.5, 70.9,
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65.6, 63.99, 61.3, 51.1, 32.6, 29.1, 28.3, 25.4, 23.1, 18.1, 13.6. HRMS (ESI): m/z calcd for
C28H45O8N3SiNa [M + Na] 602.1575, found 602.1570.
Allyl 3,5-di-O-tetraisopropyldisiloxyl-α,β-D-ribofuranoside (415). A solution of 414
(0.94 g, 4.9 mmol) in pyridine (3.7 mL) was treated with TIPDSCl2 (1.6 ml, 4.9 mmol) at 0 °C.
The reaction mixture was gradually warmed to rt and stirred for 1 h while monitoring by TLC
(hexane:ethyl acetate 2:1, Rf = 0.7). The reaction was then quenched by addition of saturated
aqueous NH4Cl, and then diluted with ethyl acetate. The organic layer was washed with water and
brine, dried over anhydrous Na2SO4, filtered and concentrated at reduced pressure. The residual
syrup was purified by silica gel column chromatography (hexane:ethyl acetate 2:1) to give 415
(1.38 g, 65%) as a colorless syrup. 1H NMR (500 MHz, CDCl3) δ 5.97 – 5.86 (m, 2H), 5.33 – 5.07
(m, 5H), 4.79 (d, J = 3.7 Hz, 1H), 4.68 (dd, J = 7.8, 4.1 Hz, 1H), 4.29 – 4.19 (m, 3H), 4.18 – 4.10
(m, 2H), 4.06 – 3.90 (m, 5H), 3.89 – 3.82 (m, 2H), 3.70 (dd, J = 11.8, 4.8 Hz, 1H), 3.63-3.60 (m,
1H), 3.36-3.34 (m, 1H), 3.18 (d, J = 9.8 Hz, 1H), 1.07 – 0.91 (m, 57H).13C NMR (126 MHz,
CDCl3) δ 134.5, 133.9, 133.5, 117.9, 117.4, 99.6, 98.1, 73.5, 73.3, 73.0, 71.9, 71.8, 71.1, 705, 69.9,
69.6, 69.3, 68.5, 67.96, 67.8, 64.7, 63.8, 17.7, 17.6, 17.5, 17.44, 17.38, 17.34, 17.29, 17.22, 17.15,
13.9, 13.63, 13.57, 13.5, 13.44, 13.38, 13.3, 13.2, 13.1, 12.99, 12.9. HRMS (ESI): m/z calcd for
C20H40O6Si2Na [M + Na] 455.0120, found 455.0115.
Allyl 2-O-acetyl-α,β-D-ribofuranoside (417). A solution of 415 (0.84 g, 1.9 mmol) in
pyridine (2 mL), was cooled to 0 oC. 4-dimethylaminopyridine (0.12 g, 1.0 mmol) was added
followed by the addition of acetic anhydride (0.18 mL, 1.9 mmol) The reaction mixture was stirred
at 0 oC till completion with monitoring by TLC (hexane:ethyl acetate 3:1, Rf = 0.5). After
completion, the reaction mixture was concentrated under reduced pressure and the residue (0.88
g, 1.9 mmol) was dissolved in THF (5 ml). the solution mixture was then treated with TBAF (1.9
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ml) at 0 oC. The reaction mixture was gradually warmed to rt and stirred for 3 h while monitoring
by TLC (hexane:ethyl acetate 1:1, Rf = 0.1). The reaction was then quenched by addition of
saturated aqueous NH4Cl, and then diluted with ethyl acetate. The organic layer was washed with
water and brine, dried over anhydrous Na2SO4, filtered and concentrated at reduced pressure. The
residual syrup was purified by silica gel column chromatography (hexane:ethyl acetate 1:1) to give
417 (0.33 g, 75%) as a colorless syrup 1H NMR (500 MHz, CD3OD) δ 6.00 – 5.82 (m, 2H), 5.39
– 5.21 (m, 2H), 5.15-5.10 (m, 3H), 4.99 – 4.81 (m, 2H), 4.79 – 4.68 (m, 2H), 4.61 (d, J = 3.0 Hz,
1H), 4.29 – 4.21 (m, 2H), 4.19-4.15 (m, 1H), 4.10 – 3.97 (m, 3H), 3.97 – 3.84 (m, 1H), 3.84 – 3.75
(m, 3H), 3.75 – 3.64 (m, 2H), 3.64 – 3.53 (m, 1H), 3.53 – 3.38 (m, 1H), 2.10-2.08 (m, 4H), 2.072.05 (m, 2H). 13C NMR (126 MHz, CD3OD) δ 168.9, 99.4, 74.6, 70.7, 67.1, 66.2, 65.4, 63.6, 61.5,
51.3, 34.97, 29.2, 28.4, 25.5, 23.2, 18.2, 13.7. HRMS (ESI): m/z calcd for C10H16O6Na [M + Na]
255.1125, found 255.1119.
Allyl 2-O-acetyl-5-O-tert-butyldimethylsilyl-α,β-D-ribofuranoside (389). To a solution
mixture of 417 (0.1 g, 0.4 mmol) in DMF (4.3 mL) was added imidazole (38 mg, 0.6 mmol) and
TBSCl (65 mg, 0.4 mmol) at 0 °C. The reaction mixture was gradually warmed to rt and stirred
for 2 h while monitoring by TLC (hexane:ethyl acetate 2:1, Rf = 0.3). The reaction was then
quenched by addition of saturated aqueous NH4Cl, and then diluted with ethyl acetate. The organic
layer was washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated at
reduced pressure. The residual syrup was purified by silica gel column chromatography
(hexane:ethyl acetate 2:1) to give 389 (0.11 g, 80%) as a colorless syrup.1H NMR (500 MHz,
CDCl3) δ 5.94 – 5.81 (m, 2H), 5.29-5.26 (m, 1H), 5.25-5.20 (m, 1H), 5.18-5.16 (m, 2H), 4.98 (t, J
= 3.1 Hz, 1H), 4.90 (d, J = 2.3 Hz, 1H), 4.86 – 4.76 (m, 2H), 4.27 – 4.13 (m, 3H), 4.13 – 4.06 (m,
2H), 4.01-3.98 (m, 1H), 3.96 – 3.84 (m, 2H), 3.80-3.77 (m, 1H), 3.72 (dd, J = 11.6, 4.3 Hz, 1H),
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3.62-3.59 (m, 2H), 0.93 – 0.88 (m, 18H). 13C NMR (126 MHz, CDCl3) δ 170.4, 133.9, 133.8,
117.7, 117.3, 100.6, 97.2, 77.4, 77.1, 76.8, 71.4, 69.95, 69.8, 69.5, 68.5, 68.4, 68.1, 64.0, 63.6,
25.8, 25.7, 21.3, 21.1, 18.1. HRMS (ESI): m/z calcd for C16H30O6SiNa [M + Na] 369.2300, found
369.2296.
Allyl 2-O-acetyl-3,5-di-O-benzyl-α,β-D-ribofuranoside (420) and Allyl 3-O-acetyl-2,5di-O-benzyl-α,β-D-ribofuranoside (421). To a solution of 417 (0.2 g, 0.9 mmol) in dry DMF (8.6
mL) were added sodium hydride (0.14 g, 3.4 mmol) and BnBr (0.4 ml, 3.4 mmol) at 0 °C. The
reaction mixture was gradually warmed to room temperature and stirred till completion with
monitoring by TLC (hexane:ethyl acetate 20:1, Rf = 0.5).The reaction was quenched by the
addition methanol, then was diluted with ethyl acetate. The organic layer was washed with water
and brine, dried over anhydrous Na2SO4, filtered and concentrated at reduced pressure. The
unreacted benzyl bromide was removed via flash column chromatography yielding to (0.33 g,
89%) of desired intermediate 418 and the regioisomeric form 419. A solution mixture of 418 and
419 (0.33 g, 0.8 mmol) in methanol was treated with PdCl2 (28 mg, 0.2 mmol) and stirred at rt till
completion. The solid residue was filtered, and the filtrate concentrated at reduced pressure. The
residual syrup was purified by silica gel column chromatography (hexane:ethyl acetate 2:1) to
afford a mixture of 420 and 421 (0.25 g, 84%) as a colorless syrup. 1H NMR (500 MHz, CDCl3) δ
7.42 – 7.20 (m, 18H), 5.87 (d, J = 3.5 Hz, 1H), 4.97 – 4.92 (m, 1H), 4.73 (d, J = 11.6, 1H), 4.67 –
4.55 (m, 4H), 4.45 (t, J = 12.1 Hz, 1H), 4.14 – 4.07 (m, 1H), 3.90 – 3.77 (m, 2H), 3.74 – 3.67 (m,
1H), 3.60-3.55 (m, 2H), 3.24-3.22 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 170.6, 137.8, 137.7,
137.5, 128.7, 128.62, 128.58, 128.5, 128.1, 127.98, 127.9, 106.96, 94.6, 91.4, 82.4, 80.3, 72.8,
72.6, 72.5, 72.4, 71.96, 71.7, 71.3, 70.9, 68.1, 67.1, 63.1, 62.8, 56.7, 55.7. HRMS (ESI): m/z calcd
for C21H24O6Na [M + Na] 395.1907, found 395.190.
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88. Adero, P. O.; Amarasekara, H.; Wen, P.; Bohé, L.; Crich, D. Chem. Rev. 2018, 118, 8242−8284.
89. Bock, K.; Duus, J. O. J. Carbohydr. Chem. 1994, 13, 513−543.
90. a) Crich, D.; Sun, S. J. Org. Chem. 1996, 61, 4506−4507. b) Crich, D.; Sun, S. J. Org. Chem. 1997,
62, 1198−1199.
91. Andrews, C. W.; Rodebaugh, R.; Fraser-Reid, B. J. Org. Chem. 1996, 61, 5280-5289.
92. Jensen, H. H.; Nordstrom, M.; Bols, M. J. Am. Chem. Soc. 2004, 126, 9205−9213.
93. Moume-Pymbock, M.; Furukawa, T.; Mondal, S.; Crich, D. J. Am. Chem. Soc. 2013, 135,
14249−14255.
94. Dharuman, S.; Crich, D. Chem. Eur. J. 2016, 22, 4535-4542.
95. Kancharla, P. K.; Crich, D. J. Am. Chem. Soc. 2013, 135, 18999−19007.
96. Dhakal, B.; Buda, S.; Crich, D. J. Org. Chem. 2016, 81, 10617−10630.
97. Dhakal, B.; Crich, D. J. Am. Chem. Soc. 2018, 140, 15008−15015.
98. Unger, F. M.; Stix, D.; Schulz, G. Carbohydr. Res. 1980, 80, 191−195.
99. McMahon, C. M.; Isabella, C. R.; Windsor, I. W.; Kosma, P.; Raines, R. T.; Kiessling, L. L. J. Am.
Chem. Soc. 2020, 142, 5, 2386-2395.
100 . Dong, L.; Roosenberg, M. J.; Miller, J. M. J. Am. Chem. Soc. 2002, 124, 15001–15005.
101 . Degenstein, J. C.; Murria, P.; Easton, M. J. Org. Chem. 2015, 80, 1909-1914.
102 . Elchert, B.; Li, J.; Wang, J.; Hui, Y.; Rai, R.. J. Org. Chem. 2004, 69, 1513–1523.

170
103 . Li, J.; Todaro, L. J.; Mootoo, D. R. Org. Lett. 2008, 10, 1337-1340.
104 . Sadaaki. Nu.; Yuhsuke. K.; Yuya, Y. Bull. Chem. Soc. Jpn. 1981. 54, 2831-2054.
105 . Kawakami, Y.; Yamashita, Y. J. Org. Chem. 1983, 48, 1912-1914.
106 . Tamao, K.; Sumitani, K.; Kiso, Y. Bull. Chem. Soc. Jpn. 1976. 49, 1958-1969.
107 . Ohmiya, H.; Tsuji, T.; Yorimitsu, H.; Oshima, K. Chem. Eur. J. 2004, 10, 5640 – 5648.
108 . Masahiro, S.; Hideki, Y.; Koichiro, O. Bull. Chem. Soc. Jpn. 2009. 82, 1194-1196.
109 . Someya, H.; Ohmiya, H.; Yorimitsu, H.; Oshima, K. Org. Lett. 2008, 10, 969-971.
110 . Perez, V. M.; Fregoso-Lopez, D.; Miranda, L. D. Tetrahedron Lett. 2017, 58, 1326111 . Mobley, J. K.; Yao, S. G.; Crocker, M.; Meier, M. RSC. Adv. 2015, 105136-105148.
112 . Cardona, F.; D’Orazio, G.; Silva, A. M. S. Eur. J. Org. Chem. 2014, 2549-2556.
113 . Cram, D. J.; Kopecky, K. R. J. Am. Chem. Soc. 1959, 81,2748–2755.
114 . a) Grubbs, R. H.; Chang, S. Tetrahedron.1998, 54, 4413-4450. b) Chatterjee, A. K.; Sanders, D.
P.; Grubbs, R. H. Org. Lett. 2002, 4, 1939-1942. c) Fu, G. C.; Grubbs, R. H. J. Am. Chem. Soc.
1993, 115, 3800-3801. d) Miller, J. F.; Termin, A.; Koch, K.; Piscopio, A. D. J. Org. Chem. 1998,
63, 3158-3159. e) Peeck, L. H.; Plenio, H. Organometallics 2010, 29, 2761–2766.
115 . a) Trachtenberg, E. N.; Carver, J. R. J. Org. Chem. 1970, 35, 1646-1653. b) Guillemonat, A. Ann.
Chim. 1939, 11, 143-211.
116 . a) Luche, J-L.; Rodriguez-Hahn, L.; Crabbẻ, P. Chem. Commun. 1978, 601-602. b) Ching, T. K.
M.; Cheng, H. M.; Wong, W. F.; Kwong, C. S. K.; Li, J.; Lau, C. B. S.; Leung, P. S.; Cheng, C. H.
K. Org. Lett. 2008, 10, 3145-3148.
117 . Davies, S. G.; Fletcher, A. M.; Thomson, J. E. Org. Biomol. Chem. 2014, 12, 4544-4549.
118 . a) Graham, A. R.; Millidge, A. F.; Young, D. P. J. Chem. Soc. 1954, 2180-2200. b) Winstein, S.;
Ingraham, L. L. J. Am. Chem. Soc. 1952, 74, 1160-1164. c) Parker, R. E.; Isaacs, N. S. Chem.
Rev.1959, 59, 737-799.
119 . a) Fürst, A.; Plattner, P. A. Helv. Chim. Acta. 1949, 32, 275−283. b) Alt, G. H.; Barton, D. H. R.
J. Chem. Soc. 1954, 4284-4294.

171
120 . Chiu, M. K. T.; Sigillo, K.; Gross, H. P.; Franz, H. A. Synth. Commun. 2007, 37, 2355-2381.
121 . Panchaud, P.; Renaud, P. Adv. Synth. Catal. 2004, 346, 925-928.
122 . a) Brown, H. C.; Midland, M. M. Angew. Chem., Int. Ed. Engl. 1972, 11, 692−700. b) Kabalka,
G. W.; Brown, H. C.; Suzuki, A.; Honma, S.; Arase, A.; Itoh, M. J. Am. Chem. Soc. 1970, 92,
710−712. c) Brown, H. C.; Midland, M. M. J. Am. Chem. Soc. 1971, 93, 1506−1508.
123 . a) Nozaki, K.; Oshima, K.; Utimoto, K. Tetrahedron Lett. 1988, 29, 1041-1044. b) Nozaki, K.;
Oshima, K.; Uchimoto, K. J. Am. Chem. Soc. 1987, 109, 2547−2549.
124 . Matsushita, T.; Sati, G. C.; Kondasinghe, N.; Pirrone, M. G.; Kato, T.; Waduge, P.; Kumar, H. S.;
Sanchon, A. C.; Dobosz-Bartoszek, M.; Shcherbakov, D.; Juhas, M.; Hobbie, S. N.; Schrepfer, T.;
Chow, C. S.; Polikanov, Y. S.; Schacht, J.; Vasella, A.; Böttger, E. C.; Crich, D. J. Am. Chem. Soc.
2019, 141, 5051-5061.
125 . Ogawa, A.; Curran, D. P. J. Org. Chem. 1997, 62, 450-451.
126 . Curran, D. P.; McFadden, T. R. J. Am. Chem. Soc. 2016, 138, 7741–7752.
127 . Keck, G. E.; Enhdlm, E. J.; Yates, J. B.; Wiley, M. R. Tetrahedron. 1985, 41, 4079-4094.
128 . a) Guyader, L. E.; Quiclet-Sire, B.; Seguin, S.; Zard. S. Z. J. Am. Chem. Soc. 1997, 119, 74107411. b) Quiclet-Sire, B.; Zard. S. Z. J. Am. Chem. Soc. 1996, 118, 1209-1210. c) Kim, S.; Kim, S.
Bull. Chem. Soc. Jpn. 2007, 80, 809–822.
129 . Nguyen, J. D.; D'Amato, E. M.; Narayanam, J. M. R.; Stephenson, C. R. J. Nat. Chem. 2012, 4,
854-859.
130 . Feng, Y.; Dong, J.; Xu, F.; Liu, A.; Wang, L.; Zhang, Q.; Chai, Y. Org. Lett. 2015, 17, 2388−2391.
131 . Crich, D.; Li, W. J. Org. Chem. 2007, 72, 7794−7797.
132 . Wang, C.-C.; Luo, S.-Y.; Shie, C.-R.; Hung, S.-C. Org. Lett. 2002, 4, 847−849.
133 . Crich, D.; Li, W.; Li, H. J. Am.Chem. Soc. 2004, 126, 15081−15086. b) Garegg, P. J.; Iversen,
T.; Oscarson, S. Carbohydr. Res. 1976, 50, C12- C14.

172
134 . Barandun, L. J.; Ehrmann, F. R.; Zimmerli, D.; Immekus, F.; Giroud, M.; Grünenfelder, C.;
Schweizer, W. B.; Bernet, B.; Betz, M.; Heine, A.; Klebe, G.; Diederich, F. J. Chem. Eur. 2015,
21, 126 – 135.
135 . Jung, M. E.; Koch, P. Org. Lett. 2011, 13, 3710−3713.
136 . a) Crich, D.; Vinod, A. U. Org. Lett. 2003, 5, 1297−1300. b) Bauer, T.; Tarasiuk, J.; Paśniczek,
K. Tetrahedron. Asymmetry. 2002, 13, 77-82.
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Chapter one provides a general view on the background to the research in two parts. The
first part begins with an introduction on the significance of the lectin-carbohydrate interactions in
leguminous plants. Then the structure and role of O-antigen lipopolysaccharides in the symbiotic
nitrogen cycle, and the mechanism and significance of the cycle in leguminous plants growth are
introduced. The role, isolation and characterization of bradyrhizose are also introduced; and the
previous syntheses of bradyhizose and of related bicyclic compounds presented.
The second part of chapter one starts with an introduction on the biosynthesis, role and occurrence
of KDO in bacterial LPS and CPS. The second part also introduces the implications of KDO in
glycoconjugate vaccine development, and highlights literature syntheses of equatorial KDO
glycosides. The role of side chain conformation in stereocontrolled glycosylation reactions, in
particular the influence of side chain conformation in stereoselective synthesis of neuraminic and
pseudaminic glycosides, are then broadly discussed.
Chapter two describes the synthesis of bradyrhizose in 14 steps and 6% overall yield from
commercially available and cheap D-glucose. Unlike the literature synthetic approaches to this
unsual bicyclic sugar, the synthesis involves the elaboration of a trans-fused carbocyclic ring onto
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the pre-exisiting glucopyranose framework followed by adjustment of the oxidation levels by
simple practical methods. The key steps in this synthesis are radical extension of the glucopyranose
side chain under photocatalytic conditions using fac-Ir(ppy)3 as the catalyst, construction of the
bicyclic motif using ring closing metathesis, regioselective allylic oxidation, Luche reduction,
hydroxy-directed epoxidation, regio- and stereoselective acid-catalyzed epoxide opening, and
deprotection.
Chapter three begins with an introduction to the pseudosymmetric relationship of the
bacterial pseudaminic acid and 3-deoxy-D-manno-oct-2-ulosonic acid. Then, a brief discussion on
the excellent equatorial selectivity obtained with the pseudaminic acid donor having the
equatorially selective tg conformation about its C6-C7 bond is presented. This is followed by a
prediction that suitably protected KDO donors will adopt the trans,gauche conformation of their
side chain and consequently be highly equatorially selective in their coupling reactions conducted
under standard conditions. The synthesis and conformational analysis of peracetylated,
perbenzylated KDO donors, acetonide protected donor, and the silylene‐protected KDO donor is
then described. Consistent with the predictions, good to excellent equatorial selectivity is observed
on coupling of acetonide-protected, per-O-acetyl or benzyl-protected KDO donors at low
temperatures, while axial selectivity is seen on coupling of the axially selective silylene‐protected
KDO donor at low temperature.
Chapter four presents progress on the proposed convergent synthesis of the pentasaccharide
containing the tetrasaccharide repeating unit of K. kingae type c capsular polysaccharide. The
chapter begins with the background on K. kingae and its mode of infection. The synthesis of key
donors and acceptors as building blocks is then described. Finally, a plan for completion of the
synthesis is described.
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Chapter 6 provides the full experimental details and characterization data for all
compounds prepared.
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